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Summary 
An investigation into the subcellular localisation of co-facton that stimulate 
prion protein conversion. 
Transmissible spongiform encephalopathies are a group of fatal neurodegenerative 
disorders affecting humans and animals. The prion hypothesis states that the 
infectious agent is predominantly composed of misfolded prion protein (PrpSc). One 
of the challenges to this hypothesis is the existence of prion strains. Different strains 
of the infectious agent are thought to arise from different conformations of PrpSc, 
which can be faithfully passaged onto the native cellular form (Prpc) during 
conversion. It has also been suggested that strain specific co-factors aid in the 
refolding process of Prpc during conversion. The preferential targeting of different 
transmissible spongiform encephalopathy (TSE) strains to specific brain regions, 
different cell types and even different subcellular localisations, implies the presence 
of strain specific co-factors in those disease affected areas. The production of prion 
particles in vitro, by amplification either with or without exogenous seed, supports 
this hypothesis but typically results in particles with infectivity titres less than those 
isolated ex vivo. This project investigated the involvement of accessory molecules 
and the subcellular localisation of conversion. Potential accessory molecules were 
sourced from subcellular fractionation of TSE susceptible cell lines and scrapie 
associated fibrils from TSE infected mouse brains and analysed using a cell free 
conversion assay and an oligomerisation assay for their strain specific qualities. The 
cell free conversion assay, previously shown to replicate many aspects of TSE 
disease, was used to investigate the location of disease-specific co-factors, by use of 
fractions derived from gradient centrifugation of a scrapie-susceptible cell line. 
Plasma membrane enriched fractions from the LD9 cell line enhanced the conversion 
efficiency ofME7 and 79A mouse scrapie in the CFCA. Equivalent fractions from a 
second scrapie-susceptible cell line also stimulate conversion. I also showed that 
subcellular fractions that enhance disease-specific prion protein conversion prevent 
in vitro oligomerisation of recombinant prion protein, suggesting the existence of 
separate, competing mechanisms of specific and non-specific misfolding in vivo. 
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1. Introduction 
1 
1.1 Introduction to Prions 
Prions exist as self propagating proteins that replicates autocatalytically by 
converting the native host protein into the prion state. In 2004, new data showed that 
observations on the conformational variations in yeast prions determined strain 
variation (Chien et al., 2004). The term prion describes the infectious properties of 
proteinaceous agents that are devoid of nucleic acid and are segregated based on 
differences in conformation. Critically, prions are infectious and are generally known 
to cause a fundamental change in the host phenotype. 
Mammalian prions are associated with the disease, transmissible spongiform 
encephalopathy (TSE), a neurodegenerative disorder characterised by the post-
translational conversion of the mammalian prion protein (PrP). Mammalian TSEs 
were the first set of pathological states to be implicated with a self propagating 
protein. Initially, they were the only known instance of the prion concept, however, a 
number of different fungal proteins are now known to exhibit prion-like properties 
(Coustou et al., 1997, Shorter and Lindquist, 2005, Wickner et al., 2oo7). 
1.2 Prion Hypothesis 
The identity of the agent which causes transmissible spongiform encephalopathies 
has been debated for many years. Initial observations of scrapie in sheep, described 
the infectious agent as a slow virus infection. However, work by Alper and 
colleagues in the 1960's showed that the transmissible scrapie agent was resistant to 
treatments such as nucleases and ultraviolet light, with no effect on infectivity (Alper 
et al., 1966 and 1967). This led to the hypothesis that the scrapie agent was not only 
devoid of any associated nucleic acid but was composed of an aberrant protein 
(Griffith, 1967, Bolton et al., 1982). Prusiner described the infectious agent as a 
novel proteinaceous infectious particle that was devoid of nucleic acid and was 
responsible for scrapie in sheep (1982). The term prion was coined from 
proteinaceous infectious particle and Prusiner described the prion to be a novel 
2 
pathogen that was neither a virus nor a viroid. The protein associated with the 
transmissible agent was proposed to be a host encoded sialoglycoprotein that was 
protease resistant and had a molecular weight of 27 -30 kDa (Bolton et al., 1982). The 
hypothesis that the prion protein was host encoded was inferred by sequencing of 
hamster mRNA which revealed a partial amino acid sequence for PrP (Oesch et al., 
1985). The native cellular isoform of PrP was designated Prpc ~ellular) whereas the 
disease associated isoform was designated PrpSc (Lcrapie-like). During disease there 
is a post-translational modification that causes native Prpc to misfold into the disease 
associated isoform, PrpSc• 
1.3 PriOR Protein 
The mammalian prion protein gene (Prnp) encodes a protein of between 250 and 260 
amino acids, depending on species (Oesch et al., 1985). Mammalian Prnp is 
constitutively expressed and has been well characterised in several eutherian species 
such as sheep, cattle, rodents and humans (Rheede et al., 2003). The prion protein is 
synthesised on ribosomes on the rough endoplasmic reticulum (rER) where, like 
many other plasma membrane bound proteins, it is post-translationally modified. 
During normal cellular function, PrP undergoes cleavage of its N-terminal signal and 
C-terminal hydrophobic peptide, the disulphide bridge forms, two N-linked 
mannose-rich oligosaccharides are added, as well as a glycosyl-phosphatidylinositol 
(GPI) anchor (Stahl et al., 1987). PrP is trafficked through the Golgi body where the 
two N-linked oligosaccharides are modified to contain sialic acid. Prpc is then 
packaged into vesicles and trafficked to the plasma membrane (Harris et al., 2003). 
1.3.1 PrP Structure 
The first nuclear magnetic resonance (NMR) structure of PrP was of the mouse PrP 
domain 121-231, which revealed a C-terminal globular structure composed of three 
a-helices and a short anti-parallel p-sheet (Riek et al., 1996). The a-helices are 
between residues 144 to 154, 179 to 193 and 200 to 217, and the P-strands between 
residues 128 to 131 and 161 to 164. The disulphide bridge is located between a 
3 
cysteine at residue 179 on the first turn of the second a-helix and a cysteine at 
residue 214 on the last turn of the third a-helix. In figure 1.1 the schematic diagrams 
of the primary and secondary structure of Prpc is shown. Riek and co-workers then 
published data on the NMR structure of full length murine PrP (1997), which 
highlighted the structurally disordered nature of the N -terminal region between 
residues 23-120. NMR structures for recombinant human and bovine PrP molecules 
were published, revealing structural variations implicated in the species barrier 
phenomenon, as described in section 1.9 (Zahn et al., 2000, Lopez Garcia et al., 
2000). In 2004, the first NMR structure for Prpc was published (Homemann et al., 
2004). This was achieved through the isolation of Pr pC, in the absence of detergents, 
from healthy calf brains and demonstrated that the structure was identical to that of 
recombinant bovine PrP expressed in E.coli. This data showed that recombinant 
proteins, which are deficient in glycosylation, can be utilised in prion protein 
structural studies. In contrast, X-ray crystallography of Prpc has been difficult with 
only two publications to date, which include the crystal structure of the truncated 
recombinant human PrP in a dimeric form (Knaus et al., 2001) and the globular C-
terminus region (123-230) ofrecombinant ovine PrP (Haire et al., 2001). 
The prion protein has two variably occupied sites for glycosylation, at asparagine 
residues 180 and 196 and generate either di-, mono- or un-glycosylated PrP as shown 
in figure 1.1 (Stimson et al., 1999). Glycan analysis of PrP reveals a broad range of 
sugars at the two glycosylation sites with at least 52 different sugars found on Syrian 
hamster (SHa) PrP (Rudd et al., 2001). The significance of glycoform diversity is not 
fully understood in terms of the normal function of PrP. However, PrP glycosylation 
is proposed to be a factor in determining TSE strains and is discussed later (Tuzi et 
al., 2008). 
1.3.2 PrP Function 
PrPC is ubiquitously expressed in most cell types, suggesting that it may be important 
and functionally significance as PrP-null (Prpo~ transgenic mice appear to develop 
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Figure 1.1: Schematic dia2rams of Prpc. 
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(A) Diagram of the primary structure of Prpc (B) Ribbon diagram of the structured 
C-terminus domain of Prpc where a-helices are represented in red/yellow, p-sheet 
are represented by blue arrows and the glycosylation of Prpe as indicated at 
asparagine residues 180 and 196. (Asp = asparagine, CRO = carbohydrate, GPI = 
glycosyl-phosphatidylinositol anchor) 
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and reproduce normally (Manson et al., 1994). This panel of transgenic mice were 
initially characterised as healthy, however perturbations in circadian rhythm (Tobler 
et al., 1997), alterations in copper binding and loss of superoxide dismutase activity 
(Brown et al., 1997) have been attributed to the ablation of PrP. The function of 
Prpc, however, is still under debate due to the variation in published data. It is known 
that PrP is abundant in neurons and has a high selectivity for Copper 11 (Cu2i ions 
through its octapeptide repeat region (Brown et al., 1997). In healthy brain, the prion 
protein has been hypothesised to localise predominately in the synaptic region of 
neurons (Taraboulos et al., 1992, Sales et al., 1998). Furthermore, it has been 
suggested that Prpc is more precisely localised in the presynatic membrane region, 
firstly through the co-localisation with the presynapytic protein synaptophysin 
(Fournier et al., 1995) and secondly, by observations made on the regulation of 
copper concentration at the presynaptic membrane (Herms et al., 1999). 
PrPC can bind up to six Cu2+ ions, depending on species, and these analyses suggest a 
role for PrP in copper homeostasis or at least a function related to a copper dependent 
pathway. Functional studies of Prpc have generated observations that upon copper 
binding, Prpc is endocytosed, carrying bound copper ions into the cell (Pauly et al., 
1998). Copper binding to Prpc has also been implicated in the prevention of 
oxidative stress through the regulation of CuZn superoxide dismutase activity 
(Brown et al., 2001). This observation was supported by Rachidi and co-workers 
who demonstrated that copper uptake correlated with detoxification of reactive 
oxygen species in neurons (Rachidi et al., 2002). However, the same study showed 
no correlation between copper uptake and copper delivery into the cell interior. 
Increasing evidence linking Prpc function with cellular pathways involved in the 
elimination of reactive oxygen species suggests a model for Prpc loss of function 
being responsible for TSE disease-specific neurodegeneration (Milhavet et al., 2000, 
Wong et al., 2000, Klamt et al., 2001). The in vitro analysis of immortalised 
hippocampal neurons isolated from Prp% transgenic mice were more susceptible to 
oxidative stress and apoptosis than the same cell type that was expressing Prpc 
(Kuwabara et al., 1999). Furthermore, observations made in vivo showed that Prpc 
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protects the brain against mediated cell death (Behrens et al., 2002, Atarashi et al., 
2003). 
In this study three lines ofPrp% transgenic mice (ZrchII, Nsgk. and RcmO) were used 
to study loss of PrP function. The ablation of PrP and the resultant phenotype was 
attributed to a gene that was 16 kb downstream of Prnp and encoded a PrP-like 
protein termed Doppel (Dpl). This was because, in the absence of PrP, Dpl then came 
under control of the PrP promoter in these transgenic mice. Although Dpl shares 
-25% amino acid sequence homology with PrP (Moore et al., 1999) it lacks the 
octapeptide repeat region and structurally resembles a truncated form of PrP (Mo et 
al., 2001). Experiments using transgenic mice expressing this truncated form of PrP 
that resembles Dpl, displayed similar ataxic phenotypes (Shmerling et al., 1998). In 
1999, Weissmann and Aguzzi proposed that Prpc and Dpl may compete with each 
other for the same ligand (PrPL). Binding of the ligand by Prpc generates a survival 
signal whereas binding of Dpl or truncated Prpc fails to produce the necessary 
survival signal. This raises implications for Dpl in TSE disease where Prpc is 
sequestered into amyloid and therefore preventing binding to PrPL. However, 
transgenic studies in mice expressing wild type PrP (prPWT) and PrpO/O mice 
. comprehensively ruled out any implication of Dpl influencing the clinical phenotype 
of TSE disease at the terminal stages of disease in these lines of transgenic mice 
(Tuzi et al., 2002). 
Although PrP has been associated with oxidative stress and copper mediated 
pathways, other functions have been reported. These include a neuroprotective 
function of Prpc through the interaction with the 37-kDa / 67-kDa laminin receptor. 
This interaction induces PrP internalisation via clathrin-coated pits and it has been 
proposed that the co-localisation with the laminin receptor initiates a survival signal 
by either playing a role in important cell to cell communication, or by cellular 
internalisation (Rieger et al., 1997, Gauczynski et al., 2001). The latter of these 
hypotheses was supported by data that had been previously published exemplifying 
the involvement of PrP in the activation of an intracellular tyrosine kinase, Fyn 
(Mouillet Richard et al., 2000). However, the importance and exact involvement of 
this tyrosine kinase in cell survival is yet to be determined. 
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Finally, Prpc has been implicated in other signal transduction pathways linked to cell 
survival, specifically mitochondrial mediated apoptosis. Prpc has been shown to 
suppress Bax-mediated apoptosis by preventing the conformational change in Bax 
required to initiate the apoptotic signal (Roucou et al., 2005). This is not through co-
localisation of Prpc with Bax but instead, through the initiation of a signal stemming 
from Prpc on the cell membrane. 
1.4 PrpSe and TSE Disease 
During TSE disease, the host protein Prpc is converted to a disease associated 
isoform that is believed to be the principal component of the infectious agent 
(Prusiner, 1982). The misfolded isoform of Prpc is known as PrpSc where the 'Sc' 
refers to scrapie-like. Other terms include Prpd (disease associated isoform), PrpR' 
(protease resistant isoform), Prp27-30 (27-30 kDa proteolytic cleavage product ofPrP) 
and PrP TSE. The conformational changes in Prpc during disease are associated with 
an increase in the p-sheet structure of PrP (Caughey et al., 1991a). This change in 
secondary structure is shown in figure 1.2, which is a hypothetical schematic 
diagram of Prpsc. This increase in p-sheet causes PrP to form an oligomeric isoform 
before maturation into fibrils (Hill and Collinge, 2003, Kayed et al., 2003, Wetzel et 
al., 2007). The formation of amyloid fibrils is a hallmark of neuropathology for most 
TSE diseases and these plaques are insoluble and partially resistant to proteolytic 
digestion. When treated with proteases, the unfolded N-terminus is cleaved, leaving 
behind a 27-30 kDa protease resistant core which can be detected by Western 
blotting with an antibody that detects a C-terminus epitope. Figure 1.3 shows the 
Western blot profile when using a C-terminal specific antibody (BC6) or a N-
terminal specific antibody (FHll). 
Insoluble amyloid plaques composed primarily of Prpsc are generally associated with 
neurodegeneration, gliosis (astrocytes and microglial invasion) and spongiform 
change in the brain, as illustrated in figure 1.4 (Budka, 2003). Typically, PrpSc 
deposits are found in the brain, however the distribution and severity of vacuolation 
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Figure 1.2: Schematic diagram of the secondary structure of Prpsc• 
Hypothetical ribbon diagram of the structured C-terrninal domain of Prpsc where (l-
helices are represented in red and ~-sheet are represented by blue arrows. The 
disulphide bridge is represented by a yellow line. 
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Figure 1.3: Differential identification of the proteolytic resistance of Prpsc 
associated with scrapie associated fibrils isolated from brains of TSE infected 
sheep. 
Uninfected and scrapie infected brain homogenates (10 % (w/v)) were treated with 
and without PK (50 )lg/ml) prior to SDS PAGE and Western blotting with the anti-
prion primary antibodies (A) BC6 (C-terminal specific epitope at residues 141- 152) 
at 1 )lg/ml (lanes 1 to 4) and (B) FH11 (N-terminal specific epitope at residues 54-
58) at I )lg/ml (lanes 5 to 8). Secondary antibody was goat anti-mouse HRP (Dako) 
at 1 :20,000. Lanes 1 and 3 show full length and truncated Prpc whereas lanes 5 and 7 
show only full length Prpc. After treatment with PK, Prpc is degraded as shown in 
lanes 2, 4, 6 and 8. In scrapie infected brain homogenates only BC6 can detect PK-
truncated Prpsc (lane 4) due to the location of the antibody epitope in the PK-
resistant C-terminus, whereas the epitope for FH11 has been cleaved offby PK (lane 
8). Western blots courtesy of Dr Sandra McCutcheon and Boon Chin Tan (The 
Roslin Institute). 
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A B 
Figure 1.4: Neuropathology of RML infected mouse brains. 
Brain sections from Swiss white mice inoculated with Rocky mountain laboratory 
(RML) strain of scrapie were fixed in 10 % formalin and embedded in paraffin 
before (A) hematoxylin and eosin staining of the hippocampus and (B) 
immunohistochemistry of the hippocampus for the astrocyte marker, glial fibrillary 
acidic protein (GF AP). Py is the pyramidal cell layer and SR is the stratum radiatum 
(Bar = 50 )lm). Reproduced without permission from Prusiner, 1998 (Nobel Prize 
Lecture). 
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are used to characterise TSE strains (Fraser and Dickinson, 1968, Bruce et al., 1989, 
Bruce et al., 1991, Fraser, 1993). 
1.5 Human TSEs 
Human TSEs were first reported by the German neurologist Hans Gerhard 
Creutzfeldt in 1920 and then soon afterwards by Alfons Maria Jakob. The term 
Creutzfeldt-Jacob disease (CID) was coined in 1922 and used as a general term to 
describe human TSEs (Spielmeyer, 1922). This term originally encompassed all 
human TSEs, however it has changed over the years due to the heterogeneity of 
phenotypes displayed in human TSE patients. The variation in disease phenotypes 
can be determined by the origin of the prion and the route of infection (Gambetti et 
al., 2003). Typically the first manifestations of CID are dementia and memory loss 
which progress into physical impairments such as speech impairment and ataxia. The 
disease is invariably fatal and are caused by the progressive loss of neuronal cells in 
the brain (Budka, 2003). 
There are three epidemiological types of human TSEs; sporadic, familial, and 
acquired (table 1.1). These diseases are rare, with approximately 1: 1 ,000,000 cases 
per annum being classified as sufferers (Collinge et al., 2001). From this number, 85 
% of all TSE patients have sporadic CID (sCID) with the majority of the remainder 
consisting of familial TSEs (familial CID (fl:ID), fatal familial insomnia (FFI) and 
Gerstmann-Stdiussler-Scheinker syndrome (GSS), Kong et al., 2003). Acquired 
TSEs are the rarest and arise from either the ingestion of TSE contaminated 
foodstuffs or by iatrogenesis. A recent example of an acquired TSE is variant CID 
(vCID), which was caused by the consumption of meat products contaminated by the 
prion responsible for bovine spongiform encephalopathy (BSE) (Bruce et al., 1997). 
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Sporadic human TSEs Familial human TSEs Acquired human TSEs 
Sporadic CID Familial CID Iatrogenic CID 
Sporadic FI FFI New variant CID 
-
GSS Kuru 
Table 1.1 The spectrum of human TSEs. 
Key: Fatal familial insomnia (FFI), fatal insomnia (FI) Gerstmann-Straussler-
Scheinker (GSS), Creutzfeldt-lacob disease (CID). 
13 
such as blood transfusion (Houston et al., 2000) Transmission studies using sheep . 
infected with scrapie and BSE, identified that TSE infection can be carried efficiently 
The BSE epidemic in cattle raised concerns for human health and the risk of 
transmission from not only BSE but other animal prions. More recently it has been 
the risk of vCJD infected blood and blood-related products used in medical practices 
by blood transfusion from donor to recipient (Hunter et al., 2002, Houston et al., 
2008). Consequently, strict regulations have been put in place to prevent TSE spread 
by blood transfusion. These include the purchase of plasma from non-UK sources 
and leucoreduction of whole blood and red-blood cell derived products (Gregori et 
al., 2004). 
1.6 Animal TSEs 
Scrapie is an animal TSE and has been endemic in the UK for over 200 years 
(McGowan, 1922). It is the most abundant TSE and was described as a disease that 
caused persistent lumbar pruritis and resulted in sheep fatality (Stamp, 1962, Parry, 
1983). In 1943, it was observed that the presence of vacuolated nerve cells in the 
medulla oblongata was indicative of scrapie (Holman & Pattison, 1943), yet it wasn't 
until 1959 when W. J. Hadlow, explained in a letter to The Lancet, that Kuru, a CNS 
disorder of the South Fore tribe of Papau New Guinea, and sheep scrapie shared 
many parallels in terms of clinical and pathological features (Hadlow, 1959). The 
proposal by Hadlow was that although they were not identical, the lack of evidence 
of a causative microbiological agent implied pathological similarities. Work by 
Chandler opened up the possibility of using the mouse to study the disease in a 
manageable model (1961). In this publication Chandler, demonstrated that scrapie 
could be transmitted to a mouse model by intracerebral inoculation. After 7 Y2 
months incubation, neurological disturbances were observed and histological 
examination showed considerable astrocytosis as well as severe vacuolation of the 
medulla oblongata. 
Since the BSE epidemic in the 1980's, the devastating effect on farming and the rural 
economy emphasized the importance of TSE research both politically and 
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economically. The threat of a TSE epidemic in humans from contaminated animal 
foodstuffs prompted a ban on the recycling of animals unfit for human consumption, 
into animal feeds. The BSE epidemic may have started from BSE infected meat and 
bone meal (MBM) that was provided as protein supplements for cattle (Prusiner et 
al., 1997). However, due to the sudden occurrence of BSE, the origin of the 
infectious agent is still under review. For example, it is not known whether BSE 
emerged through a spontaneous mutation of the bovine PrP gene or if the scrapie 
agent mutated and crossed species from sheep to cattle initially via scrapie-infected 
MBM. 
More recently, it was reported that a number of BSE infected cattle in Italy and 
France exhibited atypical molecular characteristics coupled with differences in 
amyloid distribution to that of classical BSE. The Italian case showed that the 
unglycosylated PrpSc had a lower molecular weight than unglycosylated PrpSc 
associated with BSE (Casalone et al., 2004). This new form of BSE is more 
prevalent in older cattle and was called L-type BSE but has also been described as 
bovine amyloidotic spongiform encephalopathy (BASE). The French atypical BSE 
case on the other hand, exhibited a higher molecular weight for unglycosylated PrP 
and this form ofBSE was named H-type BSE (Biacabe et al., 2004). 
Atypical BSE may pose a new threat to human health due to the unknown virulence 
of this strain with regards to the current knowledge regarding susceptibility conferred 
by different human genotypes. This reasoning was supported by data from the sheep 
model where the characteristics of atypical scrapie had different pathological 
characteristics to that of classical scrapie (Benestad et al., 2003). Atypical scrapie 
predominately affects sheep with genotypes that are associated with resistance to 
classical scrapie whereas in contrast, sheep that are susceptible to classical scrapie 
were resistant to atypical scrapie (Benestad et al., 2008). Atypical scrapie was 
discovered in a Norwegian sheep flock in 1998 and after intensive surveillance, has 
since been identified in several other countries. This strain differs from classical 
scrapie most notably in its distribution of neuropathology and its Western blot profile 
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where a lower molecular weight form of PrpSc is detected between 7-12 kDa 
(Benestad et al., 2003). 
Another emerging TSE in animals is chronic wasting disease (CWD) of deer and elk. 
This naturally occurring animal TSE is rapidly spreading through these species in 
North America by an unknown transmission route, although it has been suggested 
that environmental contamination is responsible (Williams and Miller, 2002, Miller 
et al., 2003). Currently, CWD poses an unknown risk to human health; however, 
studies have crucially shown that CWD prions can be detected in deer skeletal 
muscle, implying the possibility of a zoonotic transmission to humans via infected 
meat products (Angers et al., 2006). 
Other than BSE, scrapie and CWD, other animal TSEs have been reported in the 
literature. These include feline spongiform encephalopathy (FSE) of domestic and 
zoological cats and transmissible mink encephalopathy (TME) of farmed mink. TME 
has been observed in mink since 1947; however outbreaks in mink populations are 
rare (Marsh and Hadlow, 1992). This TSE is of unknown origin however mink are 
susceptible to intracerebral inoculation with scrapie and BSE, raising questions over 
the epidemiology of TME (Hanson et al., 1971, Marsh et al., 1997). However, FSE 
has been identified as being linked to the BSE epidemic where a total of 15 animal 
species unknown to of previously developed TSE disease, were transmitted BSE 
prions. The 15 new species known to have contracted BSE include seven bovid, four 
fetid and four primate species (Sigurdson and Miller, 2003). 
1.7 Prion Genetics 
In 1968, it was suggested that a gene controls the incubation time of scrapie in mice 
and has two alleles, s7 and p7 (Dickinson et al., 1968a, Dickinson and Meikle, 
1971). In these seminal experiments, CS7BL mice (SincS7) gave shorter incubation 
times for ME7 infection than VM mice (SincP\ The Sine gene (gene controlling 
incubation period of ME7) has since been shown to be congruent with Prnp and Pmi 
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genes (Moore et al., 1998). The following sections (1.7.1 and 1.7.2) describe the 
influence of prion genetics in humans and animals, respectively. 
1.7.1 Human Prion Genetics 
As previously discussed, human TSEs can be inherited, in a dominant autosomal 
manner, acquired or arise sporadically in an individual. Mutations in the human 
PRNP gene have been associated with determining the clinical and pathological 
outcome of the disease (Palmer and Collinge, 1993, Horwich and Weissman, 1997). 
Genetic analysis of PRNP has also identified a number of polymorphic sites 
throughout the human prion protein that are associated with susceptibility to TSE 
infection (figure 1.5). 
In some family lines, there are mutations in the PRNP gene that mean some 
individuals develop a familial TSE. In particular, the Dl18N mutation, in 
combination with a methionine at residue 129 in Prpc, results in the rare familial 
human TSE, fatal familial insomnia (FFI). This is an autosomal dominant prion 
disease that causes plaques of PrpSc to develop in the thalamus, the region of the 
brain responsible for sleep. Other mutations in Prpc include the PI02L substitution, 
which is associated with the occurrence of Gerstmann-StIilussler-Scheinker 
syndrome, another autosomal inherited prion disorder. However, the most common 
inherited human prion disease is the E200K variant of CID. The substitution of 
glutamic acid to lysine at residue 200, results in a very similar disease phenotype to 
scm (Meiner et al., 1997). 
Sporadic cm encompasses a wide variety of polymorphisms and mutations in PrP 
that cause the misfolding of human PrP to a disease associated isoform. Somatic 
mutations, which account for 85 % of all sporadic cases, include PI05L, A1l7V, 
Y145stop, F198S and M232R to identify a few (Kitamoto and Tateishi, 1994, Ghetti 
et al., 1996a,b). In addition, the methionine/valine polymorphism at residue 129 has 
been correlated with variances in clinical phenotype of sem, such as survival time 
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and type of PrpSc deposited in the brain (Collinge et al., 1991, Palmer et al., 1991, 
Brown et al., 1994,· Parchi et al., 1996). In general, homozygosity for methionine at 
residue 129 was more abundant in scm sufferers and correlates with reduced 
survival times (Pocchiari et al., 2004). Statistical analysis of this study correlated 
increased survival time with factors such as the female gender, younger age of 
clinical disease onset and expression of PrP type. These mutations and other 
prevalent polymorphisms are detailed in figure 1.5. 
1.7.2 Animal Prion Genetics 
One of the most extensively studied examples of prion genetics that influence 
susceptibility and resistance to TSE disease, is the ovine PrP gene. Studies into 
natural scrapie showed the importance of three codons within the ovine PrP gene; 
136, 154 and 171 (Goldmann et al., 1991). These three codons dictated incubation 
time of disease for natural and experimental scrapie in sheep (Goldmann et al., 
1994). Interestingly, of these three codons it is only residues at 136 and 171 that 
influence the rate of infection for sheep inoculated with BSE (Foster et al., 2001). 
The most resistant genotype is AAt36 RRIS4 RRl7l, which confers resistance to 
natural and experimental scrapie. On the other hand, sheep with the genotype W 136 
RRIS4 QQl7l are extremely susceptible to scrapie. Table 1.2 summarises the level of 
susceptibility of the 15 different ovine genotypes to scrapie and their approximate 
prevalence in the UK sheep population. 
Our understanding of how genes influence resistance and susceptibility to TSE 
infections in other animal species are not as well understood as to the ovine model. 
In cattle, there are no correlations between polymorphisms in the bovine PrP gene 
and an increased incidence of BSE in cattle. However, the insertion/deletion (indel) 
mutations of a 23-bp indel in the promoter region and a 12-bp indel in intron 1 have 
been significantly associated with an increased susceptibility of cattle to BSE (Juling 
et al., 2006). The authors of this publication implied that exposure to contaminated 
feed was likely the main risk factor, out with genetics, for cattle acquiring BSE. 
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Figure 1.5: Polymorphic variants of human PrP. 
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Diagram of human PrP with the octapeptide repeat sequence filled in grey. Mutations 
that are associated with disease are shown below human PrP. Polymorphisms that do 
not cause disease but are implicated in susceptibility or resistance are shown above 
human PrP. (ORD = octapeptide repeat deletion, ORI = octapeptide repeat insertion). 
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Genotype 
ARRIARR 
ARRIAHQ 
ARRIARQ 
ARRIARH 
AHQ/AHQ 
ARQ/AHQ 
AHQ/ARH 
ARHIARH 
ARQ/ARH 
ARQ/ARQ 
ARRNRQ 
AHQNRQ 
ARQNRQ 
ARHIVRQ 
VRQNRQ 
Genotype Occurrence (%) 
>20% 
< 10% 
>20% 
<5% 
<5% 
<5% 
< 1 % 
<2% 
<2% 
> 10% 
<10% 
<5% 
< 10% 
< 1 % 
< 1 % 
Table 1.2: Ovine PrP genotype and susceptibility to scrapie. 
Susceptibility 
Resistant 
Susceptible 
Table listing the ovine prion protein variations at amino acid residues: 136, I S4 and 
171 and their approximate occurrence in UK. sheep populations (Adapted from 
Baylis et al., 2004). 
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In cervids a number of polymorphisms in different species have been identified as 
influencing susceptibility to CWD e.g. mule deer, elk and white-tailed deer. Mule 
deer that were heterozygous for serine and phenylalanine or homozygous for 
phenylalanine at codon 225 were suggested to be less susceptible to CWD (Jewell et 
al., 2005). Elk however, were more susceptible to CWD if homozygous for 
methionine at codon 132 (O'Rourke et al., 1999) and in white-tailed deer the 
polymorphisms Q95H and G96S were associated with decreased susceptibility to 
CWD (Johnson et al., 2006). 
1.8 TSE Strains 
In 1961, Pattison and Millson published data indicating that genetic susceptibility 
was not the only significant factor affecting clinical symptoms of the disease. Sheep 
that had scrapie exhibited two distinct behaviours i.e. scratching or nervous 
behaviour. Brain homogenate from sheep with the scratching syndrome was 
intracerebrally (ic) passaged into goats where it was observed that the number of 
animals that showed scratching symptoms was reproducible. This experiment was 
repeated with brain homogenate from sheep with the nervous form of scrapie and 
recipient goats predominantly exhibited the same nervous behaviour characteristics. 
This was the first study that provided researchers with insights into different strains 
of the TSE agent (Pattison and Millson. 1961). In the same year, preliminary work 
published by R. L. Chandler at the Agricultural Research Council Field Station, 
Compton, showed that Pattison and Millson' s nervous scrapie strain could also be 
transmitted to Swiss white mice by intracerebral inoculation (Chandler, 1961). This 
work opened up the possibility of using the mouse model to analyse the identity of 
the infectious agent and the intriguing phenomenon of different strains of the 
infectious TSE agent (Dickinson et al., 1968a,b, Fraser et al., 1968, Dickinson et al., 
1969). 
It is believed that naturally occurring sheep scrapie is a crude mixture of scrapie 
strains, which, when transmitted into mice, can be characterised into new distinct 
strains. The incompatibility between Prpc and PrpSc from different species causes the 
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selection of the most pathological strain of the agent. Discrimination by semi-
quantitative methods such as lesion profiling and incubation period allows for the 
characterisation of new distinct strains (pattison and Jones, 1968, Prusiner, 1998). 
Initial experiments on mouse scrapie described that on the second passage of sheep 
scrapie in Swiss white mice, the time before the onset of scrapie like symptoms 
shortened to within 5 to 9 months after intracerebral inoculation (Zlotnik and Rennie, 
1963). Today, there are many distinct strains of scrapie that have been identified over 
multiple passages in mice of different genotypes. Mouse scrapie strains differ in their 
incubation period, pathology and clinical features. The incubation period of mouse 
scrapie in mice varies from 4 to 24 months and is incredibly reproducible but is 
dependent up on the host PrP sequence. 
The most notable set of scrapie strain experiments came from the sheep scrapie brain 
pool (SSBP/l), which was originally generated from three natural scrapie cases in 
Cheviot sheep (Bruce and Fraser, 1991). The SSBP/l main passage line involved 
multiple passes in sheep before cloning into mice homozygous for either the s7 or p7 
allele of Prnp. From the main line of SSBP/1, mouse passages revealed the presence 
of 5 strains of scrapie that were called 22A, 22C, 22F, 22H and 22L (Carp and 
Callahan, 1991, Bruce, 1993). During the initial passages of SSBP/l in sheep (prior 
to inoculation into mice), a branch line of experiments was carried out and included 
the inoculation of the scrapie agent into goats. This approach enabled the separation 
of scrapie and the isolation of other novel strains. The goats were split into two 
groups according to whether they displayed scratching or the drowsy clinical 
phenotypes. Infectious brain homogenate from goats with the drowsy form of goat 
scrapie were ic inoculated into mice, which resulted in the characterisation of two 
new strains of scrapie, 79A and 139A (Chandler, 1961, Somerville et al., 2005). 
During these experiments, a sample of mouse passaged scrapie was sent to the Rocky 
Mountain Laboratory (USA) where it was propagated frrstly in Swiss white mice 
then Swiss CD-l mice. The new strain of scrapie was called RML and is 
biochemically similar to that of 79A (Bruce et al., 1991). Finally, scrapie was also 
inoculated into Golden hamsters which isolated a novel mutant strain, called 263K, 
which was pathologically completely different to the original scrapie inoculum 
(Marsh and Kimberlin, 1975). 
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Other animal TSEs such as BSE have also been transmitted into mice and these 
experiments generated additional experimental models of murine TSEs. Infectious 
material isolated from four BSE infected Holstein-Friesian cows was transmitted into 
mice that were either homozygous for the s7 or p7 allele of Pmp. This resulted in the 
classification of two mouse-derived strains of BSE, which were called 301 C and 
301 V, respectively (Bruce et al., 1994). 
1.9 Species Barrier 
The species barrier is one factor believed to control transmission of prions between 
different species (Bruce and Fraser, 1991). Cross species prion propagation is 
generally rare and is thought to be limited by the differences in PrP sequence of the 
donor and the host (Prusiner et al., 1990). Furthermore, the differences in sequence 
may relate to subtle alterations in conformation resulting in an incompatibility 
between donor and host PrP molecules. If there is sufficient compatibility enough 
host PrP molecules will be converted to the disease associated isoform to begin the 
infection. Generally, effects of a species barrier will cause an elongation in the 
incubation period. However, studies in mice have demonstrated that on serial passage 
of the TSE agent can result in a shortening of the incubation period, indicating that 
the infectious agent has adapted to its new host and overcome the initial species 
barrier. The species barrier therefore, has been a key factor in the determination and 
isolation of novel strains of TSEs from a mixture of natural strains. 
Since the BSE crisis, the possibility that BSE could cross the species barrier 
represented a major health threat to human health. This proved to be more than a 
theoretical risk., as BSE prions crossed the species barrier from cattle to humans 
causing the TSE termed vCJD (Will et al., 1996). CWD that is sweeping through 
deer and elk populations in North America poses a new threat, although 
transmissibility to humans is unknown, its ability to infect cattle, opens a route for a 
new form of TSE that could potentially effect humans (Miller and Williams, 2004). 
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Specific traits associated with a species barrier have been replicated in vitro using 
assays such as the cell free conversion assay (CFCA, Kocisko et al., 1995, Raymond 
et al., 1997, 2000, Kirby et al., 2003). In these publications it was shown that 
rMoPrP did not convert to a PK-resistant isoform in the CFCA when using the 
hamster derived strain, 263K. Conversely, HaPrP was also resistant to conversion by 
the mouse scrapie strains Chandler and 87V in the CFCA. 
1.10 Protein X and Co-Fadon 
Many advances have been made in TSE research in recent years, however the 
identity and composition of the prion agent is still unclear. Isolation of host PrP from 
the infectious agent has implicated a pathological change in the conformation of 
Prpc, which ultimately results in a neurological disorder. Prusiner's protein only 
hypothesis states, that the interaction between Prpc and PrpSc is the principal 
pathological event and occurs in the absence of any nucleic acid (Prusiner, 1982). 
This hypothesis proposed that the pathological isoform, PrpSc, propagates itself by 
interacting and converting Prpc in a still undefined reaction. This hypothesis remains 
unproven, but in the absence of any alternative theorem, remains the most attractive 
explanation of prion propagation. Other hypotheses do exist and moreover involve 
the inclusion of viral nucleic acids as the information coding molecule associated 
with the infectious agent. However, an alternative theory was proposed in 1991, to 
answer the question of prion propagation and is known as the unified theory 
(Weismann, 1991). This data suggests that a small host-specific nucleic acid is a 
crucial component of PrpSc and encodes features such as strain specificity but needs 
not be a virus or viroid. Support for this theory has been reported by the discovery of 
small RNAs that stimulate prion protein conversion in the protein misfolding cyclic 
amplification assay (PMCA, Deleault et al., 2003, 2007). This group demonstrated 
that enhanced propagation of prions in vitro was facilitated by accessory polyanion 
molecules such as RNA. However, in the 2007 study they attempted to make 
synthetic infectious prions from minimal components which, although causing a 
neurological disorder in a panel of mice, lacked defming strain characteristics; in 
other words there was strain convergence. There is a possibility that this is a flaw of 
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the particular assay used (pMCA is discussed elsewhere) and there is the possibility 
that small RNA molecules play a valid role in acting as either a scaffold of PrpSc or a 
catalyst of conversion. 
TSE strains were historically distinguished by differences in disease incubation time 
and lesion profiles of the brain (Fraser & Dickinson et al., 1968, Bruce et al., 1989). 
Since then it has been suggested that strain differences are encoded by different 
conformations of PrpSc (Bessen et al., 1992, Bessen et al., 1994, Safar et al., 1998, 
Polymenidou et al., 2005). However, work on yeast prions has revealed that different 
strains of yeast prions are determined by non-prion components (Toyama et al., 
2007). Yeast prions share many biochemical traits with mammalian prions and it is 
conceivable that PrpSc conformation, in cooperation with specific co-factors, help to 
differentiate one strain from another. 
Protein X was the first suggested co-factor and was thought to play an important role 
in prion replication (Telling et al., 1995). The evidence to suggest a prion co-factor 
was to explain the results acquired when monitoring the susceptibility of transgenic 
mice expressing either mouse, human or a mouse-human chimeric PrP, to human 
prions. Mice expressing both mouse and human PrP were resistant to a human prion 
infection. However, mice expressing both mouse and a mouse-human chimeric PrP 
were susceptible to infection to the same human prions. It was hypothesised that a 
murine co-factor (i.e. protein X) that selectively bound to mouse PrP, was 
responsible and necessary for successful conversion. Protein X had a higher affmity 
for murine PrP and therefore prevented conversion in mice expressing both murine 
and human PrP but supported conversion in mice expressing murine and the mouse-
human chimeric PrP, by binding to the murine part of the chimeric PrP. 
Alternative ideas into the identification of co-factors have included the 
demonstration that lipids interact with Prpc and PrpSc and promote conformational 
changes in PrP during conversion (Sanghera and Pinheiro, 2002, Kazlauskaite et al., 
2003). Prpc is localised at the plasma membrane and evidence suggests that this is a 
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possible site of PrP conversion, thus supporting the potential involvement of lipids in 
this reaction (Shyng et al., 1994, Fournier et al., 1995). 
The search for prion co-factors takes into account the location ofPrpc in the cell and 
the nature of the interaction with PrpSc. Prpc is a GPI anchored protein that is 
translated on ribosomes attached to the surface of the rough endoplasmic reticulum 
(rER) before entering the secretory pathway to the plasma membrane (Campana et 
al., 2005). Protein degradation will generally occur by entry into the endosomal 
pathway and degradation in the lumen of lysosomes by acid hydrolases. Therefore, 
there are many locations within the cell that Prpc will reside, with many interaction 
partners along the way as described earlier in this chapter and supported by the 
literature (Lee et al., 2003, Rutishauser et al., 2009). In addition, the site of 
conversion, or indeed the accumulation of Prpsc, has been observed in multiple 
locations, from the plasma membrane to the endosomal pathway (Caughey et al., 
1991, Borchelt et al., 1992, Kaneko et al., 1996, Vey et al., 1996, Sanghera and 
Pinheiro, 2002). If PrpSc has been detected in these cellular compartments, it was 
therefore considered to contain the necessary prion co-factors for the successful 
conversion of Prpc. 
1.11 Cell Models of TSE Infection 
To research the molecular and biochemical characteristics of PrP in vivo is difficult, 
expensive and time consuming. Transmission experiments into mice rather than 
sheep or cattle gives increased manageability and reduced costs but incubation times 
are still relatively long and the use of animals in experiments can be ethically 
challenging. Cell cultures therefore represent a practical and relevant model to study 
some major questions in TSE research i.e. Prpc function and PrpSc infectivity. 
There are two approaches to obtain cell culture models that are susceptible to prion 
replication. Firstly, cell lines can be cultured ex vivo and exposed to infectious 
material, such as brain homogenate from infected animals and cells would 
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incorporate some of the PrpSc units and become infected. Over many washes and 
passages, to dilute the original inoculum, persistent infection would be detectable 
thus demonstrating that infected cultures are generating newly synthesised PrpSc 
molecules. The second approach involves the isolation of an infected cell line 
directly from infected animals. This was the method used to create the scrapie mouse 
brain (SMB) cell line, which was derived from cultures of Chandler infected mouse 
brain (Clarke and Haig, 1970, Birkett et al., 2001). A list of currently available cell 
lines used in TSE research is shown in table 1.3. 
Most cell culture models are of neuronal origin as this is the cell line most affected 
during disease in vivo (DeArmond et al., 1987, Prusiner et al., 1987). The first cell 
line shown to support infection in vitro was the neuroblastoma cell line, N2a (Race et 
al., 1987). In this study, the cell line was persistently infected with RML and once 
infected, the cell line remained viable. Other neuronal cell lines investigated include 
the hypothalamic cell line GT1, which was differentiated from immortalised 
gonadotropin-releasing hormone neurons (Schatzl et al., 1997). Quite surprisingly, 
efficient cell culture models have also been found in non-neuronal cell lines such as 
fibroblasts and myoblast cells. 
TSE susceptible cell models offer a convenient and relevant approach to study Prpc 
and PrpSc within the cell. The function of Prpc is still unknown, however cell culture 
models have contributed to our understanding of Prpc and its function as previously 
described in this chapter. Furthermore, cell models of prion infection allow for the 
investigation into the subcellular localisation of PrpSc for the site of PrP conversion 
(Taraboulos et al., 1990, McKinley et al., 1991, Lehmann et al., 1996, Beranger et 
al., 2001, Pimpinelli et al., 2005). 
Cell cultures susceptible to TSE infection also form good models for therapeutic 
research into inhibitors of PrpSc formation. Cell lines can be cultured in 96-wellplate 
format which allows for the design of a high-throughput assay to determine 
compounds with anti-prion properties (Brown, 2002). Cell cultures can also be used 
to search for molecular markers that could be used as a diagnostic test for 
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CeULine Species of Origin CeUType Prlon Susceptibility References 
5MB Mouse Microglial 22F, 79A, 22C, 87A, 301V Birkett et al., 200 1 
N2a Mouse Neuroblastoma RML, Chandler Race et al., 1987 
N2a-58 Mouse Neuroblastoma 22L, 139A, Chandler Nishida et al., 2000 
N2a-PKl Mouse Neuroblastoma RML,22L Mahal et al., 2007 
N2a-R33 Mouse Neuroblastoma 22L Mahal et al., 2007 
GTl Mouse Hypothalamic neural cells 22L, 139A, Chandler Nishida et al., 2000 
SN56 Mouse Septal neural cells ME7, 22L, Chandler Magalhaes et al., 2005 
CAD-5 Mouse Catecholaminergic cells RML,22L,79A,ME7,30IC Mahal et al., 2007 
HpL3-4 Mouse Hippocampus cells 22L Maas et al., 2007 
IV MSC-80 Mouse SchwannceU Chandler Follet et 01.,2002 
00 
L929 Mouse Fibroblast 22L, ME7, Chandler Clarke & Millson, 1976 
NIHI3T3 Mouse Fibroblast 22L Vorberg et al., 2004 
LD9 Mouse Fibroblast ME7,22L,RML Mahal et al., 2007 
C2C12 Mouse Myoblasts 22L Dlakic et al., 2007 
moRK13 Rabbit Kidney epithelial Fulruoka-1, 22L, Chandler Courageot et al., 2008 
ovRK13 Rabbit Kidney epithelial Natural sheep scrapie Vilette et 01.,2001 
PC12 Rat Pheochromacytoma 139A Rubenstein et al., 1984 
MDB Deer Fibroblast-like CWD Raymond et al., 2006 
Table 1.3: Prion susceDtible cell lines. 
distinguishing prion disease. This is a very important aspect of TSE research because 
the disease has long incubation times with little or no clinical signs. The sooner the 
disease is detected, the less neurodegeneration has occurred and the better the chance 
of survival, post therapeutic intervention (Mallucci et al., 2007). Another useful 
application for cell culture models is to identify the molecular determinants that 
make up and segregate TSE strains from each other. For instance, the standard 
scrapie cell assay (SSCA) is a panel of four cell lines that were selectively 
susceptible to four different strains of mouse scrapie (Mahal et al., 2007). This assay 
could provide the means to use differences in cell line susceptibilities to identify 
intrinsic co-factors that are involved in strain specificity. 
1.12 In Vitro Misfolding of PrP 
TSE disease is characterised by long incubation periods, making quick and accurate 
biochemical analyses of the infectious agent in vivo, technically difficult. In vitro 
assays that utilise recombinant PrP have played a major role in determining the 
misfolding characteristics of PrP and the conformational change it undergoes. 
Recombinant PrP purified from bacteria folds into an a-monomeric isoform similar 
to that of Prpc. Recombinant PrP is unglycosylated but it is hypothesised to have 
very similar misfolding properties to that of PrpSc, particularly since unglycosylated 
PrP has been identified in TSE infected individuals (Kascsak et al., 1985, Collinge et 
al., 1996, Somerville et al., 1997). Recombinant PrP has successfully been 
incorporated into several seeded in vitro assays and has been converted to an 
infectious PK-resistant isoform, similar to that of Prpsc (Swietnicki et al., 2000, 
Castilla et al., 2005). Seeded in vitro assays can be used to provide detailed 
information on strain characteristics, infectivity and the interaction between the 
infectious agent and Prpc. 
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1.12.1 Unseeded In vitro Misfolding Assays 
In addition to in vitro seeded assays, unseeded misfolding assays have been 
developed to understand how refolding of PrP occurs and the intermediate 
conformations that are possible and in particular, their potential role in neurotoxicity. 
Multiple pathways of misfolding and the formation of distinct fJ-sheet rich isoforms 
have been studied in vitro. Early work on the conformational transitions of Prpc to 
Prpsc revealed the presence of soluble oligomers of 4 to 6 Prp27-30 molecules as 
viewed by electron microscopy (EM) (Riesner et al., 1996). Although no infectivity 
was associated with these oligomers, the analysis into PrP misfolding and soluble 
prions was shown. It was then reported that a fJ-sheet rich oligomer may represent an 
intermediate species in the assembly of Prpc to PrpSc (Swietnicki et al., 2000, 
Baskakov et al., 2001). However, further analysis by Baskakov and colleagues 
revealed that the fJ-oligomer was energetically stable and was unlikely to assemble 
further into amyloid without prior dissociation back to the monomeric form (2002). 
Studies in TSEs and other amyloidoses such as Alzheimer's disease, have suggested 
that insoluble proteinaceous aggregations are instead a neuroprotective process that 
sequesters smaller, neurotoxic, oligomeric forms of the disease causing agent 
(Bucciantini et al., 2002, Caughey et al., 2003). 
In vitro protein misfolding assays reveal that unglycosylated recombinant PrP can be 
influenced by partially destabilising conditions, the addition of denaturants or by 
application of an acidic pH, to misfold PrP into defined structures that have similar 
biochemical characteristics to Prpsc (Rezaei et al., 2002, Tahiri-Alaoui et al., 2004, 
Martins et al., 2006). In chapter 6 the optimisation of an in vitro refolding assay is 
explored to provide an assay that is predictive of PrP misfolding in vivo as well as 
providing an assay to analyse the interaction of co-factors with PrP. 
30 
1.12.2 Seeded In vitro Misfolding of PrP 
The CFCA was first published in 1994 and demonstrated the in vitro formation of 
PrpSc using purified constituents (Kocisko et al., 1994). Purified 3sS-labeUed 
recombinant hamster Prpe from cell culture was incubated with purified PrpSc from 
263K infected hamster brain in the presence of 3 M guanidine hydrochloride for 48 
hours at 37 °C. Treatment with proteinase K (PK) produced protease-resistant C-
terminal fragment of 3sS-labelled Prpe that had been converted by 263K PrpSc. The 
PK-resistant product was termed PrP"" where 'res' is short for resistance to 
proteolytic digestion. This assay has since shown to replicate the species barrier as 
mouse Prpe is not converted by the hamster PrpSc strain 263K, and vice versa 
(Kocisko et al., 1995). In addition, PrpSc strain properties have also been replicated 
using the CFCA (Bessen et al., 1995). Differences in the extent of PK-resistance 
have been described in the two strains of hamster TME, hyper TME (HY) and 
drowsy TME (DY). Incubation of the two hamster TME strains with recombinant 
hamster Prpe resulted in the generation of PrP"" that reproduced the extent of PK-
resistance in HY and DY hamster TME. Finally, the CFCA has been shown to reflect 
polymorphic barriers in PrP (Bossers et al., 1997, Bossers et al., 2000). Experiments 
using recombinant ovine PrP (rOvPrP) and sheep scrapie in the CFCA showed that 
variations in recombinant ovine PrP sequence altered susceptibility to conversion in 
the CFCA. Ovine PrP variants linked to increased resistance to scrapie were poorly 
converted, whereas ovine PrP variants associated with increased susceptibility to 
scrapie were ably converted in the CFCA. 
The CFCA has since been modified to be more physiological relevant and 
incorporate a biochemically purified recombinant PrP substrate. Originally, the 
recombinant PrP substrate was purified from cell culture, however this was 
considered to contain cellular artefacts that may interact or even disrupt conversion. 
Subsequent publications have shown a baculovirus system where infected insect cells 
were used to produce rHaPrP that was successfully converted by hamster derived 
TME in the CFCA (Iniguez et al., 2000). The assay buffer was originally designed 
with 3 M guanidine hydrochloride, a chaotrope that caused a denaturising effect on 
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the PrpSc seed and resulted in increased conversion efficiency. In fact, a recent 
publication reported that ovine scrapie would only convert rOvPrP to a PK-resistant 
isofonn in the presence of 3 M guanidine hydrochloride (Piening et al., 2006). 
However, this denaturant has since been omitted from the assay so that it was more 
representative of cellular conditions (Kirby et al., 2003, Kirby et al., 2006). 
1.13 Synthetic PriORS 
The creation of synthetic prions in vitro from defined reaction constituents is the 
most compelling way to prove the prion hypothesis. Replication of PrP conversion in 
vitro has previously used purified Prpc and PrpSc to propagate Prpre' with strain 
associated conformations (Kocisko et al., 1994, Kocisko et al., 1995 Bessen et al., 
1995). The association of newly synthesised Prpre' with PrpSc makes analysis into the 
infectivity of newly synthesised Prpre' impossible. Alternative unseeded fibrilisation 
assays impose destabilising conditions on Prpc, molecules causing refolding to a 
more stable ~-sheet rich isofonn such as an oligomer or a fibril. The experiment that 
got closest to proving the prion hypothesis was the fibrilisation of truncated MoPrP 
(89-230) (Legname et al., 2004). This aggregated peptide caused a neurological 
disease in transgenic mice, which over-express truncated MoPrP(89-230). However, 
there were two strong criticisms of this result, firstly in vitro generated fibrils were 
significantly less infectious than PrpSc and secondly -30 % of the transgenic mice 
used in this study have been reported to develop a spontaneous neurological disease. 
Recently, a seeded in vitro assay has provided an alternative approach to the 
generation of infectivity from minimal components. The protein misfolding cyclic 
amplification (PMCA) involves the incubation of small amounts of PrpSc (- 1 
attogram) with uninfected brain homogenate (Saborio et al., 2001). Prpc in the brain 
homogenate is converted to Prpres and through cycles of incubation and sonication, 
amplification of PrP"'s occurs. After many cycles, 10 % of the reaction is removed 
and incubated with fresh uninfected brain homogenate and cyclic incubation and 
sonication is resumed. When the PMCA method is repeated several times, the 
original PrpSc seed is diluted out leaving behind only newly generated Prpre'. 
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Infectivity studies in mice of the material generated by PMCA have shown robust 
infectivity (Castilla et al., 2005, Castilla et al., 2008). In these studies, the newly 
generated Prpres was comparable to PrpSc, demonstrating similar disease phenotypes 
and biochemical characteristics in vivo to that of the parental strains used. 
In addition to these studies, Supattapone and co-workers used the PMCA method 
with partially purified components to propagate infectious Prptes (Deleault et al., 
2005, Deleault et al., 2007). In these studies, Prpc was purified from uninfected brain 
material and seeded with PrpSc together with a synthetic polyanion which helped to 
stimulate conversion to Prpre5. Polyanion molecules that stimulated conversion 
included poly(A) and poly(dT) nucleic acids and non-nucleic acid molecules such as 
heparan sulphate proteoglycan. This addition of a polyanion molecule to the PMCA 
suggests that a non-PrP molecular scaffold is associated with amyloid fibrils helping 
to support the fibril structure. However, the presence of a polyanion to stimulate 
PMCA conversion with purified components was not strain specific, thus suggesting 
a ubiquitous role. in prion conversion rather than one that acted as a specific prion co-
factor (Deleault et al., 2007). Unfortunately, PMCA generated Prpres seeded from 
two different strains showed no statistical significance in incubation time or disease 
phenotype characteristics when inoculated into wild type hamsters. The convergence 
of strain properties was not explained in this publication; however it would appear 
that PMCA generated nonspecific aggregates of PrP due to the lack of strain specific 
co-factors that were previously included by the use of un-purified brain homogenate 
material. 
Deleault and co-workers observed that incubation of purified hamster Prpc with 
poly(A)RNA molecules caused spontaneous formation of Prp1'Cs in an infrequent and 
stochastic manner (2007). The de novo generation of Prr from the unseeded 
PMCA reaction was shown to be infectious to wild type hamsters. Incubation times 
before clinical onset were variable and the guanidine denaturation profile of de novo 
generated Prptes from that of an unseeded PMCA reaction was identical to the control 
PrpSc seeded PMCA reaction. These observations question the credibility and 
validity of PMCA experiments to propagate Prptes that is apparently indicative of 
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PrpSc and maintains strain properties such as PrP confonnation and its crucial and 
distinct biochemical profiles. 
Recent development of the PMCA has seen the invention of the quaking-induced 
conversion assay (QUIC), an assay that incorporates periodic shaking, rather than 
sonication, to convert recombinant PrP to a PK-resistant isofonn (Atarashi et al., 
2008). Atarashi and co-workers reported no false positive results in negative control 
experiments which is something that occurs spuriously when using the PMCA and 
therefore the QUIC assay may represent a more robust assay for future diagnostic 
tests. 
1.14 Scientific Objective and Experimental Approach 
In prion diseases, the strain phenomenon is one of the most puzzling and intriguing 
characteristics associated with the infectious agent. Previous studies have concluded 
that it is the conformation of PrpSc that plays a key role in establishing the properties 
that detennine strain variation (Safar et al., 1998, Tanaka et al., 2004, Tanaka et al., 
2006). Different strains of TSEs appear to have different conformations of PrP and, 
as a result, may have different fibril morphologies (Jones and Surewicz, 2005). It has 
been hypothesised that different interaction partners or prion co-factors are necessary 
for the propagation of PrpSc• The identity of these co-factors is'likely to be strain 
specific, either because of the variation in the structural confonnations and therefore 
interaction sites of Prpsc, or perhaps the involvement of different co-factors with 
Prpsc, influences the structural conformation of Prpsc. 
In this project, my aim was to identify the subcellular localisation of strain specific 
co-factors that are necessary for the efficient conversion of Prpc to Prpsc. To 
approach this, TSE susceptible cell lines were acquired to analyse for prion co-
factors. As previously indicated in section 1.11, TSE susceptible cell lines can be 
differentiated based on their susceptibility or resistance to certain mouse scrapie 
strains. It was hypothesised that differential expression of prion co-factors dictate 
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whether a cell line is susceptible to infection from a TSE strain. The location of co-
factors within the cell was unknown and therefore subcellular fractionation of the 
cell into distinct compartments provided a series of fractions enriched for different 
organelles, which enabled the testing for the presence of prion co-factors. This was 
carried out on two different cell lines, LD9 fibroblasts and 5MB-PS microglial cells 
which are susceptible to the mouse-adapted scrapie strains, ME7 and 79A 
respectively. 
Subcellular fractions from LD9 and 5MB-PS cell lines were tested in the cell free 
conversion assay (CFCA) and the effect on conversion assessed. This involved the 
incubation of recombinant MoPrP with either ME7 or 79A and supplemented with 
LD9 or 5MB-PS subcellular fractions. During these experiments it was identified 
that LD9 plasma membrane-enriched fractions significantly enhanced the conversion 
efficiency of ME7. However, this effect was not cell line specific as 5MB-PS low 
density subcellular fractions also significantly enhanced ME7 conversion. It was 
hypothesised that the lipid bilayer of the plasma membrane provided a scaffold 
support that increased the interaction between Prpc and PrpSc.lnterestingly, 5MB-PS 
Golgi body enriched fractions enhanced the conversion efficiency of 79A in the 
CFCA, thus suggesting a different site of conversion and therefore a different set of 
co-factors involved in the conversion ofPrpc by the 79A strain of mouse scrapie. 
In addition to the CFCA, I optimised an alternative in vitro PrP misfolding assay for 
the analysis of interactions between PrP and fractions that enhance conversion in the' 
CFCA. This oligomerisation assay involved the refolding of recombinant PrP to P-
sheet rich oligomers when incubated at 45°C in an acidic buffer. Comparisons of the 
rate of oligomerisation of wild type rMoPrP were made in the absence or presence of 
fractions that enhanced the conversion of SAF in the CFCA. Surprisingly, low 
density subcellular fractions from the LD9 cell line inhibited the oligomerisation of 
rMoPrP to ~-sheet rich oligomer isoforms. 
I also used mass spectrometry to identify prion co-factors of SAF preparations. 
Amyloid fibrils were crudely purified from mouse scrapie infected mouse brains and 
35 
are hypothesised to contain prion co-factors that have co-aggregated with PrpSc 
during polymerisation of the amyloid fibril. Tryptic digestion of SAP preparations in 
the presence of a low molar urea buffer provided tryptic peptides for the analysis and 
identification by mass spectrometry. Different strains of mouse scrapie associated 
fibrils (ME7, 79A and 22F) were compared to attempt to identify strain specific co-
factors. Different proteins were identified from each of the three strains, indicating 
the possibility of strain specific markers. Pre-treatment of the isolated SAP narrowed 
down the list to single protein identifications for each mouse scrapie strains. Analysis 
of the literature provided insights into the function of these proteins. 
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2. Materials and Methods 
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2.1 Methods 
All chemicals were sourced from Sigma Aldrich except where otherwise stated. 
2.1.1 DNA methods 
2.1.1.1 Transformation of E. coli with plasmid DNA 
The following ligation was carried out by a previous co-worker, Dr Louise Kirby. 
The plasmids pTrcHis (Invitrogen) and pTrcHisB (Invitrogen) were digested with the 
restriction enzymes Ncol and EcoRI to remove the six histidine tag. Recombinant 
vectors were ligated with polymerase chain reaction (PCR) fragments that code for 
full length recombinant mouse PrP and full length recombinant ovine PrP 
respectively. 
Both modified vectors were separately transformed into the Escherichia coli (E. coli) 
strain IB392 (Wright et a1., 1986). On ice, 40 Jil of competent E.coli cells were 
combined with I Jil of plasmid DNA and incubated for 30 minutes. Competent cells 
were heat shocked at 42°C for 45 seconds, followed by 2 minutes incubation on ice. 
Using a sterile spreader, competent cells were spread on a Luria Bertani (LB) agar 
plate (10 g tryptone, 5 g yeast extract, 0.5 g sodium chloride, 1.5 % (w/v) agar and 
made up to I litre with dH20) with ampicillin (from IAH media services, 100 Jig/ml) 
and incubated overnight at 37°C. 
2.1.1.2 Glycerol stocks of transformed E.coli 
One colony of IB392 E.coli bacteria was isolated from an LB agar plate of 
transformed E. coli and used to inoculate 10 ml of LB media (lOg tryptone, 5 g yeast 
extract, 0.5 g sodium chloride and made up to I litre with dH20). This was incubated 
overnight at 37°C, shaking at 220 rpm (Innova, New Brunswick Scientific). From 
this culture, 100 J11 was pipetted into 10 ml of LB, with ampicillin (100 J1g1ml) and 
incubated for 4 hours at 37°C, shaking at 220 rpm. 500 J11 of this culture was mixed 
with 500 Jil of a glycerol solution (30 % (v/v) glycerol in LB media) in a 1.5 ml 
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screw top eppendorf (Sarstedt). Glycerol stocks were snap frozen in liquid nitrogen 
prior to storage at -80 °C. 
2.1.2 Protein methods 
2.1.2.1 SDS PAGE 
Samples to be analysed by SDS PAGE were mixed 3:1 with LDS sample buffer (4x) 
(Invitrogen) and heated at 100 °C for 10 minutes. For silver staining of SOS PAGE 
gels, samples were suspended in modified Laemmli sample buffer (MLSB, 4 M urea, 
5 % (v/v) glycerol, 5 % (w/v) SOS, 5 % (v/v) p-mercaptoethanol, 65 mM Tris (PH 
6.8» rather than LDS sample buffer. Samples were centrifuged at 10,000 g for 15 
seconds prior to loading samples into separate wells of a 12 % bis-tris pre-cast 
NuPAGE gel (Invitrogen). For every gel used, 10 ~l of SeeBlue Plus2 pre-stained 
marker (Invitrogen) was used as the molecular weight standard. Pre-cast gels were 
subjected to 180 volts for approximately one hour and either stained with Instant 
Blue coomassie (Expedeon Solutions), silver nitrate or transferred onto PVOF 
membrane (Millipore) by semi-dry blotting followed by Western blotting. 
2.1.2.2 Coomassie staining 
Instant Blue Coomassie stain was added to SDS PAGE gels and protein bands 
resolved within 5 minutes. 
2.1.2.3 SHyer staining 
All buffers were prepared with freshly de-ionized H20 (dH20). Silver nitrate staining 
of SDS PAGE gels was carried out by following the Plus One silver staining protocol 
as suggested by GE Healthcare (www.gelifesciences.com).Briefly.this protocol 
involved the submersion of the SDS PAGE gel in 20 ml fixing buffer (3,0 % (v/v) 
ethanol, 15 % (v/v) glacial acetic acid) in a clean petri dish for I hour with gentle 
shaking on a platform shaker (Innova 2100, New Brunswick Scientific) at 50 rpm. 
The gel was then transferred to sensitizing buffer (30 % (v/v) ~thanol, 0.2 % (w/v) 
sodium thiosulphate, 6.8 % (w/v) sodium acetate, 0.5 % (v/v) glutardialdehyde) for 1 
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hour with shaking. The gel was then washed with 20 ml dH20 for 15 minutes, four 
times. Next, the gel was submerged in silver solution (0.25 % (w/v) silver nitrate and 
0.1 % formaldehyde) for 1 hour with gentle shaking. Silver solution was removed 
and the gel was washed twice with 20 m1 dH20 for precisely 1 minute for each wash. 
Finally, the gel was placed in development buffer (2.5 % (w/v) sodium carbonate, 
0.025 % formaldehyde) and development was halted by transferring the gel to a 
clean petri-dish with 20 ml of stop solution (40 mM EDTA) 
2.1.2.4 Western blotting 
Immobilon-P PVDF transfer membrane with a pore size of 0.45 Jim and grade 1 
filter paper (Whatman) were cut to 8 cm x 9 cm. Eight pieces of filter paper were 
stacked together and submerged in transfer buffer (0.19 M glycine, 0.1 M tris-HC1, 5 
% (v/v) methanol). Wet filter paper was mounted on the semi-dry blotter 
(Invitrogen), and air bubbles rolled out. The PVDF membrane was soaked in 
methanol for 2 minutes followed by submersion in transfer buffer and layering on top 
of the stack of eight pre-soaked filter papers. The SDS PAGE gel was briefly washed 
in transfer buffer and placed on top of the pre-soaked PVDF membrane and filter 
paper stack. Finally, the stack was completed by eight pieces of filter paper also pre-
soaked in transfer buffer. Air bubbles were rolled out and semi-dry blotter unit was 
closed and connected to a Pharmacia Biotech EPS-I000 electrophoresis power 
supply at 100 mA per blot for 1 hour 30 minutes. The membrane was removed and 
placed in block solution (5 % marvel (w/v) dissolved in TBS-T (0.13 M sodium 
chloride, 10 mM tris-HC1, 0.05 % (v/v) Tween-20» for one hour at room 
temperature (RT). The blocking buffer was replaced with primary antibody solution 
(primary antibody in 1 % marvel (w/v) in TBS-T) and the membrane was incubated 
at RT for one hour. The membrane was washed initially in TBS-T for 30 seconds 
followed by a further 3 x 15 minute washes in TBS-T. The final wash solution was 
removed and the membrane incubated in the secondary antibody solution (secondary 
antibody in 1 % marvel (w/v) in TBS-T)) at RT for 1 hour. The membrane was 
washed, initially in TBS-T for 30 seconds, followed by a further 3 x 15 minutes in 
TBS-T. The final wash solution was removed and the membrane incubated for 1 
minute in ECL Western blotting detection reagent (GE Healthcare). The membrane 
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was dried and exposed to hyperfilm-MP (GE Healthcare) for varying time intervals. 
Film was developed by a Compact Xograph X4 (Xograph Imaging Systems). 
2.1.2.5 Densitometry analysis 
To capture images for densitometric analysis, films were scanned using an Image 
Scanner ID (GE Healthcare) with the operating program Labscan 6.0 (GE 
Healthcare) was used. The image scanner was calibrated every 30 days using a 
photographic step tablet (Kodak) between a density range 0.07 - 4.27 optical density 
(OD). 
Scanned images were transported into ImageQuant TL (GE Healthcare) where a ID 
gel analysis was carried out to determine densitometric values of protein bands 
relative to bands of known protein concentrations as indicated where appropriate. 
2.1.2.6 Reduction and alkylation of PrP 
All solutions in sections 2.1.2.6 and 2.1.2.7 were prepared with LC-MS grade water 
(Fischer Scientific). 
To enhance tryptic digestion of protein samples, disulphide bonds were reduced and 
alkylated to prevent reforming of the disulphide bridge. To do this, 19 Jll of 6 M 
guanidine hydrochloride, 100 mM ammonium bicarbonate (PH 8.5) were added for 
every I JlI of protein sample. Dithiothrietol (DTT) solution (5 mglml) was added to 
give a 5 fold molar excess over the number of cysteines in the protein. There are 2 
cysteines in PrP and with a PrP concentration of I mglml, 40 JlM of DTT was added. 
Samples were incubated at RT overnight, whereupon 5 mglml iodoacetamide (JAA) 
was added to give a 4 fold molar excess over the concentration of DTT used. To this, 
I Jll of 100 mM ammonia bicarbonate solution was added to keep the pH alkaline. 
Samples were incubated in the dark. at room temperature for I hour. 
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2.1.2.7 Tryptic digestion of PrP 
Tryptic digestion of proteins provided tryptic peptides for mass spectrometric 
analysis. To concentrate and purify protein from the previously added OTT and IAA, 
reduced and carboxylmethylated proteins were precipitated at -20°C for 12 hours in 
20 volumes of ethanol. Samples were centrifuged at 13,000 g for 15 minutes at 10°C 
to pellet precipitated species. The supernatant was removed and discarded and pellets 
were incubated for 2 hours at RT to ensure the pellet was completely dry. The pellet 
was re-suspended in 100 J11 of re-suspension buffer (4 M urea, 100 mM ammonium 
bicarbonate). Calculating 1I20tb of the approximate amount of protein in the sample 
is the mass of trypsin (Promega) to be added. Samples were incubated at 37°C for 8 
hours. Tryptic digestion was stopped by snap freezing at -20°C. 
2.1.2.8 Mass spectrometry 
All mass spectrometry was carried out in the proteomics facility of the Institute for 
Animal Health by proteomics staff. Samples were thawed and tryptic peptides were 
concentrated using a 180 J1m x 20 mm, 5 J1m Symmetry C 18 trap (Waters) for 3 min 
at 10 J1l1min, and resolved on a 1.7 J1m, 100 J1m x 100 mm, BEH 130 C 18 column 
(Waters) at 400 nllmin that was attached to a nano Acquity UPLC (Waters). Peptides 
were eluted over a linear gradient of 0-50 % (v/v) acetonitrile, 0.1 % (v/v) formic 
acid for 30 minutes with a flow rate of 400 nVmin. To complete elution, the column 
was washed with 85 % (v/v) acetonitrile, 0.1 % (v/v) formic acid for 7 minutes. 
Ionised peptides were analysed by a quadrupole time of flight (Q-ToF) Premier mass 
spectrometer (Waters) and the acquired data analysed by ProteinLynx Global Server 
version 2.2.5 (Waters) to generate the list ofpeptides detected. This peptide list was 
submitted to MASCOT version 2.2 (Matrix Science, UK) and searched against the 
IPI murine protein database. 
2.1.2.9 Circular dichroism 
Far-UV circular dichroism (CD) spectra were recorded on a Jasco J-710 
spectropolarimter using a scanning speed of 100 nmlmin and a step resolution of 1 
nm. For each sample, 20 spectra were accumulated at RT between wavelengths as 
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indicated on each CD spectra. Cell path lengths were dependent on protein 
concentrations and are indicated where appropriate. 
2.1.2.10 UV spectroscopy 
A Beckman DU-650 spectrophotometer was used to determine the concentration of 
recombinant protein by measuring the absorbance of the sample between 200 run and 
400 run in a 10 mm path length quartz cuvette (Hellma). The amino acids tyrosine 
and tryptophan absorb UV light typically with a wavelength of 280 run. The 
absorbance value obtained allows for the quantification of protein concentration. To 
accurately predict protein concentration, a background absorbance at 320 run was 
subtracted from the absorbance measured at 280 run. Serial dilutions were made of 
the sample to further ensure an accurate measurement of protein concentration was 
determined. Molecular weight and extinction coefficients used to calculate protein 
concentration are summarised in Table 2.1 (Gill and Von Hippel, 1989). 
2.1.2.11 Induction ofrecombinant PrP expression 
Glycerol stocks of E.coli bacteria used for the expression of recombinant PrP were 
streaked out onto LB (10 g tryptone, 5 g yeast extract, 0.5 g sodium chloride and 
made up to 1 litre with dH20) agar plates with ampicillin (100 Jiglml) and incubated 
at 37°C overnight. Single colonies were picked and used to inoculate 10 ml LB 
aliquots with ampicillin (100 Jiglml) and these were incubated overnight at 37°C in a 
shaking incubator at 220 rpm (lnnova, New Brunswick Scientific). 4 ml of confluent 
overnight growth cultures were used to inoculate 400 ml of terrific broth (TB) 
growth media (12 g tryptone, 24 g yeast extract, 4 ml glycerol in 900 ml dH20. 
Media was autoclaved at 121°C after which 0.017 M potassium phosphate and 72 
mM di-potassium phosphate was added and media made up to 1000 ml) plus 
ampicillin (100 Jiglml) in a 2 litre flask. Cultures were grown at 37°C in a shaking 
incubator at 220 rpm until an OD600 between 0.6 - 1 was reached. Recombinant PrP 
expression was induced by the addition of 1 Jil/ml of 1M IPTG and cultures were 
incubated for a further 7 hours at 37°C. Bacterial cells were harvested by 
centrifugation at 10,000 rpm for 10 minutes in a Sorvall RC5B centrifuge with a 
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Recombinant Protein 
Full length Murine PrP 
Full length Ovine PrP 
Molecular Weight 
23113.6 
22902.2 
Extinction Coefficient 
62280 
57780 
Table 1.1: Molecular weight and extinction coefficients of various PrP types 
(Gill and von HioDeL 1989). 
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Sorvall SLAI500 rotor. The resultant supernatant was discarded and cell pellets were 
stored at -20 °C overnight. 
2.1.2.12 Bacterial cell lysis 
Bacterial cell pellets were thawed from -20 °C storage and re-suspended in 10 mUg 
of bacterial lysis buffer (lOO mM sodium chloride, 1 mM EDTA, 50 mM tris-HCI 
(PH 8» and 2 f.l.Vml of phenylmethylsulfonyl fluoride (PMSF) for 2 hours. The cell 
suspension was treated with 20 f.l.Vml of lysozyme and incubated at 4 °C for 20 
minutes. To solubilise membrane components, 1 mglml of sodium deoxycholate was 
added. Suspensions were vortexed followed by incubation at RT until viscous. Once 
viscous, 5 f.l.Vml of 1 mglml bovine deoxyribonuclease (DNase) and 500 f.l.1 of 2 M 
magnesium chloride were added and suspensions incubated at RT for 15 minutes. 
Suspensions were centrifuged in the RC5B centrifuge with the SLA 1500 rotor at 10 
°C for 15 minutes at 15,000 rpm. Supematants were discarded and the inclusion 
body pellets stored at -20 °C. 
2.1.2.13 Purificadon of recombinant PrP with Ni-IMAC 
This protocol was used for the generation of rMo3F4PrP for its use in the CFCA. 
Inclusion body pellets were suspended in 10 mVg immobilised metal anion 
chromatography (lMAC) buffer A (8 M urea, 0.1 M sodium phosphate, 10 mM tris-
HCI (PH 8), 0.07 % (v/v) p-mercaptoethanol), vortexing thoroughly to ensure 
maximum solubilisation of recombinant protein. Suspensions were centrifuged at 
IS,OOO rpm for IS minutes in the RCSB centrifuge with the SLAlSOO rotor. The 
supematant was retained for rPrP purification using an AKTA FPLC (Pharmacia 
Biotech). 
A nickel-sepharose superflow column (Amersham Biosciences) was packed with S 
ml superflow resin and attached to the FPLC and the column equilibrated with IMAC 
A. Solubilised material from the inclusion body pellet was loaded into a superloop 
collection tube for injection onto the IMAC column. Full length rMoPrP is purified 
without a six histidine tag and instead relies upon the natural nickel chelating affinity 
of the octapeptide repeat sequence. Once protein was loaded, the column was washed 
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with 50 ml of IMAC A buffer and eluted with IMAC buffer B (8 M urea, 0.1 M 
sodium phosphate, 10 mM tris-HCI (PH 4.5». Samples were collected in 5 ml 
fractions. Samples from all stages of growth and purification were analysed by SOS 
PAGE and stained with Instant Blue coomassie to determine which fraction 
contained recombinant PrP. 
IMAC eluted fractions that contained the highest concentrations ofrecombinant PrP, 
as revealed by SOS PAGE, were pooled together and the total volume doubled with 
ion exchange buffer A (8 M urea, 50 mM HEPES-NaOH (PH 8». Second stage 
purification was cation exchange chromatography BJ:ld was also performed on an 
AKTA FPLC system. A 5 ml SP Sepharose fast flow (Amersham Biosciences) 
column was prepared and attached to the FPLC and the column equilibrated with ion 
exchange buffer A. Pooled fractions of Ni-IMAC elute were loaded into a superloop 
collection tube for injection onto the ion exchange column at a flow rate of 2 mlImin. 
Once loaded, the column was washed with SO ml of ion exchange buffer A. Protein 
bound to the column by ion exchange affinity were eluted over a 0-100 % gradient 
with ion exchange buffer B (8 M urea, 1.5 M sodium chloride, 50 mM HEPES-
NaOH (PH 8» over 30 minutes. Samples were collected in 5 ml fractions. From each 
stage of the purification, 100 J11 samples were retained for separation by SOS PAGE 
and resolution of protein species by staining with Instant Blue coomassie stain. 
Elution fractions that contain purified recombinant PrP were pooled and their protein 
concentration determined by use of a UV spectrophotometer at a wavelength of 280 
nm. 
2.1.2.14 Refolding and concentration of purified recombinant PrP 
Pooled fractions from ion exchange were diluted to 0.1 mg/ml and oxidised in the 
presence ofa 5-fold molar excess ofCu2+ ions for 12 hours at 4°C. Recombinant PrP 
was refolded into its native conformation by dialysis against 5 litres of SO mM 
sodium acetate, 10 mM EDTA (PH 5.5). Dialysis buffer was replaced every 4 hours 
over a 20 hour period. The first 5 litres of dialysis buffer included 10 mM EDT A to 
remove any free eu2+ ions from solution. 
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After 20 hours of dialysis, samples were recovered and centrifuged at 4,000 g for 15 
minutes at 10°C to pellet any precipitated protein. The supematant was removed and 
concentrated to approximately 2 mg/ml by ultra filtration with a 10 kDa filter 
(Amicon). Samples were snap frozen in liquid nitrogen and stored at -80°C until 
used. 
2.1.2.1S Purification of scrapie associated fibrils 
Based on a method described by Hope et al. 1986, PrpSc was purified from the brains 
of terminally TSE infected animals. A 5 % (w/v) brain homogenate was prepared 
from 4 mouse brains infected with mouse scrapie by homogenisation with a dounce 
homogeniser, in a buffer containing 10 % (w/v) N-lauroylsarcosine, 0.1 M sodium. 
phosphate (PH 7.4). The homogenate was centrifuged at 22,000 g for 30 min at 10 
GC. The pellet was discarded and the supematant centrifuged at 215,000 g for 
150 minutes at 10°C. The pellet was re-suspended in 3 ml H20 by repetitive 
vortexing followed by incubation at RT for 1 hour. To this, 9 ml of a solution 
containing, 0.9 M potassium. iodide, 15 mM sodium phosphate, 9 mM sodium 
thiosulphate, 1.5 % (w/v) N-Iauroylsarcosine (PH 8.5) was added. Finally, the 
suspension was centrifuged at 285,000 g for 90 minutes at 10°C through a cushion 
of 20 % (w/v) sucrose in 0.6 M potassium. iodide, 10 mM sodium. phosphate, 6 mM 
sodium thiosulphate, 1 % (w/v) N-Iauroylsarcosine sodium salt (PH 8.5). The 
resultant pellet was washed in dH20 and centrifuged at 13,000 g for 30 minutes at 
RT. The final SAF pellet was re-suspended in dH20 by sonication to approximately 
1 J1g/JiI, as estimated by 10 Jig/mouse brain. Western blotting using the AG4 
antibody against a serial dilution of rMoPrPWT of known concentrations gave a 
more accurate concentration and appropriate modifications were made to give 
1 J1g/Jil. 
2.1.2.16 Proteinase K Digest of SAF 
Samples of SAF were sonicated in 3 x 15 second bursts to disrupt PrpSc aggregates 
and yield a homogeneous suspension. The equivalent of I J1g of PrpSc was made up 
to 18 Jil with water and 2 Jil of 600 Jig/ml proteinase K (PK) to give a final PK 
concentration of 60 flglml. The SAF sample was incubated for 1 hour at 37°C before 
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adding 25 mM pefabloc se to stop PK digestion. Samples were precipitated for I 
hour at -20°C by adding 20 Jig of BSA and 4 volumes of ice cold methanol. Samples 
were centrifuged at 13,000 g for 30 minutes to pellet digest products. The resultant 
pellets were analysed by SDS PAGE and Western blotting. 
2.1.2.17 CFCA 
Scrapie isolated fibrils were disrupted by sonication to yield a homogenous solution. 
In an eppendorf, I J.1l of fibrils was mixed with 16.5 f.ll of conversion buffer (100 mM 
sodium chloride, 50 mM sodium citrate, 50 mM potassium chloride, 10 mM 
magnesium chloride, 0.1 % (v/v) Nonident P-40 (pH6.5» and 200 ng ofrecombinant 
mouse 3F4 PrP and then made up to a final volume of 20 f.ll with water. In some 
experiments, water was replaced with re-suspended pellets from subcellular 
fractionation. Reaction mixtures were incubated at 37°C for 24 hours. Samples were 
briefly centrifuged in the benchtop centrifuge to pull down condensate from the sides 
of tubes. 20 j.11 of water was added, vortexing to mix. From this, 2 J.1l (l/20th, which is 
abbreviated to -PK) of sample was removed for future analysis and the remaining 38 
J.1l (19/20th, which is abbreviated to +PK) was treated with 4 j.11 of diluted PK and 
incubated at 37°C for 1 hour. To stop the PK treatment, 4 J.1l ofpefabloc was added 
and sample was incubated at room temperature for 5 minutes. To these PK treated 
samples, 20 j.11 of 600 j.1g/J11 BSA and four volumes of ice-cold methanol were added 
prior to incubation at -20°C for 1 hour. The 2 j.11 sample removed prior to treatment 
with PK, represented the non-PK treated sample. To this, 20 j.11 of 600 J1g/Jil BSA 
and four volumes of ice-cold methanol was added, followed by incubation at -20°C 
for 1 hour. All samples were centrifuged at 13,000 rpm for 30 minutes to pellet 
precipitate. The supernatant was removed and discarded and the pellets resuspended 
in SDS PAGE loading buffer. This was then followed up by the protocols described 
in sections 2.1.2.1 (SDS PAGE), 2.1.2.4 (Western blotting) and 2.1.2.5 
( densitometric analysis). 
2.1.2.18 Purification of recombinant PrP for the ollgomerisation assay 
Inclusion body pellets from IB392 E.eoli expressing rMoPrP and rOvPrP (see 
sections 2.1.2.11 and 2.1.2.12) were used as the starting material to generate purified 
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recombinant PrP in the required oligomerisation buffer. Protocols for the purification 
of recombinant PrP from inclusion bodies for each of the different oligomerisation 
assays are described in chapter 6. 
2.1.3 Cell Culture Methods 
All cell manipulations took place in a class IT microbiological safety cabinet (Envair 
UK Limited) and all cell culture flasks (TPP) were incubated in a Hera Cell 240 
incubator (Heraeus) at 37 °C and 5 % C02. 
Aliquots of the LD9 fibroblast cell line were acquired frozen on dry ice from Or 
Sukhvir Mahal (Scripps, Florida) and are cultured in Eagles's minimal essential 
media (EMEM) media (Gibco) supplemented with 10 % (v/v) foetal calf serum 
(FCS). The 5MB-PS cell line was acquired from Ruth Hennion (TSE Resource 
Centre, IAH) who supplied aliquots from a liquid nitrogen frozen cell bank and are 
cultured in media 199 (IAH in-house media services) supplemented with 10 % (v/v) 
newborn bovine serum (NBBS) and 5 % FCS. 
2.1.3.1 Cell culture 
Frozen cell lines were thawed in a 37 °C waterbath (Grant) for 2 minutes. LD9 cell 
line samples were gently mixed with 4 ml of EMEM media and 5MB-PS cell line 
samples were mixed with 4 ml of media 199. Samples were transferred to a T25 flask 
and incubated overnight at 37 °C and 5 % C02. Media was replaced to remove 
DMSO that was present in the freezing media. Cell monolayers were returned to the 
incubator to grow until 90 % confiuency, replacing media every 3 days. 
2.1.3.2 Cell passaging 
When cell monolayers reached 90 % confluency, media was removed and cell 
monolayers were washed twice with 10 ml of Hank's buffered salt solution (HBSS). 
HBSS was removed and the cells were treated with trypsin according to the method 
under liquid N2 storage section. Cell suspensions were split 1:4 (SMB-PS) or 1:20 
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(LD9). Flasks were labelled and the passage number of the cell line incremented by 
one. 
2.1.3.3 Liquid Nz storage 
Cell lines were stored in liquid nitrogen to preserve cell line viability. Cell 
monolayer was washed twice with HBSS prior to incubation with 5 ml trypsin 
(Gibco) at RT for 2 minutes with gentle agitation. Trypsin solution was removed and 
flask incubated for 5 minutes at 37°C. Detached cells were re-suspended in 1 ml of 
freezing media (90 % (v/v) foetal calf serum (FCS), 10 % (v/v) dimethyl sulfoxide 
(DMSO». The cell suspensions were transferred to 2 ml cryovials (Greiner), labelled 
and placed in a Mr Frosty container (Nalgene) filled with isopropanol and cooled to -
80°C. After 24 hours, cryovials were transferred to liquid N2 storage. 
2.1.3.4 Subcellular fractionation 
Samples were kept on ice for all steps of the subcellular fractionation. Subcellular 
fractions were prepared from 3 x T75 culture flasks of confluent cells. Each flask 
was washed twice with 10 ml PBS and twice with 10 ml homogenisation buffer (0.25 
M sucrose, 1 mM EDTA, 20 mM HEPESINaOH (PH 7.4» containing complete 
EDTA-free protease inhibitors (Roche). Cell monolayers were collected by using a 
cell-scraper (Greiner) and scraping off into 9 ml of homogenisation buffer and placed 
in a tight-fitting glass dounce and homogenised with 10 strokes of the Teflon 
homogneiser. Homogenate was transferred to 1.5 ml centrifuge tubes and centrifuged 
at 1000 g for 10 minutes in a Sorvall hiofuge fresco to pellet nuclei and cell debris. 
The postnuclear supematant (PNS) was removed and a protein assay (2D Quant Kit, 
Amersham Biosciences) performed, with 1.5 mg of PNS layered on top of a 
continuous 10 - 20 % OptiPrep gradient diluted in 0.25M sucrose, 6 mM EDTA, 120 
mM HEPESlNaOH. The gradient was generated by placing 2 ml of 20 % OptiPrepTM 
in a Beckman Ultraclear tube (14 x 89 mm) and layering this with subsequent 2 ml 
volumes of 17.5 %, 15 %, 12.5 % and 10 % OptiPrepTM followed by a 12 hour 
incubation at 4 °C to generate a continuous gradient. The gradient was centrifuged in 
a Sorvall TH-641 rotor at 228,000 g for 8 hours at 10°C. After centrifugation, 500 III 
fractions were removed starting from the top of the gradient and each fraction was 
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precipitated by incubation with 1000 ~l ice cold methanol for 12 hours. To recover 
precipitate, fractions were centrifuged at 13,000 g for 30 minutes and supernatant 
removed. Pellets were either re-suspended in Laemmli's sample buffer for SDS 
PAGE and Western blotting or were re-suspended in dH20 for addition to the CFCA. 
2.1.4 Stadsdcal analysis of CFCA Western blots 
To analyse the effect of subcellular fractions on the effect of different strains of 
mouse scrapie in the CFCA the protocols outlined in sections 2.1.3.4 and 2.1.2.17 
were followed. Densitometric analysis of the resultant photographic exposures 
provided data on the conversion efficiency of each strain of mouse scrapie. These 
experiments were repeated and data points were plotted ± SEM. Statistical analysis 
was applied to the data to determine the significance of each result against the 
conversion efficiency of a particular strain of mouse scrapie in the CFCA in the 
absence of any subcellular fraction supplement. A one-sample t-test was applied 
using the following equations. 
x - J.1 t= -
X is the sample mean 
J.1 is the population mean 
Sx is the sample estimate of the 
standard error of the mean 
The sample estimate of the standard error of the mean (Sx) is based on the sample 
standard deviation (S) and the square root of the sample size (n). 
s 
Sx=---~n 
To test the statistical hypothesis I used the t distribution or student's distribution 
which required the t statistic (t) and the degrees of freedom (sample size minus one) 
and was calculated using the Microsoft Excel package. 
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3. Preparadon and validadon of subcellular fracdons from LD9 
and 5MB-PS cells 
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3.1 Introduction 
In vitro studies on TSE susceptible cell lines provide a model system with which to 
study the function of Prpc as well as the molecular and cellular basis of PrP 
conversion. Principally, they can be used to identify the localisation of Prpc 
conversion, the identity of the infectious agent and how the subsequent cell to cell 
spread of prions occurs (Vey et al., 1996, Naslavsky et al., 1997 Kanu et al., 2002, 
8en-Zaken et al., 2003). To propagate prions ex vivo, infected brain homogenates or 
purified scrapie associated fibrils (SAF) are added to the cell culture. After multiple 
washes and sufficient passages to dilute out exogenous infectivity, the presence of 
newly replicated PrpSc can be detected using PrP antibodies by Western blot analysis 
of celllysates for proteinase-K resistant PrP. 
The susceptibility of TSE susceptible cell lines is often strain specific, such that only 
a selection of TSE strains will infect any given cell line. Susceptibility is believed to 
come primarily from the presence or absence of strain specific co-factors within each 
cell line. If a certain cell line does not express a protein that is necessary for the 
efficient conversion of Prpc to PrpSc, then the cell will survive infection. This 
hypothesis predicts that strain specific co-factors exist within certain cells and that 
this explains how some cells are susceptible and others are resistant to a given strain 
of TSE. 
This chapter describes the use of TSE susceptible cell lines and their subsequent 
fractionation by differential centrifugation to give fractions associated with different 
subcellular organelles. Purified organelles were identified and validated by the 
detection of specific protein markers using Western blotting. Fractions were then 
used to supplement the CFCA and conversion efficiency assessed in a range of 
experiments, as described in chapter 4. This strategy assumes that the susceptible cell 
lines have strain specific co-factors required for the replication of set prion strains. 
I considered many factors before selecting the TSE susceptible cell line for my 
experiments. Firstly, the cell line needed to be murine in origin as the SAF 
preparations I had used to seed the CFCA were taken from infected mouse brains and 
to alleviate any potential problems posed by a species barrier effect, the cell line and 
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CFCA seed were selected from a homologous species. Secondly, the selected cell 
line would need to be susceptible to the mouse scrapie strain used in the CFCA. 
Table 1.3 summarises the cell lines that have been described in the literature to be 
susceptible to one or more strains of mouse scrapie. The CFCA however was the 
limiting factor as there were only a few strains of mouse scrapie known to catalyse 
the conversion reaction. Typically, the mouse scrapie strain 87V was used to convert 
rMoPrP to a PK-resistant isoform, however there were no cell lines known to be 
susceptible to this particular strain of mouse scrapie. Previous work in the lab had 
shown that ME7, 22F, 79A and the mouse derived aSE strain 301V, can all convert 
rMoPrP in the CFCA with varying efficiencies. The mouse derived BSE strain 301 V 
was excluded however, on the grounds that it required higher containment facilities. 
That left three strains; ME7, 22F and 79A, with which to test subcellular fractions in 
the CFCA. 
The mouse scrapie strain ME7 was derived from mice intracerebrally inoculated with 
mouse brain homogenates that previously had been infected with spleen tissue from 
sheep with natural scrapie (Zlotnik & Rennie, 1963). ME7 has been used to infect 
different cell culture models. Neuronal cell models such as N2a neuroblastoma cells, 
however, required unglycosylated PrP to be expressed for a persistent infection 
(Korth et al., 2000). Other neuronal cell lines include the septal neural cell line 
SN56, which had a low efficiency of infection by ME7 and only an acute infection 
was possible whereas the PCl2 cell line required growth factor to sustain prion 
infection (Chiesa and Harris, 2000). The requirement for growth factor suggests that 
prion co-factors have low expression in PCl2 cells and to rectify this prion co-factor 
deficiency, growth factor was required. To increase the chance of detection of strain 
specific co-factors I concluded that this cell line was likely unsuitable. The non-
neuronal cell line L929 is of fibroblast origin and can sustain ME7 infection for a 
maximum of 10 passages (Personal communication with Or I. Vorberg). It is 
unknown how the cells were able to overcome infection, however, it was 
hypothesised that an unknown biological clearance mechanism maybe in place and 
potentially in addition to deficiencies in co-factor expression. However, the L929 cell 
line was subsequently cloned and selected for susceptibility to the scrapie strain 
RML (Mahal et al., 2007). This led to the demonstration of the L929 clone, LD9, 
being susceptible to a persistent infection with ME7 scrapie. This cell line was 
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therefore identified as a candidate cell line to fractionate and test for the presence of 
co-factors in the CFCA. 
The mouse scrapie strains 79A and 22F have not been extensively used in vitro and 
the only known cell line that is susceptible to infection by these strains, is the 5MB-
PS cell line. The mouse scrapie strain 79A originates from an s7/s7 mouse line that 
was infected with drowsy goat strain of scrapie (Chandler, 1961). The 22F strain of 
mouse scrapie originates from SSBP/l, which when inoculated first into a p7/p7 
mouse line results in a strain of scrapie called 22A. When the 22A strain of scrapie 
was inoculated into mice with an s7/s7 PrP background, a new strain with a novel 
disease phenotype was selected for and this was termed 22F. 
I reasoned that the fibroblastic cell line LD9 and the microglial cell line 5MB-PS 
were therefore suitable candidates to fractionate into subcellular compartments based 
on biological relevance, practicability and susceptibility to infection by more than 
one strain. 
3.2 Tissue culture 
The LD9 fibroblastic cell line was a gift from Dr Sukhvir Mahal, (Scripps, Florida) 
and the 5MB-PS cell line was provided by Ruth Hennion (TSE Resource Centre, 
IAH). Following tissue culture protocols for cell growth, both cell lines were 
cultured to confluence as described in chapter 2 section 2.1.3.2. Cell lines were 
visualised using an inverted light microscope (Leica Microsystems) where 
morphological observations were made, as shown in figure 3.1. The LD9 cell line is 
of fibroblastic origin and therefore heterogeneous in size and shape (see figure 3.1 
part A). Conversely, the 5MB-PS cell line is a microglial cell line and figure 3.1 part 
B, shows classic glial morphology where long branching processes emanate from the 
cellular body. 
3.3 Subcellular organelle detection 
Subcellular fractionation of TSE susceptible cell lines provided the basis for the 
investigation into the presence of strain specific prion co-factors. It has been 
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Figure 3.1: Visualisation ofLD9 and 5MB-PS cell lines. 
(A.) LD9 fibroblast cell line cultured at 37°C and 5 % CO2 in EMEM media 
supplemented with 10 % (v/v) FCS. These fibroblasts are typically heterogeneous in 
size and shape. (B.) 5MB-PS cell line cultured at 37 °C and 5 % CO2 in media 199 
supplemented with 10 % NBBS and 5 % FCS. Microglial morphology shows that 
these cells have long branching processes that emanate from the cellular body. 
Images captured with an inverted Leica DM IRB microscope (Leica Microsystems) 
using Leica FW4000 software (Diagnostic Instruments). Magnifications were at 100 
x for both A and B. 
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hypothesised that different TSE strains replicate in different cellular compartments 
thus suggesting that co-factors can be found in different subcellular locations. The 
subcellular fractionation of a cell line by ultracentrifugation through a density 
gradient separates organelles based on their densities. Analysis by immunoblotting 
for antibodies specific for organelle markers validated the presence of organelles in 
each of the fractions prepared. I selected a range of subcellular markers based on 
extensive literature searches on proteins associated with organelles from either 
fibroblasts or glial cell origin. Organelles to be isolated were based on the likelihood 
of their association with PrP i.e. trafficking of PrP through the cell means that PrP 
will be associated with many different organelles which may play a role in the 
conversion of PrP and may potentially be the site of conversion. In addition to the 
organelles PrP experiences during normal trafficking (as discussed below), the 
mitochondria have been implicated in TSE disease through the observations of 
abnormalities in energy metabolism and the detection of PrpSc in the mitochondria 
(Hachiya et al., 2004, Rossi et al., 2004). Therefore, as part of my aims, 
mitochondria were also purified from LD9 and 5MB-PS cells. 
Ribosomes on the surface of the rough endoplasmic reticulum (rER) are the location 
where mRNA is translated into an amino acid sequence. The amino acid residues are 
connected by a peptide bond and the nascent protein interacts with various 
chaperones to fold the protein into its appropriate structure (Harris, 2003). A 
common rER marker is the chaperone BiP and has been demonstrated to be present 
in the rER of fibroblasts (Chessler and Byers 1993) and microglia (Kakimura et al., 
200 1). When Prpc is folded correctly in the ER, it is trafficked to the Golgi body for 
structural modifications and processing prior to being shuttled to the plasma 
membrane. Three markers for Golgi body were tried, including antibodies for 
GMl30, 58K and ERGIC53, all of which were unsuccessful on LD9 and 5MB-PS 
homogenates. However, a known marker for the Golgi body in microglial cells, is the 
protein TCP I (23C), which had been previously detected in the 5MB cell line 
(Personal communication from Dr Enrico Cancellotti, The Roslin Institute). Once 
Prpc has been processed in the Golgi body it buds off in a membrane vesicle, which 
relocates to the plasma membrane. The plasma membrane is a proposed site for Prpc 
function and has been extensively reported to be the site of PrP conversion 
(Kazlauskaite et al., 2002, Sanghera et al., 2002). A suitable marker for plasma 
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membrane is the protein annexin-II which has been previously demonstrated to be 
present in both fibroblasts (Barwise and Walker, 1996) and microglia (Eberhard et 
al., 1994). Plasma membrane proteins, such as Prpc, only remain on the cell surface 
for a specific period of time, after which they will be endocytosed via clathrin-coated 
pits. At this point, Prpc will either be recycled back to the plasma membrane, if it is 
found to be undamaged, or will instead enter into the lysosomal pathway for 
digestion by acidic enzymes present in the cavity of the lysosomal compartment. 
Lysosomes have been hypothesised to be instrumental in the pathogenesis of cell 
death and were considered to be a highly relevant organelle to investigate (Laszlo et 
al., 2005). Locating a suitable marker for the detection of lysosomes in fibroblast and 
microglial cells was difficult, with both cathepsin D and LAMPl tested without 
success. The marker LAMP2, however, proved to be a marker that was present in 
both cell types (Maurin and Raoult, 1999, Djukic et al., 2006). Unfortunately, 
antibody cross reactivity was a problem when probing multiple fractions from 5MB-
PS and LD9 cells. Table 3.1 outlines the organelle markers and antibodies used to 
detect these markers. Figure 3.2 shows the detection of organelle markers in LD9 and 
5MB-PS cellular homogenates after separation by SDS PAGE and Western blotting. 
The endocytic pathway, from the plasma membrane to the lysosomes, transports 
plasma membrane bound proteins initially through endocytic vesicles which fuse 
with early endosomes. Early endosomes mature into late endosomes which in turn 
are suggested to convert into lysosomes (Gruenberg, 2001). Endosomes have 
previously been suggested to be important in the conversion of Pr pC to PrpSc and that 
conversion occurs after Prpc has been to the plasma membrane (Borchelt et al., 
1992, Campana et al., 2005, Marijanovic et al., 2009). A marker of early endosomes 
is the protein EEA-I, which is instrumental in tethering and docking of the early 
endosome with endocytic vesicles from the plasma membrane (Wilson et al., 2(00). 
Unfortunately this marker was not detected in either the 5MB-PS or LD9 cell line. 
An alternative early endosomal protein marker is Rabs which is a small GTPase that 
modulates effector proteins such as EEA-l and rabaptin-s (Horiuchi et al., 1997, 
Patki et al., 1997, Deneka and van der Sluijs, 2002). However, Rabs was also not 
detected in homogenates from either the 5MB-PS or LD9 cell line. 
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Organelle Marker MW Andbody Sourced From 
Endoplasmic BiP/GRP78 78kDa Mouse IgG2a BD Biosciences 
Reticulum 
Golgi Body TCPl(23C) 60kDa Rat Monoclonal Abeam 
Plasma AnnexinII 36kDa MouseIgGl BD Bioscieoces 
Membrane 
Lysosomes LAMP2 lOOkDa Rat Monoclonal Abeam 
Mitochondria BcI-2 26kDa Mouse IgGl BD Bioscieoces 
Table 3.1: Andbodies for immunoblot detecdon of mammalian cell culture 
derived organelles. 
Detection of markers was demonstrated by the analysis of crude celllysates that were 
separated by SDS PAGE and probed with appropriate antibodies to detect a given 
organelle. The reactivity of the antibodies against the purified organelles was 
validated in figure 3.2 where Western blot analysis ofLD9 and 5MB-PS celllysates 
confirms detection of organeUes as assessed by the specificity of antibodies for target 
proteins and correct molecular weight. 
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A.) Annexin-II 
1 
38 
28 
D.) Bcl-2 
1 
28 
17 
2 
2 
B.) BiP 
1 98 
62 
E.)LAMP2 
2 
1 2 
188 
98 
C.) TCP1(23C) 
62 
49 
1 2 
Figure 3.2: Western blot analysis of LD9 and 5MB-PS cell homogenates. 
Homogenates from LD9 and 5MB-PS cells (lane 1 and 2, respectively) were 
analysed by SDS PAGE and detected by Western blotting with (A.) plasma 
membrane marker annexin IT (1: 1000) and using a secondary anti-mouse HRP 
(1/2000) antibody, (B.) endoplasmic reticulum marker BiP (1 :500) and using a 
secondary anti-mouse HRP (112000) antibody, (C.) Golgi body marker TCPl(23C) 
(1:2000) and u ing a secondary anti-rat HRP (112000) antibody, (D.) mitochondria 
marker Bcl-2 (1:1000) and u ing a secondary anti-mouse HRP (112000) antibody, 
(E.) lysosomal marker LAMP2 (1:600) and using a secondary anti-rat HRP (1/2000) 
antibody for chernilumine cence detection. Molecular weight, in kDa, is shown on 
the left hand side of each We tern blot. 
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3.4 Subcellular fractionadon method development 
My experimental aim was that strain specific co-factors are necessary for prion 
conversion. To do this, subcellular fractionation of TSE susceptible cell lines was 
performed to analyse for the presence of cellular co-factors associated with distinct 
organelles. The assay that I chose to assess this was the CFCA, to which I added 
organelles to rMoPrP seeded by different strains of mouse scrapie. 
There is no definitive protocol for the subcellular fractionation of tissue culture cells 
that can be applied to every cell line. Membrane particle separation by density 
gradient media is determined predominately by the content ratio of protein and lipids 
within the membrane (Pasquali et al., 1999). For instance, mitochondrial membranes 
are protein rich and thus have a high density, whereas lysosomes are lipid rich and 
therefore are low in density. Organelle content also plays a part in density and this is 
best demonstrated by the low density lipoproteins within the Golgi body resulting in 
more buoyancy when compared to the high concentrations of secretory proteins that 
reside within secretory vesicles. Sucrose is the most common choice of gradient 
media, however medias such as Percoll, Ficoll, Nycodenz and OptiPrepTM are readily 
available and are often more practical. Crucially, sucrose solutions are required to be 
freshly made up every time to prevent bacterial infection and therefore there can be 
reproducibility issues when making up fresh sucrose gradients. I tested OptiPrepTM 
first because it was readily available as a 60 % sterile solution and reportedly offered 
superior osmotic control and balance, which I hoped would enhance organelle 
viability and reproducibility in downstream assays. 
3.4.1 Homogenisation of cultured cells 
The first critical step of subcellular fractionation was to apply the most relevant and 
appropriate homogenisation conditions for the generation of a cell homogenate that 
could be reproducibly separated by ultracentrifugation. The homogenisation 
procedure was aimed at efficiently disrupting the cell membrane without shearing 
internal organelles. The homogenisation medium (0.25 M sucrose, 1 mM EDTA, 20 
mM HEPES-NaOH (PH 7.4)) was adapted from Yang et al., 1997 and Zhang et al., 
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1998 and was iso-osmotic to aid effective cell disruption and maintain organelle 
viability during homogenisation. 
~everal methods are commonly used to homogenise cells including manual grinding, 
mechanical disruption and liquid homogenization and selected methods are listed in 
table 3.2. I trianed four methods of homogenisation to ascertain a practical and 
reproducible technique for the complete breakage of outer cellular membrane 
without compromise to internal organelles. These included Potter-Elvehjem 
homogenisation, narrow bore syringe needle, sonication and freeze/thaw techniques. 
The homogenisation method also incorporated a post-nuclear spin (PNS) 
immediately after homogenisation. This step pelleted cellular debris and nuclei 
which prevented DNA leakage and aggregation during ultracentrifugation (Graham 
and Rickwood, 1996). 
The freeze/thaw technique was tested first using both the LD9 and 5MB-PS cell 
lines; however this did not cause sufficient lysis of the cells. This was determined at 
the first centrifugation step where the PNS is separated from cellular debris and free 
nuclei. The PNS did not contain any organelles as validated by Western blotting and 
therefore the conclusion was that whole cells rather than just cellular debris and free 
nuclei were pelleted at this stage (data not shown). 
The second homogenisation technique investigated was passage of the cell 
suspension through a narrow bore syringe. Aspiration and ejection through a narrow 
orifice causes shearing of cellular membranes and the release of internal organelles. 
A range of gauges from 16 to 24 gauge were tested, however, this technique also 
proved to be inefficient at cell disruption for both LD9 and 5MB-PS cells. 
Observations made by Western blotting of organelles indicated that it was more 
efficient than freeze/thawing but the majority of cells remained intact and were 
pelleted out of the PNS (data not shown). 
Liquid based homogenisations are commonly used to disrupt tissue culture cells in 
small volumes of buffer. Cells are lysed by forcing the cell suspension through a 
narrow opening which causes shearing of cellular membranes. Dounce homogenisers 
and Potter-Elvehjem homogenisers consist of glass or PTFE pestles respectively, 
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Shearing Method 
Dounce homogeniser 
Potter-Elvehjem homogcniser 
Syringe needle 
Cell Cracker 
Stansted Cell Disruptor 
Nitrogen cavitation 
Sonication 
FreezelThaw 
Detalls 
Liquid shear with a round glass pestle 
Liquid shear with a PTFE pestle 
Aspiration and ejection 
Ball bearing homogeniser 
High pressure 
Rapid loss of pressure causes dissolved gas to form bubbles 
Pulsed high frequency sound waves 
Lysis by cyclic formation of ice crystals 
Table 3.2: Tbe principal teclmigues used for etJedive and emcient cell 
disruption. 
Table lists the techniques used to physically lyse cells and the details on how this is 
performed. 
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which are manually or mechanically forced into a glass tube. I selected a tight fitting 
manual Potter-Elvehjem homogeniser with a volume of 2 ml because it was easily 
acquired. Figure 3.3 shows that there was an improvement on the previous attempted 
homogenisation techniques, freeze/thaw and passage through a narrow bore syringe. 
The main variable with a tight fitting Potter-Elvehjem homogeniser was the number 
of strokes required to shear (>90 %) of cells but without shearing the nuclear 
membrane and causing subsequent DNA aggregation within the sample. 
The homogenisation protocol in chapter 2 section 2.1.3.4 was used with the 
following alterations. One flask of LD9 cells was resuspended in 1.5 ml of 
homogenisation buffer with 1000 J11 homogenised by 5 strokes of the pestle. From 
this, 250 J11 was removed and stored on ice. The remaining 750 J11 was homogenised 
by a further 5 strokes of the pestle (total of 10 strokes) from which another 250 J11 
was removed and stored on ice. This was repeated to achieve a total number of 15 
and 20 strokes which resulted in homogenised samples ranging from 5, 10, 15 and 20 
strokes. Each sample was crudely fractionated by the following protocol: a post-
nuclear spin to pellet cellular debris was performed at 1000 g for 10 minutes; 
supernatant was collected and centrifuged at 3000 g for 10 minutes, generating a 
heavy mitochondrial fraction (HMF) pellet. Next, the supernatant was collected and 
further centrifuged at 15,000 g for 10 minutes to generate a light mitochondrial 
fraction (LMF) pellet. The supernatant from this was collected and centrifuged at 
100,000 g for 45 minutes in an ultracentrifuge which generated a microsomal pellet. 
Each pellet was retained on ice, dried and resuspended in 40 J11 of SOS PAGE 
loading buffer for subsequent Western blot analysis. Cell debris and nuclear pellet 
was also treated with DNase (5 J1g) / MgCh (0.25 M). Western blotting for organelle 
markers representing mitochondria (Bcl-2) and Golgi body (TCPl(23C» are shown 
in figure 3.3. In addition, sonication of the cell suspension was investigated 
incorporating a 5 second, 10 second or 15 second pulse to disrupt cellular 
membranes. Samples were also analysed by SDS PAGE and Western blotting to 
determine the homogenisation efficiency of sonication and compare against a Potter-
Elvehjem homogeniser. 
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A Mitochondrial marker Bcl-2 
5 strokes 10 strokes 15 strokes 20 strokes 
1 2 3 4 1 234 123 4 1 234 
28 28 28 
-
5 s sonic. 10 s sonic 15 s sonic 
1 234 1 234 1 234 
28 28 
B Golgi body marker TCPl(23C) 
5 strokes 10 strokes 15 strokes 20 strokes 
1 2 3 4 1 234 1 234 1 2 3 4 
62 62 62 
5 s sonic. 10 s onic 15 s sonic 
1 234 1 234 123 4 
-
62 62 
Figure 3.3: Analysis of homogenisation techniques by crude subcellular 
fractionation of LD9 cell . 
The above Western blot are divided into, (A) detection of mitochondrial marker 
Bcl-2 and, (B) detection of Golgi body marker TCPl(23C). For both A and B, they 
are subdivided into 7 different approaches to homogenise LD9 cells: 5, 10, 15 or 20 
strokes of the pestle and 5, 10 or 15 second () onication pulses. There are four 
samples from each tage of the crude ubcelluJar fractionation and are labelled as (1.) 
PNS pellet, (2.) HMF pellet (3 .) LMF pellet and (4.) microsomal pellet and are 
generated as described in the main text on page 13. Molecular weight, in kDa, is 
shown on the left hand ide of each Western blot. 
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Figure 3.3 illustrates the results of increasing the number of strokes of the pestle to 
release subcellular organelles, on two organelles, mitochondria and the Golgi body. 
Mitochondria is the most dense of the organelles studied and therefore I rationalised 
that if homogenisation was effective, mitochondria would be present in fractions 2 
(HMF) and fraction 3 (LMF) and absent in fraction 4 (microsomes). The Golgi body 
was also chosen because of the nature of the Golgi body to form stacks that are 
susceptible to shearing into indistinct microsomes. I believed that the Golgi body 
would be a good indicator of homogenisation force in relation to organelle viability. 
A number of conclusions can be drawn from the experiment outlined above and 
shown in figure 3.2. Firstly, as the number of pestle strokes increase, there is an 
increase in organelle shearing. This was interpreted from the observation of 
mitochondria in fraction 4 (microsomes) after 15 strokes. This is not true for 5 or 10 
strokes of the pestle where mitochondria is present only in fraction 2 (HMF) and 
fraction 3 (LMF) as expected. This suggests that the mitochondria have been sheared 
into smaller indistinct microsomes after 15 strokes. In section B of figure 3.3, the 
Golgi body blots were difficult to interpret as the organelle marker was detected 
throughout fractions 2 to 4, regardless of the number of strokes of the homogeniser. 
These observations were suggested to be because of the large number of Golgi body 
apparatus present in the LD9 cell line and therefore were particularly prone to 
shearing even under the minimal of forces. As discussed later this result is congruent 
with later observations on the subcellular fractionation ofLD9 cells (figure 3.6). 
Secondly, sonication appeared to be an aggressive form of homogenisation. This was 
demonstrated by the increased presence of mitochondria in fraction 4 (microsomes), 
which was evident even after only a 5 second sonication pulse. In addition, there was 
increased detection in organelle markers detected by the mitochondrial marker Bc1-2, 
after sonication, than when generally compared against the Potter-Elvehjem 
homogenisation method. This was presumed to be caused by the complete 
homogenisation of all membrane surfaces by sonication and therefore more organelle 
marker i.e. more Bcl-2 and TCPI(23C) was released and detected. In section B of 
figure 3.3, the effect of sonication on the Golgi body was similar to that on 
mitochondria. 
66 
From figure 3.3 I concluded that all future experiments would incorporate 10 strokes 
of a Potter-Elvehjem pestle, which was sufficient to disrupt cellular membranes but 
not too forceful as to shear open the nucleus or other organelle membranes. 
3.5 Optimisation of OptiPrepTM density gradient media for subcellular 
fractionation 
OptiPrepTM density gradient media is a 60 % sterile solution of iodixanol, 5,5'-[(2-
hydroxy-I-3 propanediyl)-bis(acetylamino)] bis [N,N' -bis(2,3dibydroxypropyl-2,4,6-
triiodo-l,3-benzenecarboxamide)] designed for the in vitro isolation of biological 
compartments by centrifugation. I required preparing an OptiPrep TM gradient that 
would separate the complete list of organelles associated with PrP conversion. 
Therefore I investigated a range of gradients, including 10-20 %, 15-25 %,20-30 % 
and 10-30 % iodixanol. These gradients covered a wide range of OptiPrepTM 
concentrations that could potentially be utilised to isolate any given subcellular 
organelle. 
One T75 flask of confluent LD9 cells was resuspended in 1 m1 homogenisation 
buffer and homogenised by 10 strokes of a Potter-Elvehjem pestle followed by a 
PNS spin of 1000 g for 10 minutes to pellet cellular debris. From a 50 % iodixanol 
working solution (OptiPrepTM diluted with homogenisation buffer), OptiprepTM 
solutions were made up to the previously indicated concentrations of iodixanol, 
including every 2.5 % between the highest and lowest concentrations of iodixanol. 
For example, 10 %, 12.5 %, 15 %, 17.5 % and 20 % iodixanol solutions were made 
up to form a 10-20 % gradient. For each concentration of iodixanol, 1000 J11 was 
placed in the ultracentrifuge tube, resulting in a total column volume of 5 ml. 
Discontinuous gradients were left at room temperature for 30 minutes to equilibrate 
into continuous gradients, after which 500 J11 (10 % of column volume) of LD9 PNS 
sample was loaded on top of each of the four gradients and ultracentrifuged at 
145,000 g for 4 hours. For each of the 4 gradients investigated, opaque layers of 
'banded' cellular material were observed and the distance from the top of the 
gradient was measured. Figure 3.4 is a schematic diagram indicating the recorded 
heights within the tubes of each of the bands. These opaque bands presumably 
represented different organeUes separated by OptiPrepTM gradient following 
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A B C D 
6.l (1) 5.7 (1) 
5.6 (1) 5.4 (1) 5.4 (2) 
5.2 (2) 5.2 (2) 5.0 (3) 5.0 (3) 
3.9 (2) 3.7 (3) 
3.2 (4) 3.3 (4) 3.0 (5) 
2.2 (3) 
0.l5 (4) 
10-20 % 15-25 % 20-30 Of. 10-300/. 
Figure 3.4: Diagrammatic representation of cellular material forming bands, 
within a density gradient post ultracentrifugation. 
Schematic representation of ultracentrifuge tubes whereby the black lines represent 
the location of opaque bands of cellular material within the density gradient. The 
values shown for each gradient are a measurement of distance (centimetres) from 
base of ultracentrifuge tube. Density gradient was recorded as a concentration of 
iodixanol from top of the tube to the base where in (A.) there was a 10-20 % 
gradient, (B.) 15-25 % gradient, (C.) 20-30 % gradient and, (D.) 10-30 % gradient. 
Sample was 500 J.11 of PNS supernatant from LD9 homogenate and was 
ultracentrifuged at 145,000 g for 4 hours prior to measurement of opaque bands 
within density gradient. 
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ultracentrifugation. From each organelle band, a 300 ..,1 sample was removed using a 
Hamilton 1000 ..,1 syringe, then precipitated and resuspended as per the protocol in 
chapter 2 (section 2.1.3.4) for preparation of gradient fractions prior to SDS PAGE 
and Western blot analysis. Samples from the 20-30 % gradient were not processed in 
this way due to the close proximity of the 3 opaque bands to each other, which made 
isolation without contamination, technically difficult (see figure 3.4 panel C). Figure 
3.5 shows the Western blot analyses of the subcellular fractions that were removed 
from each of the three gradients. Fraction I is at the top of the gradient and fraction 4 
is towards the bottom of the gradient. 
Figure 3.5 panel A illustrates the separation of lysosomes, mitochondria and Golgi 
body using the 10-20 % OptiPrepTM gradient as assessed by Western blotting using 
the antibodies LAMP2, Bcl-2 and TCPI(23C) respectively. Lysosomes were 
enriched in fraction 2 whereas mitochondria are mainly present in fraction 4. The 
Golgi body is distributed throughout fractions I to 4, however there appeared to be 
an increase in fraction 3 which maybe due to variable sample loading doing SDS-
PAGE. The schematic diagram in figure 3.4 section A clearly demonstrates good 
separation between each of the four fractions. 
Figure 3.5 panel B shows the Western blot of the separation of Iysosomes, 
mitochondria and Golgi body when using a 15-25 % OptiPrepTM gradient resulted in 
Iysosomes being represented in fraction I. The manipulation of the OptiPrep TM 
gradient concentration resulted in an enrichment of lysosomes in fraction I only, as 
of when using a 10-20 % OptiPrepTM gradient. Mitochondria were enriched in 
fraction 4 and the Golgi body have been co-purified in fractions 1,2 and 3. The shift 
in concentrations has resulted in mitochondria travelling further down through the 
gradient into concentrations of iodixanol that are too dense for Golgi body. 
Finally, upon testing a 10-30 % gradient resulted in an extra cellular fraction 
observed in the gradient (figure 3.5 panel D). Of these five fractions, lysosomes were 
enriched in fraction 2, whereas mitochondria whilst being detected in all fractions, 
were enriched in fraction 5. Golgi body on the other hand was present throughout 
fractions I to 4. In combination with figure 3.4 panel D, it appeared that the 
organeUes were less efficiently purified using this gradient when compared to the 10 
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A 10-20 % 
Lysosomes 
1 234 
B 15-25 % 
Lysosomes 
1 234 
c 10-30 % 
Mitochondria 
123 4 
28 
Mitochondria 
1 234 
28 
62 
62 
Golgi body 
1 234 
Golgi body 
1 234 
Lysosomes Mitochondria Golgi body 
12345 12345 12345 
98 28 62 
Figure 3.5: Analysis of subcellular fractionation of LD9 post nuclear 
supernatant by ultracentrifugation of different density gradients of iodixanol. 
The above Western blots are divided into, (A) 10-20 % gradient, (B) 15-25 % 
gradient and, (C.) 10-30 % gradient. For both A, Band C, they are subdivided into 3 
different Western blots probed by 3 different primary antibodies: lysosomal marker 
LAMP2 (11600), mitochondrial marker Bcl-2 (1 /1000) and Golgi body marker 
TCP1(23C) (112000) . There are four subcellular fractions from both the 10-20 % and 
the 15-25 % gradients and five subcellular fractions from the 10-30 % gradient. Each 
subcellular fractions represents the fraction removed from the gradient where 1 is 
nearest to the top of the gradient and 4 or 5 is nearest to the base of the gradient. 
Molecular weight, in kDa i shown on the left hand side of each Western blot. 
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-20 % gradient. Using this data I concluded that a 10-20 % gradient of iodixanol 
would provide the best conditions for the separation of lysosomes, mitochondria and 
Golgi body from the LD9 cell line as validated by Western blotting of these 
organelles. 
Having optimised the experimental conditions for subcellular fractionation, the 
protocol was repeated and resultant subcellular fractions were subjected to methanol 
precipitation. The precipitate was resuspended in a standard volume of dH20 prior to 
incorporation to the CFCA. To maximise the amount of organelles that could be 
added to the CFCA, multiple subcellular fractionations were centrifuged together and 
pooled prior to addition to the CFCA. A second approach to increase sample 
organelle concentration was to increase sample volume applied to each OptiPrepTM 
gradient i.e. from 500 III to 1000 Ill. However, the volume of the sample applied to 
each gradient should represent no more than 10 % of the total column volume. This 
is because large sample volumes can cause damage to the gradient and subsequently 
alter organelle movement through the gradient. Therefore, the column volume was 
increased from 6 ml to 12 ml which consequently meant that the centrifugal force 
would have to be increased to accommodate the increase in gradient length. This 
increase in column volume was calculated to represent an increase in centrifugal 
force to 225,000 g for a period of 8 hours (Graham and Rickwood, 1996). 
3.6 SubceHular fractionation of 5MB-PS and LD9 ceH Hoes 
Following extensive optimisation, the final method for subcellular fractionation 
entailed the cellular homogenisation of either LD9 or 5MB-PS cells in a Potter-
Elvehjem homogeniser. Cellular debris was pelleted at 1000 g for 10 minutes and 
1000 III of the supernatant added to the top of a continuous 10-20 % gradient. 
Ultracentrifugation in a Sorvall TH-641 rotor at 225,000 g for 8 hours separated the 
PNS by the unique density properties of each of the organelle types. The method is 
described in more detail in chapter 2 (section 2.1.3.4). The gradient had a total 
volume of 11 ml and after centrifugation, was separated into 500 JlI fractions. This 
volume was thought to be firstly, small enough to give adequate resolution to provide 
precise analysis on organelle distribution and secondly, large enough for 
reproducibility and ease of handling. Starting from the top of the gradient, 500 III 
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fractions were taken and numbered 1 to 22. Subcellular fractionation of LD9 and 
5MB-PS cell lines were assessed and validated by Western blot as shown by 
representative Western blots in figures 3.6 and 3.7, respectively. 
In figure 3.6, LD9 subcellular fractionation showed that the plasma membrane 
marker annexin-ll was detected predominately in fractions 1 to 5 at a density of 
1.040 glml. The observation of plasma membrane marker also present in fractions 19 
to 21 presumably reflects the presence of plasma membrane derived cellular debris. 
This is due to contamination of the PNS with cellular debris that became detached 
from the pellet at this stage. The lysosomal marker LAMP2 was detected in fractions 
3 to 7 between a density of 1.043 glml and 1.047 glml. The Golgi body marker 
TCPl(23C) was detected over a wide range of fractions covering densities of 1.046 
glml to 1.078 glml. The endoplasmic reticulum marker BiP on the other hand was 
detected from fraction 11 to 16 at densities of 1.073 glml to 1.085 glml. Finally, in 
fractions 15 to 22 the mitochondrial marker Bcl-2 was enriched, which covered 
densities of 1.081 glml to 1.139 glml. There was the detection of Bcl-2 in fractions 2 
to 5 which could represent shearing of the mitochondria into smaller less dense 
microsomes. Example Western blots of the subcellular fractionation of the LD9 cell 
line are shown in figure 3.6. 
Like the results with the LD9 cell organelle purification, 5MB-PS subcellular 
fractionation also showed that the plasma membrane from marker annexin-ll was 
also enriched at the top of the gradient in fractions 1 to 6 at a density of 1.040 glml. 
However, unlike LD9 cells, 5MB-PS lysosomes ranged from fraction 3 to 12, 
covering density of 1.04 glml to 1.079 glml. The Golgi body marker TCP1(23C) was 
detected in fractions 15 to 19, which had a density of 1.081 glml to 1.01 glml. 
Finally, the mitochondrial marker Bcl-2 was detected in fractions 16 to 22, which 
had densities of 1.085 glml to 1.139 glml. The presence of Bcl-2 at lower densities 
could be due to the shearing of large mitochondria during homogenisation, into a 
range of mitochondria-derived microsomes of different sizes and densities. Together, 
these results indicate that both LD9 and 5MB-PS cell lines can be homogenised and 
fractionated into distinct fractions of subcellular organelles. Example Western blots 
of the subcellular fractionation of the 5MB-PS cell1ine are shown in figure 3.8. 
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Figure 3.6: Enrichment of different LD9 organelles as determined by Western 
blotting detection of organelle specific proteins after subcellular fractlonation 
using an ultracentrifugation gradient. 
LD9 subcellular fractions were prepared as outlined in section 3.6. Fractions of equal 
volumes were methanol precipitated, separated on a 12 % bis tris SDS PAGE and 
blotted onto PVDF membrane for immunodetection to show organelle distribution 
through the gradient. Primary antibodies used were (A.) endoplasmic reticulum 
marker BiP. (B.) Golgi body marker TCPl(23C), (C.) plasma membrane marker 
annexin n. (D.) lysosomal marker LAMP2, (E.) mitochondrial marker Bc1-2. 
Molecular weight, in kDa, is shown on the left hand side of each Western blot. 
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Figure 3.6: Enrichment of different LD9 organelles as determined by Western 
blotting detection of organelle specific proteins after subcellular fractionation 
using an ultracentrifu2ation gradient. 
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Figure 3.7: Enrichment of dift'erent 5MB-PS organelles as determined by 
Western blotting detection of organelle spdc proteins after subgllular 
fractionation using an ultracentrifugation gradient. 
5MB-PS subcellular fractions were prepared as outlined in section 3.6. Fractions of 
equal volumes were methanol precipitated, separated on a 12 % bis tris SDS PAGE 
and blotted onto PVOF membrane for immunodetection to show organelle 
distribution through the gradient. Primary antibodies used were (A.) endoplasmic 
reticulum marker BiP, (8.) Golgi body marker TCP1(23C), (C.) plasma membrane 
marker annexin IT, (D.) lysosomal marker LAMP2, (E.) mitochondrial marker Bcl-2. 
Molecular weight, in leDa, is shown on the left hand side of each Western blot. 
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Figure 3.7: Enrichment of different 5MB-PS organelles as determined by 
Western blotting detection of organelle specific proteins after subcellular 
fractionation using an ultracentrifugation gradient. 
76 
Oensitometric analysis of these Western blots allowed for the data to be plotted on a 
bar chart to represent organelle distribution through the gradient. These are exhibited 
as figures 3.8 and 3.9 for LD9 and 5MB-PS organelle distribution, respectively, and 
represent a minimum of four repeats and in some cases a maximum of seven repeats. 
Figure 3.8 and 3.9 shows that most OrganelleS are distributed over a range of 
fractions; however there is a definite enrichment of each of the organelles detected. 
The LD9 Golgi body marker TCPI(23C) was detected throughout the gradient 
indicating a wide distribution of Golgi body densities. This was most likely due to 
the nature of fibroblasts to secrete protein fibres and as such have prominent Golgi 
body apparatus. The stacks of these Golgi body would be more prone to shearing 
during homogenisation and therefore the Golgi body would subsequently be rendered 
into various different sizes and densities. The converse can be seen with the detection 
of TCPI(23C) in 5MB-PS cells where this Golgi body marker was detected over a 
much narrower range of fractions. The 5MB-PS cell line is microglial in origin and is 
not specialised for high protein production and secretion like the L09 fibroblast cell 
line. 
3.7 Discussion 
In this chapter, I have demonstrated the enrichment of subcellular organelles from 
two different lines of cultured cells, L09 fibroblasts and 5MB-PS microglia. 
Moreover, I have provided a means to assay organelle distribution and provide 
samples for analysis in the CFCA. The impact of organelle supplementation on the 
conversion efficiency of different strains of mouse scrapie in the CFCA was assessed 
and this is discussed in detail in chapter 4. 
TSE susceptible cell lines are rare with only a few cell lines known to support a 
persistent TSE infection (see table 1.3). Cell lines used for subcellular fractionation 
were chosen based on a number of criteria, including species of origin, mouse scrapie 
strain susceptibility and availability. In previous studies the L-fibroblast cell line 
L929, was reported to be capable of replicating 22L, ME7 an RML prions (Vorberg 
et al., 2004). The L929 cell line has subsequently been cloned to alter its strain 
susceptibility to be permissive to RML prions (Mahal et al., 2007). 
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Figure 3.8: LD9 organelle distribution profile after subcellular fractionation by density gradient centrifugation. 
This figure illustrates the subcellular distribution of LD9 organelles through a 10 to 20 % density gradient after ultracentrifugation. The data are 
presented as percentage of organelle in each fraction from 1 (low density) to 22 (high density) including plasma membrane (blue), lysosomes 
(yellow), Golgi body (red), endoplasmic reticulum (purple) and mitochondria (green). 
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Figure 3.9: 5MB-PS organelle distribution profIle after subcellular fractionation by density gradient centrifugation. 
This figure illustrates the subcellular distribution of 5MB-PS organelles through a 10 to 20 % density gradient after ultracentrifugation. The data 
are presented as percentage of organelle in each fraction from 1 (low density) to 22 (high density) including plasma membrane (blue), lysosomes 
(yellow), Golgi body (red), endoplasmic reticulum (purple) and mitochondria (green). 
The new clone of L929 cell line was called LD9 and was susceptible to not only the 
RML strain but to ME7 and 22L prions. 
The LD9 cell line was procured from Or Sukhvir Mahal to supplement CFCA 
reactions seeded with the mouse scrapie strain ME7. The LD9 cell line was highly 
susceptible to ME7 mouse scrapie and was successfully included in the standard 
scrapie cell assay (SSCA) thus demonstrating that fibroblasts are a valid and valuable 
cell culture line to study TSE infectivity (Mahal et al., 2007). The SSCA consists of 
a panel of cell lines grown ex vivo that have different susceptibilities to different 
strains of mouse scrapie. The aim of this assay is to discriminate one strain of mouse 
scrapie from another within 2 weeks. In addition the SSCA can be used to understand 
strain variation and strain specific co-factors. 
A second cell line that met the selection criteria for the subcellular fractionation of a 
TSE susceptible cell line with the downstream application of incorporating fractions 
into in vitro refolding assays was the 5MB-PS cell line. This cell line was originally 
isolated from scrapie infected mouse brains and subsequently cured of TSE infection 
with pentosan polysulphate (Birkett et al., 2001). Historically, this cell line was one 
of the first cell lines to be grown ex vivo and established as a TSE susceptible cell 
line. The 5MB-PS cell line was only until recently revealed to be of microglial 
origin and is susceptible to a number of mouse scrapie strains including 22F, 79 A 
and 22C. This cell line was fractionated into endoplasmic reticulum, Golgi body, 
plasma membrane, lysosomes and mitochondria to supplement the CFCA seeded by , 
22F and 79A. 
Subcellular fractionation involves the separation of organelles into distinct fractions. 
The components of each of the fractions were determined using an array of 
antibodies that detect unique protein markers associated with each organelle. The 
murine L929 fibroblast cell line is commonly used in many different experiments out 
with TSE research. This provided a catalogue of publications to search for organelle 
markers that already have commercially available antibodies directed against them. 
An organelle detector sampler kit (BD Transduction Laboratories) contained an 
extensive list of antibodies that can be used for examining each organelle. Crucially, 
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the kit contained the endoplasmic reticulum antibody for BiP/GRP78, the plasma 
membrane antibody for annexin-II, and the mitochondrial antibody for Bcl-2, which 
all showed reactivity to the corresponding organelle markers after Western blotting 
of LD9 and 5MB-PS celllysates. The antibody for the Golgi body marker GM130 
and the antibody for the lysosomal marker LAMPl were investigated by reactivity 
on a Western blot; however no signal on exposure to photographic film was detected. 
Further investigation into antibodies directed against Golgi body markers led to the 
investigation using the antibodies GS28 (Stressgen Bioreagents), S8K (Abeam) and 
ERGIC53 (Alexis Biochemicals), with all three proving to be ineffective at detecting 
the Golgi body. Personal communication with Or Enrico Cancellotti however, 
confIrmed that the Golgi body marker TCPl(23C) was a reliable marker for 5MB-PS 
Golgi. This antibody was successful and I applied this antibody to detect Golgi body 
in the LD9 fibroblast cell line with success. After the failure of LAMPl to detect 
lysosomes, the antibodies for LAMP2 and cathepsin-D were studied for both LD9 
and 5MB-PS cell lines. Cathepsin-D was completely ineffective and did not give a 
positive identifIcation by Western blotting. The LAMP2 antibody on the other hand 
gave a positive identification of the LAMP2 protein in celllysates of both LD9 and 
5MB-PS cell lines. Unfortunately, this antibody has a degree of cross reactivity with 
a number of other proteins resulting in the detection of multiple bands on the blot. 
Finally, two antibodies were purchased to identify markers associated with 
endosomes. This organelle forms part of the endosomal pathway and has been 
implicated in TSE disease (Taraboulos et al., 1992). The cell Iysates were probed 
with the antibodies EEA-I (BD Transduction Laboratories) and RabS (Abcam) with 
both antibodies proving to be unsuccessful at detecting endosomes within cell 
lysates. This line of investigation into early endosomal markers was halted due to 
time and financial constraints. The selection of antibodies for the range of organelles 
selected at this stage was deemed to be sufficient for the analysis of crude subcellular 
fractionation. However, future work would include the isolation of early and late 
endosomes, amongst others, because of the possible involvement of the endocytic 
pathway in prion conversion (Borchelt et al., 1992, Beranger et al., 2002, 
Marijanovic et al., 2009). 
Homogenisation of cultured cells followed by subcellular fractionation by 
. ultracentrifugation using a density gradient media is an experimental approach for 
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the isolation of organelles based on their densities. Homogenisation combined with a 
low speed centrifugation step generated a post nuclear supematant that contained the 
cellular constituents. This cellular suspension was then applied to an OptiPrepTM 
gradient and centrifuged under high g forces to separate individual organelle 
components based on size and density. Fractions were collected from top to bottom 
and cellular constituents in each fraction were concentrated by methanol 
precipitation for separation by SDS PAGE. Western blotting onto PVDF membrane 
followed by immunodetection of organelle markers by relevant antibodies provided 
the means for analysis of organelle distribution. Western blots were evaluated by 
densitometric analysis to accurately predict the enrichment of a given organelle 
within the gradient. 
The first critical step in subcellular fractionation is the homogenisation of cellular 
material to release internal organelles from their compartments. Organelles include 
nuclei, mitochondria, Golgi body, lysosomes, early and late endosomes, 
peroxisomes, microsomes and the cytosol. The homogenisation step is critical to 
produce a homogenate that is a suspension of free and intact organelles. The forces 
applied to disrupt the cell membrane are required to be adequate to rupture the 
plasma membrane but not sufficient to break open organelle membranes. Several 
homogenisation procedures were trialled, with the Potter-Elvehjem homogeniser 
providing a manual and controllable procedure that generated reproducible levels of 
membrane disruption. The Potter-Elvehjem homogeniser offered greater stability and 
reproducibility during the downward strikes of the PTFE pestle than other attempted 
homogenisation methods. 
There are many subcellular ftactionation techniques that can be applied to separate 
organelles from a cellular homogenate. Typically, subcellular fractionation utilises 
density gradients that are coupled with centrifugation to efficiently separate 
organelles. However, this conventional method is not without its limits. Often 
different organelle groups share similar densities, which make separation into 
homogenous organelle populations problematic. 
Other subcellular fractionation methods have been previously described in the 
literature. Firstly, these include immunoisolation using antibodies to bind to 
82 
organelle specific antigens (Howell et al., 1988, Howell et al., 1989). The antibodies 
are tagged and purification is effected by binding the antibody to magnetic beads 
prior to retrieval. Secondly, organelles can be separated by the characteristic charge 
density associated with membrane bound particles (Heidrich and Dew, 1976). 
Different organelles display differences in the composition of charged surface 
molecules and when subjected to an electric current, will influence electrophoretic 
mobility. This method is known as free flow electrophoresis (FFE) and has been 
effectively used as a preparative technique in combination with other fractionation 
techniques (Marsh et al., 1987). FFE has since been modified to incorporate a 
density gradient that is separated by two electrodes and offers high resolution of 
charged organelles (Tulp et al., 1993). Both FFE and density gradient electrophoresis 
(DGE) have only been used successfully for organelles in the endosomal pathway. 
The current method of crude subcellular fractionation provided a method for 
producing fractions that have been enriched for different organelles. This method 
satisfied the aim: to analyse the effect of a range of fractions containing different 
constituents and correlate conversion efficiency with organelle distribution. The 
knowledge that further organelle purification is possible is something to consider for 
future experiments that would require more refined samples. 
The isolation of subcellular compartments provided enriched samples for input into 
the CFCA. It was hypothesised that some fractions would contain the necessary 
factors, proteinaceous or non-proteinaceous, to increase efficiency of PrpSc to 
convert rMoPrP to a PK-res isoform in vitro. The results on the addition of LD9 and 
5MB-PS fractions to the CFCA in the presence of different seeds is analysed and 
discussed in chapter 4. 
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4. The addition of subcellular fractions from TSE susceptible cell lines to the 
cell free conversion assay 
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4.1 Introduction 
The hypothesis of the project was to identify co-factors that interact with Prpc and/or 
PrpSc during prion conversion, which may provide a mechanism of strain 
differentiation. Subcellular fractionation of TSE susceptible cell lines, as described in 
chapter 3, provided enriched subcellular organelle samples for the analysis of co-
factors in the CFCA. It was hypothesised that subcellular fractions would provide the 
necessary co-factors required by different strains of mouse scrapie to convert rMoPrP 
to a PK-resistant isoform in an in vitro system. 
The CFCA is the primary assay used in this project to analyse samples for potential 
PrP conversion-enhancing properties. The assay was originally designed to use 35S_ 
labelled rPrP purified from cell culture as a substrate and entailed a 48 hour 
incubation with a PrpSc seed at 37°C (Kocisko et al., 1994). Over 48 hours, the PrpSc 
seed converts the rPrP substrate into a PK-resistant isoform. Treatment with 
proteinase-K generates a PK-resistant fragment that can be resolved using SDS 
PAGE and assessed by Western blotting. Previous publications on the CFCA have 
documented replication of the species barrier, strain properties and conversion 
efficiency of polymorphic variants ofPrP (Kocisko et al., 1995, Bessen et al., 1995, 
Bossers et al., 1997, Raymond et al., 1997, Bossers et al., 2000, Horiuchi et al., 
2000). 
Successful modifications to this assay involve incorporation of rMoPrP purified from 
bacteria and use of an incubation buffer that omits any denaturant (Kirby et al., 
2003). The rMoPrP contains the hamster epitope 3F4 (tetra-peptide: Met-Lys-His-
Met, between residues 109-112), which allows for the specific identification of 
protease-resistant isoforms of rMoPrP that have been converted by the murine SAF 
seed. These modifications make the assay more physiological and therefore a better 
in vitro model for prion conversion. This version of the CFCA was capable of 
mimicking the species barrier and in addition was also inhibited by Congo red 
analogues, a known inhibitor of PrP conversion (Kirby et al., 2003). Recently, the 
CFCA was used to study the effect of a novel ovine polymorphism that was 
associated with resistance to scrapie and BSE transmission (Kirby et al., 2006). The 
ovine PrP variant ARLl68Q was resistant to conversion in the CFCA, displaying 
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similar resistance characteristics to the resistance-associated ovine variant, ARR. The 
CFCA therefore represents an ideal model to analyse the effect of subcellular 
fractions from TSE susceptible cell lines on conversion. 
TSE susceptible cell lines offer a valuable resource for the in vitro analysis of 
potential prion co-factors. The cell lines LD9 and 5MB-PS form the basis for this 
project due to the unique characteristics of both cell lines. The cell line LD9 is of 
fibroblastic origin and has only recently been cloned from the L929 fibroblast cell 
line (Mahal et al., 2007). Mahal and co-workers described the successful 
incorporation of LD9 cells into the standard scrapie cell assay (SSCA) and 
demonstrated variability in susceptibility to different prion strains. The LD9 
fibroblast was derived from the L929 fibroblast cell line by serial cloning against 
RML infection. The LD9 cell line and other non-neuronal cell lines have proved to 
be surprisingly susceptible to prion infection and have added to the arsenal of cellular 
models of TSE infection. 
The 5MB cell line was derived by culturing, ex vivo, mouse brains infected with the 
mouse scrapie strain Chandler (Clarke and Haig, 1970). Subsequent cloning of the 
cell line produced cells that were stably TSE infected. The 5MB cell line has since 
been cured by incubation with pentosan sulphate (PS) and the cured cell line, 5MB-
PS, is susceptible to multiple strains of mouse scrapie (Birkett et al., 200 I, personal 
communication with Ruth Hennion). Table 1.3 illustrates the variety of mouse 
scrapie strains that can infect the 5MB-PS cell line in an acute or persistent manner. 
This brain derived cell line is selectively susceptible, depending on the strain of 
mouse scrapie and therefore was a suitable and relevant model to investigate for the 
presence of co-factors. 
4.2 Proteinase K Digest of Scrapie Associated Fibrils 
The CFCA requires a PrpSc seed to convert the rMo3F4PrP substrate into a PK-
resistant isoform. In this study I isolated scrapie associated fibrils from infected mice 
and this process required verification to determine the success of purification and 
validation of the identity of the scrapie strain. Scrapie associated fibrils for four 
different mouse scrapie strains (87V, ME7, 79 A and 22F) were isolated from 
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infected mouse brains by detergent separation and differential centrifugation as 
described in chapter 2 using methods described by Hope et al., (1986). The presence 
of PrpSc was confirmed by treatment of the sample with PK, which after Western 
blotting reveals the characteristic three bands associated with di-, mono- and 
unglycosylated Prprcs. Treatment with PK cleaves the N-terminus of PrpSc resulting 
in isoforms that are detectable by Western blotting with the PrP C-terminus antibody, 
8H4. Densitometric analysis yields the relative amount ofPrpSc as well as the ratio of 
diglycosylated to monglycosylated to unglycosylated for each mouse scrapie strain. 
Figure 4.1 shows the differential occupation ofglycosylation sites of 79A, ME7, 87V 
and 22F when compared against each other. Densitometric analysis of these allowed 
comparison of the relative proportions of the three glycosylation states for each of 
the four strains. Values are a percentage of the total PK -resistant core of PrpSc and 
are shown in table 4.1. The values for glycosylation states are consistent with 
previous publications (Somerville et al., 1997, Kuczius et al., 1998). 
4.3 Cell free conversion assay with difTerent mouse scrapie seeds 
The cell free conversion assay traditionally used the mouse scrapie strain 87V as a 
seed for which there are multiple publications illustrating the successful conversion 
ofrecombinant mouse PrP when using this strain (Kocisko et al., 1994, Wong et al., 
2001, Kirby et al., 2003, Eiden et al., 2006). In order to demonstrate that other 
strains could be used, SAF preparations for ME7, 79A and 22F were added to the 
CFCA at a PrpSc concentration of I J.1g/J.11. Figure 4.2 shows the different conversion 
efficiencies of four different mouse scrapie strains to convert recombinant mouse 
3F4 PrP (rM03F4PrP) to a PK-resistant isoform. Briefly, after rM03F4PrP was 
incubated with a mouse-adapted scrapie seed at 37°C for 24 hours, 19/20tiJ of the 
reaction volume was treated with PK (abbreviated to +PK) and the remaining 1I20tiJ 
was not treated (abbreviated to -PK). Proteins in both samples were resolved using 
SDS PAGE and assay products detected by Western blotting with the Syrian hamster 
antibody 3F4. Proteolytic treatment of the conversion reaction shows a - 17 kDa 
which represents the protease-resistant core of PrpSc• Densitometric analysis of the 
intensity of the bands representing +/- PK treated samples provided data on the 
amount of rM03F4PrP converted to a PK-resistant isoform by the particular strain of 
mouse scrapie tested (figure 4.2). Typically, 87V, ME7, 79A and 22F strains of 
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Figure 4.1: Proteina ociated fibrils for multiple 
strain. 
Scrapie as ociated fibril were i olated from crapie infected mouse brains and SAF 
preparation were treated with and without PK. ample were erially diluted and 
separated by D PAG. We tern blotting wa carried out by use of the murine 
prion antibody H4: (A 7V fibril treated with (+) and without (-) PK. Lane 1 and 
lane 2 ha e a 1I1Oth diluti n f the ample and lane 3 and lane 4 have 1I20th dilution 
of the ample. B) 79A fibril treated with (+) and without (-) PK. Lane I and lane 2 
have a 1/Sth dilution of the ample and lane 3 and lane 4 have 1110th dilution of the 
sample. () 7 fibril treated v ith (+) and without (-) PK. Lane 1 and lane 2 have a 
1I1Oth dilution of the ample and lane 3 and lane 4 ha e 1120th dilution of the ample. 
(D) 22F fibril treated with +) and without (-) PK. Lane I and lane 2 have a 1I4th 
dilution of the ample and lan and lane 4 ha e 11 th dilution of the ample. 
Diglycosylated Monoglycosylated Unglycosylated 
S7V 76% 20% 4% 
79A 19% 37% 34% 
ME7 35% 37% 21 % 
22F 51 % 32% 17% 
Table 4.1: Glycoform rado of different mouse scrapie isolates. 
The ratio of the three protease-resistant PrP glycoforms in four different strains of 
mouse scrapie. Data represents the mean relative proportions of di-, mono- and un-
glycosylated PrP as a percentage for 87V, 79A, ME7 and 22F. Total percentage of 
the glycoforms of87V and 22F equal 100 %, however 79A and ME7 equal 90 % and 
93 %, respectively. This is because 79A and ME7 have a protease-resistant isoform 
of lower molecular weight that corresponds to a truncated isoform of Prpsc. 
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A 87V SAF Seed B 79A SAF Seed 
Lane 2 3 4 Lane 2 3 4 
87V + + 79A + + 
PK + + PK + + 
28 28 
17 17 
14 14 
C ME7SAFSeed D 22F SAF Seed 
Lane 2 3 4 Lane 2 3 4 
ME7 + + 22F + + 
PK + + PK + + 
28 28 
17 17 
14 14 
Fi2;ure 4.2: Cell free conversion assay with four different mouse scrapie seeds. 
200 ng rMo3F4PrP with 1 Jlg of mouse adapted scrapie associated fibrils in 
conversion buffer for 24 hours at 37°C. From this, the reaction volume was divided 
into +PK sample (lane 4) and - PK sample (lane 3). Both samples were separated by 
SDS PAGE and assessed by Western blotting with the Syrian hamster antibody, 3F4. 
A control experiment involved the incubation of 200 ng rMo3F4PrP with no mouse 
scrapie associated fibrils in conversion buffer for 24 hours at 37 °C. This was done 
for four mouse adapted scrapie strains; CA) detection of 87V converted products CB) 
detection of 79A converted products CC) detection of ME7 converted products CD) 
detection of 22F converted products. 
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mouse scrapie convert 20 %, 18 %, 3.5 % and 2.5 % of the rMo3F4PrP substrate, 
respectively. 
4.4 Optimisation of the addition of exogenous material to the CFCA 
Subcellular fractionation of cells will inevitably release proteolytic enzymes that are 
used by the cell for various functions. In particular, lysosomes are organelles that 
contain the majority of cellular acid hydrolases that destroy engulfed foreign 
particles, excess proteins and damaged organelles (De Duve and Wattiaux, 1966, 
Holtzmann, 1989). In preliminary experiments the addition of total L09 cell 
homogenates to the CFCA degraded the recombinant PrP substrate as indicated by 
no signal on the membrane after Western blotting (data not shown). This was 
presumably due to the presence of proteases that had been released by lysosomes that 
were damaged during homogenisation. To counteract the effect of proteases in future 
analyses of subcellular fractions, serial dilution of the L09 cell homogenate 
established the level of dilution required prior to addition to the CFCA. At a 114000 
dilution there was a minimal degree of proteolytic activity within the sample. Figure 
4.3 shows the degradation effect of proteases when recombinant PrP was incubated 
with serial dilutions of L09 cell homogenate. To protect the CFCA substrate from 
proteases would require the inclusion of protease inhibitors in the subcellular 
fractions. However this was not possible due to the PK treatment included later on in 
the CFCA protocol. Analogous experiments involving the incubation of rMo3F4PrP 
with 5MB-PS homogenates suggested significantly lower levels of proteolytic 
activity (data not shown). 
To discount the effect of any endogenous PrP in these cell lines, I assessed Prpc 
content and distribution by Western blotting with an ant-PrP antibody (8H4, 
appendix 1). Assessment of PrP distribution against a rMoPrPWT control of known 
concentration showed that endogenous Prpc was negligible. 
4.5 Addition of exogenous material to the CFCA 
The subcellular fractionation of TSE susceptible cell lines provided samples that 
were added to the CFCA, for which conversion efficiency was monitored by 
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Figure 4.3: Incubation of recombinant mouse 3F4 PrP with LD9 celllysates. 
Incubation of 20 ng recombinant Mo3F4PrP with serial dilutions of LD9 cell lysate 
for 24 hours at 37 QC followed by SDS PAGE and Western blotting. Serial dilutions 
of celllysates comprise of 1/125 (lane 1), 11250 (lane 2), 11500 (lane 3), 1/1000 (lane 
4), 112000 (lane 5) and 1/4000 (lane 6) of one confluent T75 tissue culture flask of 
LD9 cells. Lane 7 shows 20 ng of rMo3F4PrP and lane 8 shows the absence of any 
rMo3F4PrP in a LD9 cell lysate. 
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densitometric analysis of Western blots. Due to the susceptibility ofTSE susceptible 
cell lines to specific prion strains, they were hypothesised to contain the necessary 
strain specific co-factors required for the conversion of Prpc to PrpSc. The L09 cell 
line is susceptible to ME7 infection and the 5MB-PS cell line is susceptible to 79A 
infection. The subcellular fractionation of L09 and 5MB-PS cell lines was covered 
in chapter 3, which describes the generation of fractions that were enriched for 
different organelle subsets. L09 subcellular fractions were initially added to the 
assay using ME7 as a seed. Figure 4.4 shows the effects of those different fractions 
of L09 had on conversion efficiencies in the CFCA. On each Western blot generated 
from CFCA experiments, control experiments were positioned in lanes 1 to 4 of the 
SOS PAGE gel. In lanes 1 and 2 was the negative control CFCA whereby the 
substrate, rMo3F4PrP, was incubated at 37 °C for 24 hours in the absence of a mouse 
scrapie seed. In lanes 3 and 4 was the positive control whereby the reaction was 
complete with substrate and seed but in the absence of any subcellular fraction. Lane 
4 contained the +PK sample of one assay and demonstrated the amount of conversion 
i.e. the - 17 kDa band, that was anticipated when in the absence of any subcellular 
fractions. Upon the addition of L09 subcellular fractions to the CFCA, the 
conversion efficiency of ME7 in these new conditions was monitored by comparing 
against the positive control PK-resistant product in lane 4. To aid in this comparison, 
the samples were arranged in adjacent lanes of the gel prior to SOS PAGE. 
4.5.1 Addition of LD9 subcellular material to the CFCA seeded with ME7 
In figure 4.4 (panels A to E) the effect of the addition of L09 fractions 1 to 22 on the 
conversion of rMo3F4PrP by ME7 in the CFCA is shown. Panel A illustrates that 
upon the addition of L09 fractions 1 to 5, which are enriched for plasma membrane 
(figure 3.6), there is an increase in the amount of rMo3F4PrP converted to a PK-
resistant isoform (lanes 5 to 9) when compared against the positive control in lane 4. 
Panels B and C however, show the degradation of the rMo3F4PrP substrate by 
cellular proteases. This was deduced from the reduction in conversion followed by 
almost the complete absence of conversion, when in the presence of LD9 fractions 8 
to 13. However, more crucially, it was observed that the -PK samples exhibit bands 
that are either noticeably less dense or are absent. This clearly suggested that the 
substrate had been depleted and this was likely to be from the presence of cellular 
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Figure 4.4: The addition of LD9 subcellular fractions to the CFCA that was 
seeded with ME'. 
200 ng rM03F4PrP was incubated with 1 JIg ME7 scrapie associated fibrils in 
conversion buffer for 24 hours at 37°C. From this, the reaction volume was divided 
into +PK sample (lane 3) and -PK sample (lane 4). Both samples were assayed by 
separation on SOS PAGE and assay products detected by Western blotting and 
probing with Syrian hamster antibody 3F4. 
(A) The CFCA was supplemented with L09 fractions 1 to 5 for which +PK and -PK 
samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 1-5) and the corresponding samples that were not treated with PK 
are in lanes 10 - 14 (fractions 1-5). 
(8) The CFCA was supplemented with L09 fractions 6 to 10 for which +PK and-
PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 6-10) and the corresponding samples that were not treated with 
PK are in lanes 10-14 (fractions 6-10). 
(C) The CFCA was supplemented with LD9 fractions 11 to 15 for which +PK and-
PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 11-15) and the corresponding samples that were not treated with 
PK are in lanes 10-14 (fractions 11-15). 
(D) The CFCA was supplemented with LD9 fractions 16 to 20 for which +PK and-
PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 16-20) and the corresponding samples that were not treated with 
PK are in lanes 10-14 (fractions 16-20). 
(E) The CFCA was supplemented with LD9 fractions 21 and 22 for which +PK and -
PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5 and 6 (fractions 21 and 22) and the corresponding samples that were not 
treated with PK are in lanes 7 and 8 (fractions 21 and 22). 
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Figure 4.4: The addition of LD9 subcellular fractions to the CFCA that was 
seeded with ME7. 
95 
proteases in subcellular fractions 8 to 13. To observe the effect ofLD9 fractions 7 to 
13 on the conversion efficiency of ME7 required the dilution of these fractions to a 
point where protease activity was negligible. Earlier in this chapter, under 
optimisation of the addition of exogenous material (section 4.4), the presence of 
proteases in subcellular fractions was discussed. To achieve sufficient dilution of 
proteases within a cell lysate required a minimum dilution of 112000. Subcellular 
fractions are already diluted by approximately 1110 during homogenisation and 
fractionation and therefore only a further 11200 was required to achieve a suitable 
protease activity dilution. These fractions were diluted appropriately in dH20 prior to 
addition to the CFCA and the results are illustrated in figure 4.5. These data at the 
dilutions used indicate that the rM03F4PrP substrate was not degraded by cellular 
proteases. Conversion efficiency of ME7 in the presence of LD9 fractions 8 to 13 
were slightly reduced when compared to the positive control. This could be due to an 
inhibitory effect of factors within these fractions, however it is also possible that 
residual proteolytic activity is still present in the LD9 fractions added. 
In panels D and E (figure 4.4) are the subcellular fractions 16-20 and 21-22, from the 
LD9 cell line added to an ME7-seeded CFCA. Fractions 16 and 17 appeared to give 
a reduction in conversion efficiency however this could be attributed to the presence 
of pro teases. However, fractions 18 to 20 appear to have no discernible effect on the 
conversion efficiency ofME7. Finally, in panel E, the subcellular fractions 21 and 22 
were also added to the ME7 -seeded CFCA, which also showed no discernible effect 
on ME7 conversion efficiency. 
The CFCA experiments that were supplemented with LD9 fractions 1 to 22 were 
repeated four times and this allowed for the standard deviation and statistical 
significance to be calculated Densitometric analysis of the Western blots associated 
with the addition of LD9 subcellular fractions was presented in a bar chart format 
(figure 4.6) which allowed for easier analysis of the results. 
4.5.2 Addition of 5MB-PS subcellular material to the CFCA seeded with 79A 
In section 4.4 I have shown that the conversion efficiency of the ME7 strain of 
mouse scrapie was enhanced by low density subcellular fractions from the LD9 
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Figure 4.5: The addition of diluted LD9 subcellular fractions 8 to 13 to the 
CFCA that was seeded with ME7. 
200 ng rM03F4PrP was incubated with 1 ~g ME7 scrapIe associated fibrils in 
conversion buffer for 24 hours at 37 QC. From this, the reaction volume was divided 
into +PK sample (lane 3) and - PK sample (lane 4). Both samples were assayed by 
separation on SDS PAGE and assay products detected by Western blotting and 
probing with Syrian hamster antibody 3F4. (A) The CFCA was supplemented with 
LD9 fractions 7-11 for which +/-PK samples were taken from each of the five assays 
for treatment with and without PK, respectively. Samples treated with PK are in 
lanes 5-9 (fractions 7-11) and the corresponding samples that were not treated with 
PK are in lanes 10-13 (fractions 7-11). (B) The CFCA was supplemented with LD9 
fractions 12 and 13 for which +/-PK samples were taken from each of the five assays 
for treatment with and without PK, respectively. Samples treated with PK are in 
lanes 5 and 6 (fractions 12 and 13) and the corresponding samples that were not 
treated with PK are in lanes 7 and 8 (fractions 12 and 13). 
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Figure 4.6 Relative convenion percentage of ME' In the CFCA when In the 
presence of LD9 subcellular fractions 1 to 11. 
The ME7-seeded CFCA was supplemented with LD9 fractions 1 to 22 for which +1-
PK samples were taken. SDS PAGE and Western blotting of these samples with the 
Syrian hamster monoclonal antibody, 3F4, allows for densitometric measurements on 
conversion efficiency of ME7 in the presence of different subcellular fractions of the 
LD9 cell line. Relative conversion percentage in the presence of subcellular fractions 
was calculated using the control ME7 seeded CFCA without any subcellular 
fractions added as 100 % conversion. This is represented by a black line at 100 % 
relative conversion. Data points are displayed as a bar chart ± SEM with the 
percentage of total plasma membrane marker, annexin-II, in fractions 1 to 5 
indicated. A one-sample t-test was applied to compare the significance of the change 
in conversion percentage against 100 % conversion efficiency ofME7 in the absence 
of any added subcellular fractions (* represents a significant difference from the 
positive control). 
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Figure 4.7: Tbe addition ofSMB-PS subcellular fractions to tbe CFCA that was 
seeded witb 79A. 
200 ng rMo3F4PrP with 1 J,1g 79A scrapie associated fibrils in conversion buffer for 
24 hours at 37 °C. From this, the reaction volume was divided into +PK sample (lane 
3) and -PK sample (lane 4). Both samples were assayed by separation on SDS PAGE 
and assay products detected by Western blotting and probing with Syrian hamster 
antibody 3F4. 
(A) The CFCA was supplemented with 5MB-PS fractions 1 to 5 for which +PK and 
-PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 1-5) and the corresponding samples that were not treated with PK 
are in lanes 10-14 (fractions 1-5). 
(B) The CFCA was supplemented with 5MB-PS fractions 6 to 10 for which +PK and 
-PK samples were taken from each of the five assays. Samples treated with PK are in 
lanes 5-9 (fractions 6-10) and the corresponding samples that were not treated with 
PK are in lanes 10-14 (fractions 6-10). 
(C) The CFCA was supplemented with 5MB-PS fractions 11 to 15 for which +PK 
and -PK samples were taken from each of the five assays. Samples treated with PK 
are in lanes 5-9 (fractions 11-15) and the corresponding samples that were not treated 
with PK are in lanes 10-14 (fractions 11-15). 
(D) The CFCA was supplemented with 5MB-PS fractions 16 to 20 for which +PK 
and -PK samples were taken from each of the five assays. Samples treated with PK 
are in lanes 5-9 (fractions 16-20) and the corresponding samples that were not treated 
with PK are in lanes 10-14 (fractions 16-20). 
(E) The CFCA was supplemented with 5MB-PS fractions 21 and 22 for which +PK 
and -PK samples were taken from each of the five assays. Samples treated with PK 
are in lanes 5 and 6 (fractions 21 and 22) and the corresponding samples that were 
not treated with PK are in lanes 7 and 8 (fractions 21 and 22). 
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Figure 4.7: The addition of 5MB-PS subcellular fractions to the CFCA that was 
seeded with 79 A. 
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cell line. However, were these results repeatable using a different strain of mouse 
scrapie in the CFCA and a corresponding susceptible cell line, or would a different 
set of subcellular fractions enhance conversion? As shown in figure 4.2, the 79A 
strain of mouse scrapie converts rM03F4PrP in vitro into a PK-resistant isoform, 
albeit with low efficiency. To determine whether 5MB-PS cells contain 79A specific 
co-factors, 5MB-PS cells were fractionated into 22 fractions that were used to 
supplement CFCAs seeded with 79A (figure 4.7). Panels A to E show a 
representative series of Western blots demonstrating the effect of the addition of 
5MB-PS fractions 1 to 22 on conversion of rM03F4PrP by 79A in the CFCA. 
Densitometric analysis of these results highlighted that the inclusion of fractions 1 to 
5 to the CFCA caused a decrease in the conversion efficiency of 79A. This was 
repeated seven times and averaged densitometry values for this highlighted that for 
fraction 2 and 3 there was a significant reduction in conversion efficiency. This was 
in contrast to the previous result where ME7 conversion was increased by the 
addition of the equivalent fractions from LD9 cells. 5MB-PS fraction 8 and 9 on the 
other hand showed an enhancement on conversion efficiency of 79A in the CFCA, 
which proved to be significant (figure 4.8). The remaining fractions, 10 to 22 showed 
variable effects on conversion with fractions 11, 12, 15, 17 and 19 in particular 
showing a significant decrease in conversion efficiency. Densitometry values for 
fractions 6 to 22 were averaged from three replicate experiments. Densitometric 
values for fractions 6 to 11 was suggestive of a normal distribution profile for 
increasing conversion efficiency, with the apex of the distribution showing a 
significant increase in conversion by the addition of fractions 8 and 9. This normal 
distribution profile matches the distribution of Golgi body within the density gradient 
after subcellular fractionation ofa 5MB-PS homogenate (figure 3.9). 
Finally fractions 21 and 22 show an increase on conversion efficiency however this 
effect was not statistically significant after applying a one-sample t-test. Fractions 21 
and 22 contained a wide spectrum of constituents that ranged from cell debris to 
heavy mitochondria. This precipitate at the bottom of the ultracentrifuge tube is 
therefore likely to contain a variable range of conversion enhancing factors. The data 
from these two fractions are variable due to the differing amounts of precipitate 
present in each preparation which could not be controlled. 
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Figure 4.8 Reladve conversion percentage of 79A in the CFCA when in the 
presence of 5MB-PS subcellular fracdons 1 to 22. 
The 79A seeded CFCA was supplemented with 5MB-PS fractions 1 to 22 for which 
+/-PK samples were taken from each of the five assays for treatment with and 
without PK, respectively. SDS PAGE and Western blotting of these samples with the 
Syrian hamster monoclonal antibody, 3F4, allows for densitometric measurements on 
conversion efficiency of 79A in the presence of different subcellular fractions of the 
5MB-PS cell line. Relative conversion percentage in the presence of subcellular 
fractions was calculated using the control 79A seeded CFCA without any subcellular 
fractions added as 100 % conversion. This is represented by a black line at 100 % 
relative conversion. Data points are displayed as a bar chart ± SEM with the 
percentage of total Golgi body marker, TCPl(23C), in fractions 6 to 11 indicated .. A 
one-sample t-test was applied to compare the significance of the change in 
conversion percentage against 100 % conversion efficiency of 79A in the absence of 
any added subcellular fractions (* represents a significant difference against the 
positive control). 
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Figure 4.8: Relative convB"s1.on percentage of79A in the CFCA when in the presence of 5MB-PS subcellular fractions 1 to 2. 
4.6 Mass spedrometric analysis of LD9 low density subcellular fracdons 
The ME7 -seeded CFCA was supplemented with subcellular fractions from the ME7 
susceptible cell line LOO, for which fractions 1 to 5 (Plasma membrane enriched) 
enhanced ME7 conversion. Subcellular fractionation of the LOO cell line in a 10-20 
% OptiPrepTM gradient produced discrete fractions that were enriched for different 
compartments of the cell. The low density fractions which enhanced conversion were 
positive for the plasma membrane marker annexin-ll as assessed by Western blotting 
(figure 3.6). To validate the presence of the LOO plasma membrane-specific proteins 
in these fractions, samples were reduced and alkylated prior to trypsinisation and 
tryptic peptides were then processed for proteomic analysis by Q-ToF mass 
spectrometry . 
Mass spectrometric analysis of fraction 3 (highest enrichment of plasma membrane) 
from the subcellular fractionation of a LOO homogenate provided a list of 42 positive 
protein identifications as shown in table 4.2. Of these 42 protein identifications, there 
were 27 cytoplasmic proteins, 4 plasma membrane proteins, 4 secretory proteins, 3 
cytoskeleta1 proteins and one protein ID each from the mitochondrial, lysosomal and 
ribosomal proteins. There is an abundance of cytoplasmic proteins in LD9 fraction 3, 
however this fraction was originally believed to be enriched for plasma membrane as 
assessed by Western blotting (figure 3.6). It is known that plasma membrane proteins 
are problematic to analyse by mass spectrometry (Mirza et al., 2(07). Plasma 
membrane derived proteins interact with the lipid bilayer and as such have very 
strong hydrophobic and hydrophilic regions making them difficult to solubilise and 
analyse using this technique (Santoni et al., 2000). The protocol for mass 
spectrometry sample preparation that was used incorporates established techniques 
that increase plasma membrane protein extraction and solubilisation i.e. inclusion of 
a methanol precipitation step increases protein extraction from the lipid bilayer and 
solubilisation of the precipitate in a urea-ammonium bicarbonate buffer helps to 
solubilise more membrane associated proteins. Whilst these steps help to improve the 
detection of plasma membrane proteins using mass spectrometry, coverage is not 
always comprehensive. Nevertheless, the presence of at least four plasma membrane 
proteins suggests that there is LOO plasma membrane present in fraction 3. 
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Protein ID Gene ID Subcellular Location Peptides 
Actin. cytoplasmic I Actb Cytoplasm 20 
Tubulin alpha I b chain Tubalb Cytoplasm 12 
Tubulin beta le chain Tubb2c Microtubules 12 
Tubulin beta S chain TubbS Microtubules 3 
Heat shock cognate 71 kDa protein Hspa8 Cytoplasm 13 
Heat shock 70 kDa protein 4 Hspa4 Cytopalsm 2 
Heat shock protein HSP 9O-alpba beta Hsp9Oab1 Mitochondria 14 
Heat shock protein HSP 9O-aIpha Hsp90aaI Cytoplasm 3 
Peptidyl-prolyl cis-trans isomerise ppia Cytoplasm 4 
Pcroxircdoxin-6 Prdx6 Lysosome 4 
AJpba-enolase Eg433182 Cytoplasm 11 
Aspartate aminotrasferase Got I Cytoplasm 4 
Triosepbospbate isomerise Tpil Cytoplasm 7 
14-3-3 protein theta Ywbaq Cytoplasm 2 
14-3-3 protein zetaldelta Ywbaz Cytoplasm 7 
Isoform long of 14-3-3 protein beta/alpha Ywbab Cytoplasm 3 
Isofonn I of gelsolin Gm External matrix 6 
Isoform I of Rab GDP Gdi2 Plasma membrane 3 
Eukaryotic translation initiation factor 4b Eif4b Ribosomes 2 
D-3-pbospboglycerate debydrogenase Pbgdb ? 3 
Phosphoglycerate mutase Pgaml Cytoplasm 4 
Phosphoglycerate kinase I Pgkl Cytoplasm 7 
Glutathione Transferase omega-I Gstol Cytoplasm 3 
Famesyl pyropbospbate synthetase Fdps Cytoplasm 4 
Rho GDP-dissociation inhibitor I Arbgdia Cytoplasm 6 
Rho GDP-dissociatioD inhibitor 2 Arbgdib Cytoplasm 3 
AnnexinAI Anxal Plasma membrane 2 
AnnexinA3 Anxa3 Plasma membrane 2 
AnnexinAS AnxaS Extracellular matrix S 
Fascin Fscnl Cytoplasm 3 
Galectin-I Lgalsl Extracellular matrix 3 
Nucleoside diphosphate kinase B Nme2 Plasma membrane 2 
Glyceraldehyde-3-phospbate Gapdb Cytoplasm 4 
debydrogenase I 
Table 4.1: IdentUlgtiop of peptide! detested by mus spectrometric yalysis of 
LD9 fraCtiOD 3. 
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Protein ID Gene ID Subcellular Location Peptides 
Aldose reductase Akrlb3 Cytoplasm 4 
Ubiquitin-like modifier-activiating enzyme I Ubal Cytoplasm 4 
Alpha-actinin-4 Actn4 Cytoskeleton 2 
SerpinB6 Serpinb6a Cytoplasm 2 
GTP-binding nuclear protein Ran Ran Cytoplasm 2 
Lactoglutatbione lyase Glol Cytoplasm 2 
Malate dehydrogenase, cytoplasmic Mdhl Cytoplasm 3 
lsoform I of Sorcin Sri Cytoplasm 2 
Slit homolog 2 protein Slit2 Extracellular matrix. 2 
Table 4.2 continued: Identification of peptides detected by mass speetrometrlc 
analysis of LD9 fraction 3. 
List of protein identifications that were detected in a LD9 plasma membrane 
enriched fraction (fraction 3). A minimum of two peptide identifications by Mascot 
were required to confirm significant protein identification. 
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4.7 Specificity of low deDsity fractioDS to iDcrease cODvenioD emdeDCY OD 
tbeCFCA 
The results from the ME7-seeded CFCA experiments supplemented with low density 
subcellular fractions following the subcellular fractionation of the LD9 cell line, 
indicated that potential strain specific co-factors may be present (figure 4.4 and 
figure 4.6). To analyse the specificity of the low density subcellular fractions they 
were tested in the CFCA with the 79A strain of mouse scrapie. The 79A strain of 
mouse scrapie is unknown to cause infection in LD9 cell line or indeed the original 
L929 fibroblast cell line. 
Therefore, low density subcellular fractions (fractions 2 to 4) from the LOO cell line 
were used to supplement the CFCA seeded with the 79A strain of mouse scrapie 
(figure 4.9). The inclusion of LOO fraction 2 had no effect on the conversion 
efficiency of 79A. LOO fractions 3 and 4 caused an increase in the conversion as 
observed using Western blotting, however statistical analysis (following 
densitometric analysis) showed that this increase was not significant (figure 4.10). 
This data was acquired from only two replicates and therefore it is unknown if LOO 
low density subcellular fractions 3 and 4 were restricted to increasing ME7 
conversion in the CFCA. However, an alternative explanation of these results is that 
fraction 3 and 4 contain small quantities of LOO Golgi body which may have an 
effect on the conversion efficiency of 79A. If LOO fractions 5, 6 and 7 had of been 
tested then this may have strengthened this argument. Unfortunately, this experiment 
was not done due to time and SAF material constraints. 
To further understand the specificity of the effect LOO plasma membrane-enriched 
fractions have on ME7 conversion efficiency the ME7 seeded CFCA was 
supplemented with low density subcellular fractions from the 5MB-PS cell line. The 
5MB-PS cell line is not susceptible to ME7 infection, however the conversion 
efficiency of 79A in the CFCA was increased by the presence of 5MB-PS plasma 
membrane (figure 4.11). Densitometric analysis of the effect ofSMB-PS low density 
subcellular fractions 1 to 5 showed that 5MB-PS fractions 2 and 3 gave a significant 
increase in the conversion efficiency ofME7 (figure 4.12). 
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Figure 4.9: The addition of fractions 2 to 4 from a LD9 subcellular fractionation 
to the CFCA that was seeded with the mouse scrapie strain 79A. 
Cell free conversion assay involved the incubation of 200 ng rM03F4PrP with 1 Ilg 
79A scrapie associated fibrils in conversion buffer for 24 hours at 37 QC. From this, 
the reaction volume was divided into the +PK sample (lane 3) and the -PK sample 
(lane 4). Both samples were assayed by separation on SDS PAGE and assay products 
detected by Western blotting and probing with Syrian hamster antibody 3F4. The 
CFCA was supplemented with LD9 fractions 2 to 4 for which +I-PK samples were 
taken. Samples treated with PK are in lane 5 (fraction 2), lane 6 (fraction 3) and lane 
7 (fraction 4). The corresponding samples that were not treated with PK are in lane 8 
(fraction 2), lane 9 (fraction 3) and lane 10 (fraction 4). 
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Figure 4.10: Relative conversion percentage of 79A in the CFCA when in the 
presence of LD9 subcellular fractions 2 to 4. 
The 79A seeded CFCA was supplemented with LD9 fractions 2 to 4 for which +/-
PK samples were taken. SDS PAGE and Western blotting of these samples with the 
Syrian hamster monoclonal antibody, 3F4, allows for densitometric measurements on 
conversion efficiency of 79A in the presence of different subcellular fractions of the 
LD9 cell line. Relative conversion percentage in the presence of subcellular fractions 
was calculated using the control 79A seeded CFCA without any subcellular fractions 
added as 100 % conversion. This is represented by a black line at 100 % relative 
conversion. Data points are displayed as a bar chart ± SEM. A one-sample Hest was 
applied to compare the significance of the change in conversion percentage against 
100 % conversion efficiency of 79A in the absence of any added subcellular 
fractions. 
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Figure 4.11: The addition of low density fractions from a 5MB-PS subcellular 
fractionation to the CFCA that was seeded with the mouse scrapie strain ME7. 
200 ng rM03F4PrP was incubated with 1 J..lg ME7 scrapie associated fibrils in 
conversion buffer for 24 hours at 37 QC. From this, the reaction volume was divided 
into +PK sample (lane 3) and -PK sample (lane 4). Both samples were assayed by 
separation on SDS PAGE and assessed by Western blotting with the Syrian hamster 
antibody, 3F4. The CFCA was supplemented with 5MB-PS fractions 1 to 5 for 
which +/- PK samples were taken from each of the five assays for treatment with and 
without PK, respectively. Samples treated with PK are in lane 5 (fraction 1), lane 6 
(fraction 2), lane 7 (fraction 3), lane 8 (fraction 4) and lane 9 (fraction 5). The 
corresponding samples that were not treated with PK are in lane 8 (fraction 1), lane 9 
(fraction 2), lane 10 (fraction 3), lane 11 (fraction 4) and lane 12 (fraction 5). 
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Figure 4.12: Relative conversion percentage of ME7 in the CFCA when in the 
presence of 5MB-PS subcellular fractions 1 to 5. 
The ME7 seeded CFCA was supplemented with 5MB-PS fractions 1 to 5 for which 
+/- PK samples were taken. SDS PAGE and Western blotting of these samples with 
the Syrian hamster monoclonal antibody, 3F4, allows for densitometric 
measurements on conversion efficiency of ME7 in the presence of different 
subcellular fractions of the 5MB-PS cell line. Relative conversion efficiency in the 
presence of subcellular fractions was calculated using the control ME7 seeded CFCA 
without any subcellular fractions added as 100 % conversion. This is represented by 
a black line at 100 % relative conversion. Data points are displayed as a bar chart ± 
SEM. A one-sample Hest was applied to compare the significance of the change in 
conversion percentage against 100 % conversion efficiency of ME7 in the absence of 
any added subcellular fractions (* represents a significant difference against the 
positive control). 
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This experiment was repeated three times and fraction 2 and 3 gave relative 
conversion efficiencies of 173 % and 110 %, respectively. 
4.8 Dllution of plasma membrane enriched LD9 subcellular fractions 
The low density LD9 subcellular fractions, which are enriched for plasma membrane 
and cause an increase in ME7 conversion efficiency, were serially diluted and 
conversion efficiency monitored. This was to confirm that the effects of the LD9 
plasma membrane fractions can be diluted out. The effect was monitored using the 
CFCA and densitometric analysis of the resultant Western blots allowed for 
comparison of serial dilutions. Undiluted fractions 2 and 3 resulted in the 
characteristic increase in ME7 conversion efficiency, however fraction 4 did not. 
This can be explained by experimental variability with this particular fractionation 
experiment containing less conversion inducing factors than previous separations. By 
diluting fraction 2 to 11200 and fraction 3 to 11100, the conversion increasing effect 
was greatly reduced, with conversion efficiencies returning to the same level as an 
unsupplemented ME7 CFCA (Figure 4.13). 
4.9 CFCA supplemented with glycogen 
I also hypothesised that the lipid bilayer of the plasma membrane could be acting as a 
scaffold molecule that sequesters rM03F4PrP and PrpSc and thereby encouraging 
conversion in a nonspecific manner. To replicate this in vitro, an alternative 
molecule, such as glycogen was supplemented into the CFCA. Globular units of 
glycogen are composed of a protein core, glycogenin, surrounded by glucose 
subunits (Rybicka, 1996). Glycogen is stored as granules in the cytoplasm of most 
cell types, including the liver, muscle and brain (Gruetter, 2003). 
Glycogen is a polysaccharide that was identified as a component of the TSE agent 
and was described as a non-proteinaceous scaffold (Appel et al., 1999, Dumpitak et 
al., 2005). panza and co-workers demonstrated that by use of an in vitro fibrilisation 
assay, glycogen accelerated the conformational change of a-monomeric rSHaPrP to a 
p..sheet rich fibril and co-aggregated with glycogen polymers (SlOhr et al., 2(08). 
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Figure 4.13: The effect of serial dilution of LD9 fractions 2 to 4 on the 
conversion efficiency of ME7 in vitro. 
The ME? seeded CFCA was supplemented with serial dilutions ofLD9 fractions 2 to 
4 for which +/-PK sample were taken from each of the five assays for treatment 
with and without PK, respectively. SDS PAGE and Western blotting of these 
samples with the Syrian hamster monoclonal antibody, 3F4, allows for densitometric 
measurements on conver ion efficiency of ME? in the presence of serial dilutions of 
subcellular fraction 2 to 4 of the LD9 cell line. Relative conversion percentage in 
the presence of subcellular fractions was calculated using the control ME? seeded 
CFCA without any subcellular fractions added as 100 % conversion. This is 
represented by a black line at 100 % relative conversion. Data points are displayed as 
a bar chart ± SEM. 
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Glycogen was therefore believed to play an important role in the conversion of Prpc 
to the disease related isofonn, PrpSc. 
Glycogen (Fluka) was added to the CFCA and the effect on ME7-seeded conversion 
determined. Glycogen was re-suspended in dH20 to a concentration of 100 mglml 
and serial dilutions made to give the required final concentration of glycogen in a 
CFCA reaction mixture. To the CFCA, 7 JolI of glycogen at various concentrations 
were added to make up the final volume to 20 Joll. The CFCA constituents are 
described in detail in the methods chapter. Initially, serial dilutions from 1 mglml to 
0.0625 mglml final concentration of glycogen were added to the CFCA. Samples 
were taken for -/+ proteinase K treatment and analysis was carried out by separation 
by SDS PAGE and Western blotting. Figure 4.14 shows that at low concentrations of 
glycogen, ME7 conversion of rMo3F4PrP was inhibited. As glycogen concentration 
increases up to I mglml there is an increase in relative conversion efficiency of ME7 
in the CFCA to a maximum of 124 %, as determined using densitometry. 
To further understand and validate this result the experiment was repeated, covering 
a greater range of concentrations. Serial dilutions from 4 mglml to 0.03125 mglml 
were made and added to the CFCA in duplicate and the effect on ME7 conversion 
efficiency was determined (figure 4.15). Similar results were obtained and suggested 
that at very low concentrations of glycogen there was no discernible effect. However, 
as glycogen concentration gradually increased, the initial observation was inhibition 
of conversion at a 0.125 mglml glycogen concentration. As glycogen concentration 
increased up to 4 mglml, inhibition of conversion was replaced with an enhancement 
whereby an increase to 130 % in the relative conversion efficiency was observed 
(lanes 12 to (4). 
From the data shown in figures 4.14 and 4.15, a trend appeared to be emerging; such 
that there was an inhibitory mechanism of conversion at lower concentrations of 
glycogen and an enhancing mechanism of conversion at higher concentrations. 
However, the exclusion of the -PK samples in the previous experiment (figure 4.15), 
made it difficult to analyse and quantify the significance of the result. 
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Fig;ure 4.14: The effect of glycogen (0.0625 mg/ml to 1 mg/mt) on the conversion 
of rM03F4PrP by ME7 in the CFCA. 
Cell free conversion assay involved the incubation of 200 ng rM03F4PrP with 1 Ilg 
ME7 scrapie associated fibrils in conversion buffer for 24 hours at 37°C. From this, 
the reaction volume was divided into +/-PK samples. Samples were as ayed by 
separation on SDS PAGE and assay products detected by Western blotting and 
probing with Syrian hamster antibody 3F4. The CFCA was supplemented with 
glycogen for which +/-PK samples were taken. Samples treated with PK are in lane 5 
(0.0625 mg/ml glycogen), lane 6 (0.125 mg/ml glycogen), lane 7 (0.25 mg/ml 
glycogen), lane 8 (0.5 mg/ml glycogen) and lane 9 (1 mg/ml glycogen). The 
corresponding samples that were not treated with PK are in lane 10 (0.0625 mg/ml 
glycogen), lane 11 (0.125 mg/ml glycogen), lane 12 (0.25 mg/ml glycogen), lane 13 
(0.5 mg/ml glycogen) and lane 14 (1 mg/ml glycogen). 
116 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Glycogen 
ME7 
--++++++++++ 
--+++++++++ + 
PK - + - + - + + + + + + + + + 
28 
17 
14 
Glycogen 0.03125 
(mglml) -----·.4 
Figure 4.15: The effect of glycogen (0.03125 mg/ml to 4 mg/ml) on the 
conversion of rM03F4PrP by ME7 in the CFCA 
Cell free conversion assay involved the incubation of 200 ng rM03F4PrP with 1 Ilg 
ME7 scrapie associated fibrils in conversion buffer for 24 hours at 37°C. From this, 
the reaction volume was divided into +/-PK samples. Samples were assayed by 
separation on SDS PAGE and assay products detected by Western blotting and 
probing with Syrian hamster antibody 3F4. The CFCA was supplemented with 
glycogen for which +/-PK samples were taken. Samples treated with PK are in lane 7 
(0.03125 mg/ml glycogen), lane 8 (0.0625 mg/ml glycogen), lane 9 (0.125 mg/ml 
glycogen), lane 10 (0.25 mg/ml glycogen), lane 11 (0.5 mg/ml glycogen), lane 12 (1 
mg/m) glycogen), lane 13 (2 mg/ml glycogen) and lane 14 (4 mg/ml glycogen). 
Control experiment to monitor the effect of 4 mg/ml glycogen on the misfolding of 
200 ng rM03F4PrP are shown in lane 1 (-PK sample) and lane 2 (+PK sample). 
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Therefore, a repeat experiment was done, in duplicate and covering a larger range of 
glycogen concentrations, from 0.03125 mglml to 32 mglml. By increasing the 
effective concentration of glycogen, a trend of the effect of glycogen on conversion 
may be revealed. 
Surprisingly, in these series of experiments the addition of glycogen to the ME7-
seeded CFCA did not replicate previous results on the conversion of rM03F4PrP to a 
PK-resistant isoform in the presence of glycogen (figure 4.16). In some of the 
experiments there was evidence of significant increases in conversion in lane 3 
(0.03125 mglml glycogen), lane 6 (0.25 mglml glycogen) and lane 10 (4 mglml 
glycogen) of figure 4.16 that demonstrated no discernable pattern. The corresponding 
-PK samples in lanes 14, 17 and 21 all demonstrated a significant loss ofrM03F4PrP 
from the sample. To explain the apparent stochastic nature of this result, it is possible 
that fibrilisation is also taking place and is working in conjunction with the seeded 
conversion of rM03F4PrP to produce another PK-resistant PrP isoform. In addition, 
if these anomalous results were excluded from figure 4.16 then a similar result would 
have been achieved as shown in figures 4.14 and 4.15. 
4.10 Discussion 
The CFCA is an in vitro assay that involves incubation of recombinant PrP, over-
expressed in bacteria, with SAP purified from the brains of TSE-infected animals. 
This reaction causes a proportion of recombinant PrP molecules to be converted to a 
protease-resistant isoform. The principal method of analysis of this reaction is to take 
a sample for treatment with proteinase K, separate by SDS PAGE, and assess by 
Western blotting. In these set of experiments, the substrate is recombinant mouse PrP 
and the SAF-seed is mouse derived scrapie. To detect only the newly converted 
rMoPrP molecules, the rMoPrP substrate has the 3F4 hamster epitope (109-112) 
engineered into it allowing specific detection by the monoclonal antibody 3F4 
(Kascsak et al., 1987, Rogers et al., 1991). Unlike the SAP-seed, the recombinant 
PrP substrate is unglycosylated and therefore only a single band is observed on the 
blot after immunodetection. Scrapie associated fibrils were isolated from scrapie 
infected mouse brains by detergent extraction and differential centrifugation. 
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Figure 4.16: The effect of glycogen (0.03125 mg/ml to 32 mg/mll on the 
conversion of rM03F4PrP by ME7 in the CFCA. 
Cell free conversion assay involved the incubation of 200 ng rM03F4PrP with 1 flg 
ME7 scrapie associated fibrils in conversion buffer for 24 hours at 37 QC. From this, 
the reaction volume was divided into +/-PK samples. Samples were assayed by 
separation on SDS PAGE and assay products detected by Western blotting and 
probing with Syrian hamster antibody 3F4. The CFCA was supplemented with 
glycogen for which +/-PK samples were taken. Samples treated with PK are in lane 3 
(0.03125 mg/mt glycogen), lane 4 (0.0625 mg/mt glycogen), lane 5 (0.125 mg/ml 
glycogen), lane 6 (0.25 mg/ml glycogen), lane 7 (0.5 mg/ml glycogen), lane 8 (1 
mg/ml), lane 9 (2 mg/ml), lane 10 (4 mg/ml), lane II (8 mg/ml), lane 12 (16 mg/rnl) 
and lane 13 (32 mg/rnl). The corresponding samples that were not treated with PK 
are in section B, lanes 14 to 24. 
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Verification of the presence ofPrpSc was done by Western blotting after proteinase K 
digestion. As demonstrated in figure 4.1, proteinase K digests the N-terminus ofPrP 
leaving behind an undigested, proteinase-resistant C-terminal domain. Full length 
PrP&: can be either di-, mono- or un-glycosylated and therefore Western blotting 
reveals three bands for each type of glycoform of PrP. Proteinase K treatment causes 
each of the three bands to have an increased electromobility following SDS PAGE, 
due to the reduction in molecular weight of the protein. In addition, different strains 
of mouse derived scrapie have different glycoform ratios that are maintained across 
multiple passages in mice (Collinge et al., 1996). Glycoform ratios for four different 
TSE strains are summarised in table 4.1 demonstrating the differences in the 
percentages of PrP molecules that are either di-, mono- or un-glycosylated. 
Gycosylation profiles are believed to result as a consequence of the reaction between 
Prpc and PrpS«: and the selection by PrpS«: to preferentially convert only certain 
glycoforms ofPrpc (Vorberg and Priola, 2002). Glycoform selection by PrpS«: is also 
in part, determined by cell type and the differential expression of PrP glycoforms 
within that cell (DeArmond et al., 1997) and also by, the subcellular compartment 
that conversion of Prpc takes place (Jeffrey et al., 2OOS). 
The CFCA was originally designed with hamster derived scrapie strain 263K, which 
converted rHaPrP purified from cultured mouse fibroblast cells and radiolabelled 
with 3SS-methionine (Kocisko et al., 1994). This was subsequently modified to use 
bacterially recombinant untagged PrP that can be purified to give high yields that 
have no cellular contamination, unlike previous methods that use cell culture derived 
Prpc. In addition, the CFCA has been modified to be more physiological by 
removing the chaotrope guanidine hydrochloride from the conversion buffer. 
Typically other researchers have used the mouse scrapie strain 87V as a seed to 
catalyse the conversion of rMoPrP to a PK-resistant isoform. This strain of mouse 
scrapie is from a p7/p7 (108F/189V) mouse background and converts approximately 
20 % of the rMoPrP monomers. When I used ME7, 79A and 22F strains of mouse 
scrapie I found that they converted approximately 18%, 3.5 % and 2.5 % of the 
rM03F4PrP substrate, respectively. 
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I then supplemented the CFCA with different subcellular fractions, however any 
detrimental effects of the addition of cellular material was determined by the 
incubation of rMoPrP with LD9 cell homogenates. This was a mock CFCA 
experiment in the absence of any mouse scrapie seed and proteolytic digestion was 
observed (figure 4.3). Even at a 114000 dilution of LD9 homogenate, rMoPrP 
digestion was evident with complete digestion as low as a 1/250 dilution of the cell 
homogenate. 
Subcellular fractions of TSE susceptible cell lines were added to the CFCA and the 
effect on conversion efficiency monitored. The ME7-seeded CFCA was 
supplemented with subcellular fractions from the ME7 susceptible cell line, LD9. 
Supplementing with LD9 fractions I to 5 (enriched for plasma membrane) caused an 
increase in the conversion efficiency of ME7 in the CFCA where fractions 2 and 3 
were significantly different from the control ME7-seeded CFCA. The mouse scrapie 
strain ME7 converted approximately 18 % of the rMo3F4PrrP substrate into a PK-
resistant isoform. When supplemented with LD9 fractions 2 and 3, there was an 
increase to 36.7 % and 33.9 % ofrMo3F4PrP converted, respectively. From the LD9 
organelle distribution bar chart in figure 3.8, fractions 2 and 3 are enriched for 
plasma membrane. The positive effect of plasma membrane on conversion efficiency 
was not surprising. This compartment of the cell has previously been suggested as 
the site of conversion in vivo, with many studies implicating plasma membrane in 
this process (Jeffrey et al., 1994, Kazlauskaite et al., 2002, Sanghera et al., 2002, 
Paquet et al., 2007). I rationalised that the increase in conversion efficiency of ME7 
was because of a potential influx of specific co-factors into the CFCA by the addition 
of these particular fractions. 
Mass spectrometric analysis of LD9 fraction 3 suggested that it was principally 
composed of cytoplasmic proteins, rather than plasma membrane proteins (table 4.2). 
The predominance of cytoplasmic proteins in LD9 fraction 3 may not be an accurate 
representation of the proteins present as plasma membrane proteins are particularly 
difficult to separate from the lipid bilayer due to strong hydrophobic and hydrophilic 
regions within the protein (Santoni et al., 2000). In addition to difficulties in 
delipidation of plasma membrane bound proteins, solubilisation is greatly reduced 
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due to the inherent properties of these membrane-bound proteins. To improve the 
detection of these proteins, specific steps were included in the sample preparation to 
counteract these problems (Mirza et al., 2007). Firstly, the low density subcellular 
fractions were treated with methanol to extract the proteins from the lipid bilayer. 
Secondly, proteins were centrifuged to concentrate the sample prior to resuspension 
in 4 M urea, 100 mM ammonium bicarbonate solution which was done to increase 
the solubility of plasma membrane proteins prior to tryptic digestion. Unfortunately, 
this did not appear to give a result that supported the annexin-IT Western blot, which 
showed the enrichment of the plasma membrane in these fractions. However, I 
believe that the steps taken to increase plasma membrane extraction and 
solubilisation were not as successful as hoped. In addition, during subcellular 
fractionation the cytoplasmic proteins should be solubilised in the homogenisation 
buffer which theoretically should remain at the very top of the gradient. This was 
evident as there was an interface observed after ultra centrifugation between the 
homogenisation buffer and the OptiPrepTM gradient. The small volume of 
homogenisation buffer was consistently removed in the first fraction and therefore 
the constituents of the cytoplasm should only be present in fraction 1. An explanation 
for the presence of cytoplasmic proteins in fraction 3 could be the result of sample 
overloading causing disruptions to the gradient. Alternatively, the loss of plasma 
membrane proteins in the sample would give an artificially high reading for other 
proteins that were also present. In this case, the mass spectrometry would and did 
identify many peptides originating from cytoplasmic proteins. 
If fraction 3 was enriched for plasma membrane then the effect on ME7 conversion 
in the CFCA could have been a generalised association between Prpc and / or Prp5e 
with the lipid bilayer acting as a scaffold for conversion. Fractions 6 to 22, from the 
subcellular fractionation of the LD9 cell line, were enriched for organelles such as 
lysosomes, Golgi body, endoplasmic reticulum and mitochondria and gave no 
enhancement to ME7 conversion efficiency (figure 4.4). Fractions 7 to 13 were 
contaminated with proteolytic enzymes and therefore these fractions were diluted a 
further 11200, prior to adding into the CFCA (figure 4.5). Any potential co-factors in 
these fractions were diluted along with the proteases which resulted in conversion 
similar to that of the CFCA positive control reaction. 
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The CFCA was repeated using the 79A strain of mouse scrapie and supplemented 
with subcellular organelles purified from the cell line 5MB-PS, which is susceptible 
to 79A (figure 4.7). Supplementing the 79A CFCA with 5MB-PS low density 
subcellular fractions 1 to 5, did not result in a significant increase in the conversion 
of rMo3F4PrP into a PK-resistant isoform. However, fractions 8 and 9 were 
significantly different than the control reaction and showed an increase in the 
conversion efficiency of 79A. The conversion percentage values in figure 4.8 for 
5MB-PS subcellular fractions 7 to 10 follow the normal distribution profile of Golgi 
body (see figure 3.9). The mouse derived scrapie strain 79A is very inefficient at 
converting rMo3F4PrP in the CFCA and only 3.5 % is converted to the PK-resistant 
isoform. However, in the presence of 5MB-PS subcellular fractions enriched for 
Golgi body, there was a significant increase to 5.7 % ofrMo3F4PrP being converted 
by 79A. The fractions 12, 13, 15, 17 and 19 gave significant reductions in conv~ion 
efficiency suggesting that there may be factors that inhibit the conversion process of 
rMo3F4PrP. The addition of fraction 22 to the 79A seeded CFCA resulted in a 
significant increase in conversion. This fraction represents the base of the OptiPrepTM 
10-20 % gradient and as such will contain cellular debris that escaped the PNS spin 
as well as any dense organelles that have sedimented. It is therefore difficult to 
ascertain the contents of this fraction. To assess this, I could have used a different 
gradient that extends to 25 % or 30 % OptiPrepTM, which would separate out the 
constituents of fraction 22 from the 10-20 % gradient. 
To determine strain specificity of L09 plasma membrane enriched subcellular 
fractions, they were tested in the CFCA seeded by 79A, which was unknown to 
infect L09 cells. The L09 fractions 4 and 5 increased conversion of rMo3F4PrP into 
a PK-resistant isoform, however this was not significant (figure 4.10). Therefore, the 
observed effect of L09 subcellular fractions enriched for plasma membrane may not 
be strain specific because the enhancement is regardless of cell line susceptibility. To 
understand this result it was hypothesised that the presence of plasma membrane in 
the CFCA presented an increase in surface area thereby· increasing the number of 
interactions between rMo3F4PrP and the mouse scrapie seed. 
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To determine whether the increases in conversion efficiency observed for two 
different strains of mouse scrapie were not just cell line specific, the CFCA was used 
with a different cell line. The CFCA seeded with ME7 was supplemented with the 
corresponding 5MB-PS subcellular fractions enriched for plasma membrane. 5MB-
PS cells are not susceptible to infection by ME7; however 5MB-PS low density 
subcellular fractions significantly enhanced the amount of conversion over th~ 
control experiment (figure 4.12). This re-enforced the hypothesis that the presence of 
plasma membrane in the CFCA was an enhancement caused by an increase in the 
surface area. An experiment to answer this was to create artificial lipid membranes 
composed of cholesterol and sphingolipid. These membranes have previously been 
demonstrated to interact strongly with Prpc (Sanghera et al., 2002, Critchley et al., 
2004). These membranes do not contain any contaminants such as proteins or 
carbohydrates that are present in cellular membranes. Unfortunately, time and 
financial constraints prevented the purchase of these lipids; future experiments would 
incorporate this as a control experiment to determine the role of a lipid bilayer in 
conversion. 
I therefore rationalised that glycogen, a high molecular weight polymer, may also 
behave as a non-specific scaffold within the CFCA and provide comparative data. 
Firstly, it was proposed that glycogen was an important polysaccharide scaffold that 
was incorporated into amyloid fibrils in vivo (Dumpitak et al., 2005). Panza and co-
workers also demonstrated that the fibrilisation of rSHaPrP into amyloid fibrils was 
accelerated when in the presence of glycogen (2008). The assay used was similar to 
the CFCA, as the conversion buffer used low concentrations of detergent and salts 
(StOhr et al., 2007). Therefore, serial dilutions of glycogen were added to an ME7 
seeded CFCA to determine any potential effects glycogen may have on ME7 
conversion efficiency. Results initially appeared to indicate that at concentrations of 
approximately 0.0625 mglml to 0.25 mglml glycogen, ME7 conversion was 
inhibited. As the concentration of glycogen increased to the maximum of 4 mglml 
there was a steady increase in PrP conversion resulting in a net increase over the 
conversion efficiency of the positive control. To validate this result, an experiment 
was setup to analyse the effects of a broad range of glycogen concentrations 
(0.03125 mglml to 32 mglml glycogen) would have on conversion efficiency in the 
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CFCA. Unfortunately, on further repeats, variable and inconsistent results were 
achieved and this may require future examination to clarify the role of glycogen in 
conversIon. 
It is possible that a competing reaction, such as fibrilisation of rM03F4PrP was 
occurring during incubation of the CFCA. Previous studies have demonstrated that 
glycogen accelerates and enhances the fibrilisation pathway of rPrP and hence it is 
possible that this is occurring in conjunction with conversion in the CFCA. This was 
suggested by observations in figure 4.16 panel A (lane 3, 6 and 10) where there is an 
apparent doubling in the amount of rMoPrP converted to a PK-resistant isoform. 
However, this appeared to be happening stochastically, regardless of glycogen 
concentration. This result was replicated and not in the same pattern, in the duplicate 
set of assays setup at the same time as those shown in figure 4.16. If conversion of 
rMoPrP by ME7 was the only reaction then you would expect to see either a gradual 
change in conversion efficiencies with glycogen concentration; or no effect on 
conversion efficiency at all. The fibrilisation process appears to be a random process 
with subtle changes in the reaction mixture and/or environment responsible for this 
reaction to occur. Therefore, these experiments were stopped based on the 
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assumption that fibrilisation occurs by an uncontrollable process and was responsible 
for the prevention of measuring the effect glycogen had on rM03F4PrP in the CFCA. 
To summarise, the CFCA provided the means to study the effect of subcellular 
fractions from TSE susceptible cell lines on the conversion of rM03F4PrP in the 
presence of a mouse scrapie seed. Low density subcellular fractions from the 
fibroblastic cell line LD9, provided a nonspecific enhancement of rM03F4PrP 
conversion when in the presence of either ME7 or 79A. The strain 79A does not 
infect the LD9 cell line and therefore this cell line should not contain any strain 
specific co-factors, if the original hypothesis is correct. On the other hand, Golgi 
body enriched fractions from the 79A susceptible cell line 5MB-PS, enhanced 
conversion of rM03F4PrP to a PK-resistant isoform when in the presence of the 
mouse scrapie strain 79A. Unfortunately, these fractions were not tested in the CFCA 
experiment seeded by the ME7 strain of mouse scrapie due to shortages of infectious 
materiaL 
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s. Proteomic determination of molecules co-purifying with Prre in scrapie 
associated fibrils from different strains of mouse-passaged scrapie 
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S.l Introduction 
Chapter 4 described the identification of subcellular fractions from TSE susceptible 
cell lines that enhanced the conversion efficiency of recombinant prion protein 
seeded with PrpSc from mouse adapted scrapie by means of the CFCA. Fractions 
enriched for plasma membrane from two cell lines increased conversion efficiency 
seeded by the mouse scrapie strain, ME7. The specific cell lines used were an ME7 
susceptible cell line (fibroblastic cell line, LD9) and a non-ME7 susceptible cell line 
(microglial cell line, 5MB-PS). 
PrPC is a conserved GPI anchored sialoglycoprotein that is constitutively expressed 
in all mammalian cells of the nervous system (Oesch et al., 1985, Stahl et al., 1987). 
Its secondary structure is composed predominately of a-helices and during prion 
disease there is a conformational change in the structure of Prpc to an isoform that is 
rich in ~-pleated sheet, PrpSc (Caughey et al., 19910). This change in structure results 
in PrpSc being insoluble and partially resistant to protease digestion. The disease 
associated isoform PrpSc is hypothesised to be the principle component of the 
infectious agent in TSEs and is reported to be responsible for the neurodegenerative 
outcome of the infection (Aguzzi et al., 2007). However, the molecular basis of the 
process by which Prpc is converted to PrpSc is still unknown. It is known that Prpc is 
required for disease because PrpOIO mice are resistant to prion infection (Bueler et al., 
1993). Accumulating evidence suggests that there are interactions between PrP and 
other molecules that are necessary for the conversion of Prpc to PrpSc to take place 
(Shyng et al., 1994, Telling et al., 1995, DebBurman et al., 1997, Wong et 01.,2001). 
It is assumed that PrpSc is the catalyst which imposes its conformation onto nascent 
Prpc causing the disease associated structural changes. Additional proteins or 
molecules in conversion could act as chaperones to assist in the refolding of Prpc 
(Jin et al., 2000, Samataro et al., 2004). Alternatively, these accessory molecules 
could form a scaffold that allows for the correct interaction between Prpc and PrpSc 
(Alper et al., 1967, Priola and Caughey, 1994, Adler et al., 2003, Deleault et al., 
2003). Therefore, there is the possibility that many accessory molecules or co-factors 
exist and they could differ depending on the prion strain. Different strains are 
reported to differ by protein conformation and their structural properties; therefore 
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this is likely to influence or be influenced by any interaction with a co-factor (Safar 
et al., 1998). 
During the conversion process, Prpc is conformationally altered to the structure of 
PrpSc and is likely to become bound to PrpSc during polymerisation of the amyloid 
fibrils, which are often observed in TSE infected brains (DeArmond et al., 1985). 
Since Prpc and PrpSc are believed to interact during conversion, any co-factors that 
mediate, direct or aid this interaction in any way may become integrated into the 
fibril. Therefore, characterisation of the constituents of the fibril may help to shed 
light on the identities of the co-factors involved. 
A variety of molecules have already been reported to interact with either Prpc and/or 
PrpSc and the majority of these have been identified through affinity binding 
experiments, such as cross-linking and co-immunoprecipitation with Prpc (for a 
review, see Aguzzi et al., 2008). In general, these experiments have only been 
applied to Prpc to understand and predict the function of Prpc. In addition to 
characterising Prpc function, the identification of interaction partners may give 
insights into co-factors that are necessary for PrpSc propagation. 
The experimental observation that there are co-factors necessary for prion conversion 
was initially published in 1995 by Telling and co-workers (Telling et al., 1995). The 
co-factor was referred to as protein X and its involvement was invoked to explain 
data on the transmission of human prions to transgenic mice expressing mouse, 
human or a mouse-human chimeric PrP. Results suggested that the binding site of 
protein X to Prpc was putatively located in the carboxyl terminus after experiments 
revealed that amino acid substitution at positions 167, 171, 214 and 218 prevented 
PrpSc formation (Perrier et al. 2002). However, the identity of protein X is still 
unknown, although many co-factors have been suggested. 
One of the factors suggested to be involved in prion conversion is an unknown 
cellular receptor for Prpc that is responsible for the internalisation of Prpc and PrpSc 
into the cell, via clathrin-coated pits (Sbyng et al., 1994, Sbyng et al., 1995, Reiger et 
al., 1997). A second molecular subtype that is known to associate with Prpc and is 
suggested to play an important role in conversion and prion formation is nucleic 
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acids. Experiments on the binding of nucleic acids to Prpc were shown to cause a 
conformational change in the protein to the p-sheet rich isoform. (Cordeiro et al., 
2001). Since these experiments, it has been proposed that RNA molecules 
specifically stimulate PrpSc formation in vitro (Deleault et al., 2003, Supattapone, 
2004). Another set of molecules that bind Prpc and are implicated in PrpSc formation 
are glycosaminoglycans (GAGs), such as heparan sulphate and pentosan 
polysulphate (Priola and Caughey, 1994, Wong et al., 2001). Interestingly, these 
same GAGs have inhibitory properties in scrapie-infected cells and animals (Adjou 
et al., 2003). The conflicting data from this study would suggest that extracellular 
GAGs may sequester Prpc from intracellular GAGs, thus preventing the correct 
interaction between Prpc and PrpSc. 
In this chapter, I outline work undertaken to identify protein species that make up 
SAF. The principle component of TSE-associated amyloid fibrils is PrpSc, however it 
was hypothesised that co-factors that are necessary for PrP conversion may become 
associated with amyloid fibrils during the conversion process. Comparison of SAF 
preparations from different strains of mouse scrapie may also reveal differences in 
fibril composition, which could indicate strain specific proteins. 
As discussed in chapter 4, L09 low density subcellular fractions enhanced the 
conversion efficiency of mouse scrapie in the CFCA. Mass spectrometry of a 
subcellular fraction enriched for LD9 plasma membrane provided a list of protein 
identifications with which to compare (Table 4.2). Mass spectrometric analysis of 
mouse scrapie associated fibrils isolated from TSE infected mouse brains was 
hypothesised to reveal the presence of plasma membrane derived proteins with which 
to compare against L09 subcellular fraction 3. The identity of non-PrP proteins 
associated with mouse scrapie would provide a list of potential interaction partners 
that are relevant to PrP conversion. 
Mass spectrometry is a technique that is used to identify both individual proteins 
contained within single bands isolated from SOS PAGE gels or to identify the 
proteins present within more complex samples. Samples for mass spectrometric 
analysis were pre-treated with trypsin, which acted at specific locations along the 
peptide backbone. Trypsin is a serine protease that hydrolyses the peptide backbone 
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at the carboxyl side of lysine or arginine unless a proline is the next amino acid in the 
peptide chain. Tryptic peptides were desalted and concentrated before separation 
using high pressure liquid chromatography (HPLC) and eluted into an electrospray 
ion source. Electrospray ionisation (ESij nebulised the HPLC elute into highly 
charged droplets, which were sprayed into the mass spectrometer. In this case, 
tandem MSIMS was used, which comprised of a quadrupole mass analyser that 
measured the mass-to-charge (mlz) ratio of the ionised peptides. Ions of a particular 
mlz ratio are selected before entering a collision cell filled with helium. Collision of 
the ions with the collision gas causes fragmentation of the ions and the fragment ions 
are analysed by time-of-flight measurement in a ToF MS instrument. The Q-ToF 
MSIMS system gives high resolution and accuracy of peptide masses when 
compared against other MS instruments. ESI-MSIMS was used to provide a tandem 
mass spectra that were submitted to MASCOT (version 2.2) and compared against 
the IPI mouse database of peptides from known murine proteins. 
S.2 SHver stain detection of the proteinaceous constituents of scrapie 
associated fibrils 
The preparation of scrapie associated fibrils makes use of relatively crude techniques 
that separate fibrils on the basis of insolubility and density. After homogenisation of 
brain material, detergent extraction of insoluble material results in a pellet enriched 
for insoluble constituents, which is resuspended in dH20 and centrifuged through a 
20 % sucrose cushion. This step separates molecular species by density, such that 
proteins of a high density will pass through the sucrose cushion, whereas low density 
proteins will remain in the solution above the sucrose cushion. Amyloid fibrils are 
aggregates of PrpSc and have a high molecular density and therefore were found in 
the pellet. However, other protein species that co-purify with PrpSc may be co-factors 
that are necessary for conversion and/or prion formation (OebBurman et al., 1997, 
Saborio et a/., 1999). It has also been suggested that different strains of TSE will 
have different co-factors that aid in strain differentiation (Toyama et a/., 2007). To 
analyse the differences in proteinaceous species for different strains of TSE, SAP 
preparations of mouse adapted scrapie were mixed with modified Laemmli sample 
buffer (MLSB) (4 M urea, 5 % (v/v) glycerol, 5 % (w/v) SOS, 5 % (v/v) (3-
mercaptoethanol, 65 mM Tris (PH 6.8» prior to separation by SOS PAGE and 
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stained with silver nitrate solution following the protocol as described in chapter 2 
(section 2.1.2.3). The MLSB solution was used because of the insoluble nature of 
SAF preparations and this buffer is designed to solubilise more insoluble proteins as 
well as reduce streaking of aggregated protein through the gel. The mouse adapted 
scrapie strains ME7, 79A and 22F were analysed using this method. 
Figure 5.1 shows a silver stained gel of very few differences in protein species 
between ME7, 79A and 22F SAF preparations. It does, however, show that there are 
differences in the amount of different proteins in each SAF preparation when 
comparing the same concentration of SAF preparation separated on the gel. 
Concentration of PrpSc was done by Western blotting SAF preparations against a 
serial dilution of rMoPrPWT of known concentration and using the anti-PrP antibody 
AG4 (data not shown). Comparison oflane 2 (250 ng ME7), lane 6 (250 ng 79A) and 
lane 10 (250 ng 22F) revealed there are differences in the amounts of proteins 
detected between the molecular weight markers 17 kOa and 6 kOa. 
Due to the very few protein bands and differences in silver stained profiles of SAF 
after PK treatment, it was decided that further proteomic analysis by cutting out 
individual bands from such a SDS PAGE gel would not be advantageous. Instead, 
proteinaceous constituents of SAF preparations were analysed directly by mass 
spectrometry without pre-separation by SDS PAGE and then visualisation by silver 
staining. 
5.3 Mass spectrometry of SAF preparations from unlnfected mouse brains 
Preparation of SAF using the method as described in chapter 2 (section 2.1.2.15) 
results in an enrichment of amyloid fibrils. However, there will be 'contamination' 
from other proteins that have similar properties to SAF, such as insolubility and/or 
high molecular weight, but which are not physically associated with SAF in vivo. To 
identify and discard these proteins from future proteomic analyses, the SAF protocol 
was applied to uninfected wild type and PrP-null (PrpO/<) mouse brains. The same 
number of brains (four mouse brains) from wild type and PrpO/O mice were used 
which was also the same number of brains used in analyses of mouse scrapie infected 
brain. 
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Lane 
Strain 
188 
98 
62 
49 
38 
28 
17 
14 
6 
2 3 4 5 6 7 8 9 10 11 12 
ME7 79A 22F 
11 4 114 1/ 10 1/10 1/ 4 1/4 1/ 10 1/ 10 11 4 114 1110 1/ 10 
+ + - + - + - + + 
Figure 5.1 : Preparations of PrP C and associated proteins from ME7, 79A and 
22F infected mouse brains were visualised by silver staining. 
Scrapie associated fibrils were isolated from ME7, 79 A and 22F infected mouse 
brains and SAF preparations were made up to 1 jlg/ jll (section 2.1.2.15) prior to 
treated with and without PK. SAF were diluted to either 250 ng (114) or 100 ng 
(1110) and separated by SDS PAGE. Silver staining of the SDS PAGE gel was done 
to detect separated protein species. Molecular weight markers are in kDa. 
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Mass spectrometry of mock-SAP preparations from uninfected wild type mouse 
brains revealed five significant protein identifications, based on a minimum of two 
distinct peptides being identified by a MASCOT search of the IPI murine database. 
The results of this search are shown in table 5.1. SAF preparations from uninfected 
PrPO/O mice also had five significant protein identifications of which three were novel 
compared to the mock-SAP preparations of wild type mice (Table 5.1). This 
experiment was repeated three times from three separate SAP preparations, each on 
four uninfected wild type or Prp% mouse brains. Proteins that were detected in the 
wild type mouse brains after a mock-SAP preparation included calciumlcalmodulin 
dependent protein kinase, ferritin (light chain), versican core protein and myelin 
associated oligodendrocyte basic protein isoform 1. Mock-SAP preparations on 
PrPO/O mice contained calciumlcalmodulin dependent protein kinase and myelin 
associated oligodendrocyte basic protein isoform 1 again, the proteins histone (H1.2) 
and myomesin-2 were also identified. 
Calciumlcalmodulin dependent protein kinases (CamKII) are serine/threonine protein 
kinases located in synaptic junctions. They are important kinases involved in the 
induction of synaptic plasticity, long term memory and learning (Shulman and 
Hanson, 1993, Lisman, 1994). CamKII is a high molecular weight complex (500-600 
kDa) composed of 10 to 12 oligomers that form a holoenzyme. This protein is highly 
abundant, making up 2 % of total brain protein. Therefore the presence of CamKII in 
SAF preparations is possibly due to the high abundance of this protein coupled with 
its high molecular weight. 
Other proteins identified were ferritin and versican core protein. Ferritin is a large 
globular protein composed of 24 subunits (450 kDa total), the function of which is to 
store iron ions in the cell. Versican is a large chondroiton sulphate proteoglycan with 
a molecular mass of> I 000 kDa (Zimmermann and Ruoslahti 1990). The presence of 
these proteins in SAP preparations is also likely to be down to their high molecular 
weights. Myomesin-2 has a molecular weight of 185 kDa and is located in striated 
muscle cells. The SAP preparation is from mouse brains and this identification could 
either represent contamination of the SAP preparation or a false positive from the 
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Protein ID Gene ID Subcellular Location WT Peptide Hits Null Peptide Hits 
Ca2+!Ca! dependent protein kinase (a type) CamK2a Cell junction 6 4 
ea2+!Ca! dependent protein kinase (p type) CamK2b Cell junction 5 0 
Ferritin (light chain 1) Ftll Cytoplasm 6 0 
Histone (H1.2) Histlhlc Nucleus 0 2 
Versican core protein Vcan Extracellular 2 0 
Myomesin-2 Myom2 Cytoskeleton 0 2 
Myelin associated oligodendrocyte basic protein isoform 1 Mobp Cytoplasm 2 2 
Vomeronasal-l receptor Vlrh5 Plasma membrane 0 2 
Table 5.1: MASCOT searches of data generated by means of mass spectrometrv resulted in the identification of peptides from proteins 
associated with the mock-SAF preparations of uninfected mouse brains. 
This table outlines the identifications of proteins associated with a mock-SAF preparation on mouse brains from WT and PrpOiO mouse brains. 
Four brains (for both WT and PrPM) were homogenised prior to detergent extraction and differential centrifugation to precipitate protein species. 
Precipitated proteins were reduced and alkylated in 6 M guanidine hydrochloride prior to tIyptic digestion and separation of sample by HPLC for 
which the elute was analysed by tandem MS/MS. Peptide hits represent best data from three replicate experiments 
mass spectrometry approach. Myelin associated oligodendrocyte basic protein is an 
abundant protein that is constitutively expressed in oligodendrocytes in the CNS 
(Holz et al., 2000). The presence of this protein in the SAF preparations is likely to 
be by chance due to its high abundance in the brain. Vomeronasal-l receptors are G-
protein coupled receptors that are present on the surface of vomeronasal sensory 
neurons and are involved in pheromone and odorant binding (Grus et al., 2007). The 
vomeronasal receptor has a molecular weight of 42 kDa and its occurrence in the 
mock SAF preparation is difficult to interpret. 
In summary, these experiments have provided a background list of proteins that 
appear to be isolated by the techniques employed in SAF preparations, even in the 
absence of TSE disease in mice. This therefore, allows such proteins to be discounted 
from real results of the analyses of SAF preparations. 
5.4 Mass Spectrometry of SAF preparations 
Scrapie associated fibrils were isolated from the brains of infected mouse brains for 
proteomic analyses. SAF preparations are known to be principally composed of 
amyloid fibrils of PrpSc, however several authors have reported the presence of a 
polysaccharide scaffold and proteoglycans (Snow et al., 1989, Appel et al., 1999, 
Dumpitak et al., 2005). SAF were prepared from the brains of mice infected with 
79A, ME7 and 22F from which 5 J11 (equivalent to 5 J1g) ofpre-sonicated fibrils were 
re suspended in 95 J11 of 6 M guanidine hydrochloride. Denaturation in guanidine is 
necessary to cause significant denaturation of the fibril and expose any co-factors 
associated internally. Reduction and carboxymethylation of the disulphide bond in 
this buffer will also allow for as many cleavage sites in the amyloid fibril to be 
targeted for tryptic digestion. SAF samples were precipitated and re suspended in a 4 
M urea based buffer to aid solubility and digestion with trypsin at 37°C and the 
peptides analysed by MSIMS. 
For every protein identified by the MASCOT search, a minimum of two peptide hits 
were required to give a significant detection score. Table 5.2 lists the number of 
peptide hits identified by mass spectrometry. 
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Number of Peptide IDts 
Protein ID Gene ID Subcellular Location ME7 79A 22F 
Actin, cytoplasmic I Actb Cytoskeleton 8 13 4 
Tubulin beta-2A chain Tubb2a Cytoskeleton 0 5 0 
Tubulin beta-2B chain Tubb2b Cytoskeleton 10 11 2 
Tubulin beta-2C chain Tubb2c Cytoskeleton 10 12 0 
Tubulin beta-4 chain Tubb4 Cytoskeleton 0 0 6 
Tubulin beta-5 chain Tubb5 Cytoskeleton 0 2 2 
Tubulin alpha-lA Tubal a Cytoskeleton 5 8 3 
Tubulin alpha-lB Tubalb Cytoskeleton 0 8 0 
-
Na + /K+ transporting ATPase subunit a-3 ATPla3 Plasma membrane 5 9 4 
w 
0'1 Na+/K+ transporting ATPase subunit a-2 ATPla2 Plasma membrane 5 0 0 
Guanine nucleotide binding protein subunit-a Gnaol Plasma membrane 4 5 3 
Creatine kinase B type Ckb Cytoplasm 4 5 3 
GAPDH isofoIID I Gapdh Cytoplasm 3 5 3 
Apolipoprotein E precursor Apoe Plasma membrane/secreted 9 3 0 
Prolow density lipoprotein receptor precursor Lrpl Plasma membrane 0 3 0 
2' ,3' -cyclic nucleotide 3' -phosphodiesterase isofonn Cnpl Plasma membrane 0 2 0 
Heat shock cognate 71 kDa protein Hspa8 Cytoplasm 3 3 0 
S~sin-lisofonnlb Synl Plasma membrane/Golgi body 0 3 0 
Alpha enolase Enol Cytoplasm/plasma membrane 2 2 0 
Vesicle fusing ATPase Nsf Cytoplasm/Golgi body 2 0 0 
Disks large homolog 4 Dlg4 Plasma membrane 0 0 2 
-w ~ 
Dynamin-l 
mc 1 domain family, member lOb 
Prion protein 
Dnml 
Thcl db lOb 
PrP 
Clathrin pits 
Cytoplasm 
Plasma membrane 
o 
2 
6 
2 
o 
5 
o 
o 
3 
Table S.2: Proteomic determination of molecules co-purifying with PrpSc in scrapie associated fibrils from ME', '9A and 22F mouse 
passaged scrapie. 
This table lists the identification of proteins associated with a SAF preparation on mouse brains infected with ME7, 79A and 22F. Four brains 
(for all three strains of mouse scrapie) were homogenised prior to detergent extraction and differential centrifugation to precipitate protein 
species. Precipitated proteins were reduced and alkylated in 6 M guanidine hydrochloride prior to tryptic digestion and separation of sample by 
HPLC for which the elute was analysed by tandem MSIMS. Peptide hits represent best data from three replicate experiments. 
A MASCOT search of the IPI murine database identified multiple subunits of tubulin 
and actin in SAF preparations from ME7, 79A and 22F infected mouse brains. These 
proteins are cytoskeletal and therefore are abundant and have a high molecular 
weight. In addition to cytoskeletal proteins, many plasma membrane bound proteins 
were also identified and included proteins such as Na + /K+ transporting ATPase and 
guanine nucleotide binding protein. The subunits from these two proteins were 
detected in all three SAF preparations suggesting that they are not necessarily strain 
specific co-factors. However, the presence of these plasma membrane proteins may 
indicate that the location of conversion of Prpc to PrP&: is on the plasma membrane. 
Other plasma membrane bound proteins that were detected were apolipoprotein E 
and alpha-enolase (also found in the cytoplasm) in ME7 and 79A SAF preparations, 
2' ,3' -cyclic nucleotide 3' -phosphodiesterase isoform, prolow density lipoprotein 
receptor and synapsin-l (also found in the Golgi body), dynamin-l in only the 79A 
SAF preparation and finally disks large homolg 4 in only the 22F SAF preparation. 
In addition to plasma membrane bound proteins there were some cytoplasmic based 
proteins detected. These included creatine kinase B and GAPDH in all three SAF 
preparations, heat shock cognate 71 kDa protein in the ME7 and 79A preparations 
and fmally, TBC 1 domain family member lOb in the ME7 SAF preparation. The 
protein vesicle fusing ATPase was detected in the ME7 SAF preparation and is 
reported to be cytoplasmic, however it is also found in the Golgi body. 
Further analysis of these proteins detected by MSIMS in the literature has indicated 
that some of these proteins have previously been correlated to either Prpc function or 
associated with PrpSc (Spielhaupter and Schitzl, 2001, Magalhles et al., 2002, 
Skinner et al., 2006, Petrakis et al., 2008). The results of proteomic analysis of PrP 
interaction partners from cross-linking experiments with the P4 subunit of nicotinic 
acetycholine have suggested that a multiprotein complex is found on the plasma 
membrane of neurons (petrakis et al., 2008). This complex was reported to include 
other proteins identified in the current study, including Na+/K+ ATPase, 2',3'-cyclic 
nucleotide 3' -phosphodiesterase, p-actin, creatine kinase and synapsin-l. 
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s.s Mass spectrometry of SAF preparations pre-treated with PK 
The analysis of tryptic peptides of SAP preparations from three strains of mouse 
scrapie revealed a selection of candidate proteins that could be prion co-factors (table 
5.2). This list is relatively large and a possible method to refine the list was to 
exclude proteins that are not specifically attached to the amyloid fibril, but rather co-
purify by associating to the fibril. Amyloid fibrils are aggregates of proteins which 
will have many potential interaction sites for the non-specific binding of proteins, 
present in the local vicinity of the aggregate or which are exposed to the fibril during 
purification. To exclude these proteins, SAP preparations were pre-treated with PK, 
which digested non-specific proteins into peptides that were subsequently not 
identified by mass spectrometry techniques. This is because the peptide search 
parameters are set to peptides that are generated by tryptic digestion rather than 
generated by another proteolytic enzyme. PrpSc is partially resistant to PK digestion 
and the C-terminus of PrP, along with other protein species, survived PK digestion as 
judged by separation by SDS PAGE and stained with silver nitrate solution (figure 
5.1). 
The sample preparation protocol in chapter 2 (section 2.1.2.6 and 2.1.2.7) for mass 
spectrometry analysis of SAP was followed, with the following alterations. Pre-
sonicated SAP preparations were incubated with 60 flg/fll of PK at 37 °c for one 
hour and the reaction was stopped by the addition of pefabloc to a final concentration 
of 25 mM. Digested SAP preparations were precipitated in acetone to concentrate 
protein and to separate the protein from PK and pefabloc. Acetone precipitation was 
incorporated after PK digestion because it was believed that this organic solvent 
limited the amount of PK peptides that would be precipitated. Acetone is not as 
hydrophobic as other solvents and therefore small peptides would be less prone to 
precipitation as they would if absolute ethanol or chloroform was used. The pellet 
was resuspended in 6 M guanidine hydrochloride as per the standard protocol 
adopted for mass spectrometry of SAP preparations. 
The results of the proteomic analyses of SAF preparations pre-treated with PK 
include only a very few significant protein identifications and are given in table 5.3. 
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Number of Peptide IDts 
Protein ID Gene ID Subcellular Location ME7 79A 22F 
Myelin-associated oligodendrocyte basic protein Mobp Cytoplasm 3 0 0 
Prolow-deosity lipoprotein Lrpl Plasma membrane 2 0 0 
Ferritin heavy chain Fthl Cytoplasm 0 0 2 
Ferritin light chain 1 Ftll Cytoplasm 0 0 2 
Shugoshin-like 2 Sgol2 Nucleus 0 0 2 
Dmx-like 2 Dmxl2 Plasma membrane 0 2 0 
-~ Table 5.3: Identification of peptides detected by mass spectrometric analvsis of SAF preparations pre-treated with PK from mouse 
brains infected with three different mouse scrapie strains. 
This table lists the identification of proteins associated with a SAF preparation pre-treated with PI(, on mouse brains infected with ME7, 79A and 
22F. Four brains (for 'all three strains of mouse scrapie) were homogenised and treated with PK prior to detergent extraction and differential 
centrifugation to precipitate protein species. Precipitated proteins were reduced and alkylated in 6 M guanidine hydrochloride prior to tryptic 
digestion and separation of sample by HPLC for which the elute was analysed by tandem MSIMS. Peptide hits represent best data from three 
replicate experiments 
In this table, proteins such as ferritin and myelin associated oligodendrocyte basic 
protein were included even though they were identified in the SAF preparations of 
uninfected mouse brains (table 5.1). However, some proteins were identified 
specifically in preparations from different strains; these are, prolow-density 
lipoprotein in ME7 SAF preparations, Dmx-like 2 protein in 79A preparations and 
shugoshin-like 2 protein in 22F preparations. Prolow-density lipoprotein and Dmx-
like 2 protein are plasma membrane proteins, however shugoshin-like 2 is a nuclear 
protein that would appear, initially, to have little relevance to PrP conversion or TSE 
disease. 
5.6 Validation of proteins detected by mass spectrometry by Western blotting 
The proteomic determination of proteins associated with SAF preparations by mass 
spectrometry provided a list of protein identifications. However, to confirm the 
presence of these proteins in the sample, a second experiment to validate mass 
spectrometry results was required. Identification of proteins was therefore done by 
Western blotting with antibodies directed against a selection of proteins identified in 
SAF preparations. Primary antibodies for Na + /K.+ transporting ATPase, 
apolipoprotein E and GAPDH were obtained based on antibody availability. 
Figure 5.2 shows Western blots ofSAF preparations from the brains of mice infected 
with ME7, 79A and 22F, along side negative control mock-SAF preparations from 
both uninfected wildtype and PrpO/O mouse brains. Apolipoprotein E and GAPDH 
were found to be present in all three SAF preparations whereas Na + /K.+ transporting 
ATPase was detected only in ME7 and 79A SAF preparations. Western blotting of 
apolipoprotein and GAPDH in 22F showed only a faint band representing each of 
these proteins when compared against the more intense bands on the Western blot for 
ME7 and 79A SAF preparations. Preparation of 22F fibrils was hindered by what 
appeared to be co-purifying proteases leading to degradation of all proteinaceous 
material in the sample. This observation was made when comparisons of 22F SAF 
preparations were done by Western blotting with 8H4, 24 hours after isolation from 
mouse brains. Immediately after isolation from infected mouse brains, Western blot 
fibrils produced the corresponding fuUlength di-, mono-, and unglycosylated bands 
ofPrpSc• However, after only 24 hours, these proteins became truncated, 
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A Na+/K+ transporting ATPase B GAPDH 
Lane 2 3 4 5 Lane 2 3 4 5 
SAF ME7 22F 79A WT 0/0 SAF ME7 22F 79A WT 0/0 
188 49 
98 38 
62 28 
49 17 
C Apolipoprotein E 
Lane 2 3 4 5 
SAF ME7 22F 79A WT 0/0 
38 
28 
17 
Figure 5.2: Western blot analysis of mouse scrapie associated fibrils for proteins 
previously identified by mass pectrometry. 
0.25 ~gI~1 pre-sonicated SAF from an ME7 (lane 1), 22F (lane 2) and 79A (lane 3) 
SAF preparation wa loaded onto a 12-well 4-12% Bis-Tris SDS PAGE and protein 
species were separated at 180 V for 45 minutes. The SDS PAGE gel was blotted onto 
PVDF membrane and probed with the primary antibody for (A.) Na+/K+ transporting 
ATPase at 1:3000, (B.) GAPDH at 1:32,000 or (C.) Apolipoprotein E at 1:1000. The 
secondary antibodies applied to the blot were (A.) anti-rabbit HRP at 1 :3000, (B.) 
anti-rabbit HRP at 1:3000 ( .) anti-rat HRP at I :3000. In lane 4 and lane 5 there was 
0.25 ~gI~l of SAF preparation material from uninfected wild type (WT) and PrPO/O 
(0/0) mouse brain re pectively. Molecular weight markers are in kDa. 
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characterised by a loss in molecular weight and the presence of a 4th band on the 
Western blot that was assumed to be truncated unglycosylated PrpSc (data not 
shown). As a control experiment, SAF preparations from uninfected wild type and 
PrpOIO mouse brains were also Western blotted for these three proteins, with neither 
Na + /K.+ transporting ATPase, GAPDH or apolipoprotein E being detected in these 
samples. 
5.7 Discussion 
Proteomic determination of molecules that co-purify with PrpSc in SAF preparations 
was primarily done to identify plasma membrane derived molecules that may be 
involved in prion conversion. In chapter 4, LD9 low density subcellular fractions 
enhanced conversion efficiency of ME7 and 79A in the CFCA (figure 4.4 and 4.9 
respectively). If there are molecules in the plasma membrane that are prion co-factors 
then it is likely that during conversion ofPrpc to PrpSc, these co-factors will become 
incorporated into the amyloid fibril during polymerisation and aid in the retention of 
strain specific attributes following infection in vivo. 
To attempt to characterise non-PrP constituents of SAF preparations, SAF 
preparations from ME7, 79A and 22F infected mouse brains were separated by SDS 
PAGE followed by visualisation by silver staining (figure 5.1). SAF preparations 
were either treated or not treated with PK prior to separation by SDS PAGE. Pre-
treatment with PK will degrade any proteins that either co-purify with SAF 
preparations or are non-specifically attached to the surface of the fibril. However, 
even though I hypothesised that different TSE strains would contain different 
molecular constituents, silver staining of PK treated SAF preparations of three 
different strains of mouse scrapie did not highlight any obvious differences in their 
silver staining profile. Mass spectrometry was therefore used to analyse SAF 
preparations from mice infected with different strains of mouse scrapie. 
Preparation of SAF by detergent extraction and differential centrifugation produces 
an enrichment of PrpSc; however there will be contamination from other proteins. 
These contaminants will either have similar properties to SAF, such as a high 
molecular weight and/or insolubility, or will be associated with PrpSc non-
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specifically. To account for proteins that may co-purify with PrpSc, the SAF 
preparation protocol was applied to uninfected wild type and PrpOIO mouse brains 
(table 5.1). Proteins that were purified in these preparations were subsequently 
excluded from future results of SAF preparations that were carried out on mouse 
scrapie infected mouse brains. These list of proteins included CamKII, a 
serine/threonine protein kinase located in synaptic junctions. Not only is this protein 
very abundant but it also has a molecular weight of 500-600 kDa, making this protein 
a good example of the type of protein that will be isolated from the brain using the 
SAF preparation protocol. Other proteins isolated from brain using the SAF protocol 
included proteins such as ferritin and versican core protein which are 450 kDa and 
>1000 kDa respectively. Ferritin is also known to oligomerise which will cause 
further increases in molecular weight (Hasan et al., 2006) and has previously been 
shown to contaminate SAF preparations (Walker et al., 1996). 
SAF preparations from ME7, 79A and 22F infected mouse brains were analysed by 
mass spectrometry and peptide MSIMS data was searched against the IPI mouse 
database of known murine proteins using the MASCOT search engine. Proteins that 
were identified in the uninfected SAF preparation and listed in table 5.1, were 
excluded from table 5.2. In all SAF preparations various actin and tubulin isoforms 
were identified which are high molecular weight cytoskeletal proteins. Although 
these proteins may be adhering to PrpSc non-specifically they cannot be discounted 
yet as they may provide a scaffold that aids in misfolding and amyloid fibril 
morphology. 
Mass spectrometry of tryptic peptides from ME7, 79A and 22F SAP preparations 
was used to identify the co-purifying proteinaceous constituents from these three 
different strains of mouse scrapie. As expected, PrP was detected in all three SAF 
preparations validating the success of the SAF protocol and also the mass 
spectrometric identifications. Two of the more significant protein identifications 
were for two subunits of the Na+/K.+ transporting ATPase. This sodium pump 
distributes Na + and K+ ions across the plasma membrane which determines the 
resting potential for several important secondary functions. This plasma membrane 
bound enzyme transports two potassium ions inwards for every three sodium ions it 
transports to the extracellular matrix. It is an important enzyme found in all cells, 
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most notably in neurons where it is responsible for the resting potential necessary for 
transmitting synaptic impulses (Blanco and Mercer, 1998). Mutations and defects in 
this protein have been reported to be associated with neurodegenerative disorders. 
Work published by Palladino and colleagues observed that mutations in the 
Drosophila a-subunit of Na + /K+ transporting ATPase resulted in severe neuronal 
damage and a marked reduction in lifespan (2003). Previous work by the same group 
had indicated that inhibition of the Na + /K+ transporting ATPase caused vacuolation 
similar to that seen in the spongiform of TSE infections (CalandrieUo et al., 1995). 
The authors of this publication hypothesised that Na+/K+ transporting ATPase was 
targeted by the infectious agent and thus caused the characteristic spongiosis of TSE 
diseases. Although this is a tenuous link and probably unlikely, it can be 
hypothesised that Prpc may interact with Na + /K+ transporting ATPase on the plasma 
membrane of neurones. The loss of this enzyme by incorporation into amyloid fibrils 
may play a part in spongiosis of the grey matter of TSE infected brains. This 
hypothesis is supported by the recent publication by Petrakis and colleagues, where 
Prpc was shown to interact with the f34 subunit of nicotinic acetycholine (nACbR). 
Further study of this interaction revealed that Prpc may be a member of a 
multiprotein complex incorporating nACbR and Na+/K+ transporting ATPase 
(Petrakis et al., 2008). Other proteins included in this complex included the proteins 
2' ,3' -cyclic nucleotide 3' -phosphodiesterase and synapsin-l, which were previously 
shown to interact with Prpc (Petrakis and Sldaviadis, 2006). These two proteins were 
also detected in SAF preparations as indicated in table 5.2. 
The protein 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP1) is a membrane 
bound enzyme involved in the synthesis of the myelin sheath that surrounds the axon 
of neurons (Kursula et al., 2008). However, the identity of this enzyme is unknown, 
although it was reported that CNPI is associated with microtubules and may act as 
an anchor for tubulin (Bifulco et al., 2002). Deregulation in CNPI is believed to play 
an important pathogenic role in demyelinating diseases of the brain, such as multiple 
sclerosis (ROsener et al., 1997). A putative role for CNPl in Prpc cell biology may 
be to provide an anchor point between the previously mentioned multiprotein 
complex and the cytoskeleton. 
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Synapsin-l is a plasma membrane bound protein involved in the regulation of 
neurotransmitter release at the synaptic junction (De Camilli et al., 1990). Previous 
reports have shown that synapsin-l specifically interacts with PrP at the presynaptic 
junction, suggesting a role for Prpc in the regulation or recycling of synaptic vesicles 
(Spielbaupter et al., 2001). In another report, PrpSc was demonstrated to co-localise 
with synapsin-l and other synaptic proteins at the presynapse, indicating synaptic 
transport as a possible route of PrpSc spread throughout the brain (Kov8cs et al., 
2005). 
The literature was surveyed for indicators that the remainder of the protein 
identifications made by mass spectrometric analysis of SAF preparations may 
associate with PrP. The identification of dynamin-l in the 79A SAF preparation is 
interesting since dynamin-l has previously been reported to play an important role in 
the internalisation of Prpc (Magalhies et al., 2002). In this study, PrP was shown to 
be dependent on dynamin-l mediated internalisation into the endosomal pathway for 
degradation or recycling back to the plasma membrane. The remainder of protein 
identifications made by mass spectrometric analysis had no previously reported links 
to Prpc or PrpSc. However this does not rule out these proteins as co-factors but 
instead necessitates a more in-depth analysis of their structure and function to 
determine any potential involvement with PrP. 
The generation of an extensive list of proteins identities associated with SAF 
preparation makes analysis of strain specific markers difficult. To further process this 
list down to more specific interactions between fibrils and potential co-factors, 
treatment of SAF with PK prior to tryptic digestion was carried out. It was envisaged 
that this process would degrade all proteins that are loosely attached to the surface of 
the fibril. If co-factors are present in the amyloid fibril then they are as likely to be 
present internally as well as externally. It was hypothesised that these proteins will 
be buried away from the activity of PK but once resuspended in 6 M guanidine 
hydrochloride for reduction and alkylation of the disulphide bridge, potential co-
factors will become revealed and susceptible to tryptic digestion and detection by 
mass spectrometry. 
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MASCOT searches on the identification of peptides from PK-treated SAF 
preparations generated two proteins that were previously unidentified in SAF 
preparations. The proteins shugoshin-like 2 and Dmx-like 2 were detected in 22F and 
79A SAF preparations, respectively. Shugoshin-like 2 is located in the nucleus of the 
cell and is an important protein associated with the protection of centromere 
cohesion prior to meiosis (Kitajima et al., 2006). The function of this protein makes 
it an unlikely candidate of a prion co-factor. On the other hand, the Dmx-like 2 
(Dmx12) protein is suggested to be a scaffold protein for MADD and RAB3GA. 
These are located in the plasma membrane of synaptic vesicles and the synapse 
junction (Munton et al., 2007). However, the functional identity of Dmx12 is only by 
similarity and not through experimental data. The two proteins that Dmx12 is 
reported to interact with, MADD and RAB3GA, play significant roles in survival and 
death through MAP kinase activation and caspase-mediated cell death. PrP is 
hypothesised to play a role in cell signalling and cell survival, making an interaction 
with proteins in the MAP kinase pathway a possibility for PrP function. Whether or 
not these proteins are necessary for prion conversion is unknown and further analysis 
into possible interaction partners of PrP in the MAP kinase pathway may be a 
favourable place to start. Follow up experiments on determining the relevance of 
these proteins are discussed in chapter 7. 
Mass spectrometric analysis of ME7 SAF preparation that was pre-treated with PK 
again revealed peptides for the protein pro low-density lipoprotein receptor (Lrp 1). 
This protein was originally detected in the 79A SAF preparation that was not pre-
treated with PK which suggests that this marker is not strain specific (table 5.2). This 
protein is a multifunctional plasma membrane receptor involved in the endocytosis of 
many different types of extracellular proteins (Herz et al., 1992). One of the more 
interesting functions was the suggestion that Lrp I removes protease inhibitors from 
the extracellular matrix (Strickland et al., 1990, Kristensen et al., 1990). In addition 
to these observations, the cytoplasmic tail of Lrp I is reported to interact with 
apolipoprotein E, another protein identified in 79A SAF preparations (Chen et al., 
1990). 
Support for these findings has come from two publications published recently in 
proteomic journals. Petrakis and colleagues used LC-MSIMS techniques, which were 
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similar to my methods, to identify a series of proteins that co-purify with natural 
scrapie isolated from ovine brain (2009). In this study, proteins such as 
calciumlcalmodulin-dependent protein kinase-IT (CamKIIlA) , ferritin, versican and 
ubiquitin were identified. These proteins were also detected in my SAF preparations, 
however, I also detected these proteins in mock-SAF preparations of uninfected 
mouse brain. Nevertheless, Petrakis and colleagues did detect some novel proteins, 
including brain link protein (BRALl), desmogleinl (DSGI) and plakoglobin (JUP) 
all of which have been suggested to be involved in prion propagation and therefore 
could be used as a target for therapeutics. A separate study on the proteomic analysis 
of SAF preparations from scrapie infected hamster brain showed similar results to 
that by Petrakis and my own research (Giorgi et al., 2009). Interestingly, in this 
study, proteins such as apolipoprotein E, GAPDH and tubulin were also found to be 
associated with SAF preparations. 
The analysis of mouse scrapie strains by mass spectrometry has raised questions 
about some of the various proteins identified and their potential roles in PrP 
conversion. Some are not likely to be strain specific and may instead indicate the site 
of conversion where these proteins were accidently incorporated, rather than playing 
an important role such as strain differentiation. Ideally, recombinant protein of each 
of the potential co-factor candidates would be acquired and used to supplement the 
CFCA to analyse the effect on the conversion of rM03F4PrP to a PK-resistant 
isoform. Unfortunately, proteins such as Na+/K+ transporting ATPase are multi-
domain proteins that span the membrane several times. This is almost impossible to 
over-express and purify using models such as bacteria. In addition, time and financial 
constraints prevented further analysis into recombinant proteins and the 
supplementation into the CFCA and other PrP misfolding assays. 
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6. Development of protein misfolding assays and the addition of cell-derivecl 
conversion enhancing factors to the oUgomerisation assay 
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6.1 Introduction 
In chapter 4, results from the subcellular fractionation of TSE susceptible cell lines 
showed that plasma membrane-enriched fractions increase conversion efficiency of 
rPrP in an ME7-seeded CFCA. In addition, plasma membrane fractions prepared 
from cells that are not susceptible to ME7 infection, 5MB-PS cells, also increased 
conversion efficiency of PrP seeded by ME7 Prp8c. The mechanisms by which 
plasma membrane fractions enhance PrP conversion are not clear, but the 
constituents of the plasma membrane fractions may aid conversion by providing a 
'surface' which can enhance PrP misfolding in general, rather than TSE-specific 
conversion. The interaction between the rPrP substrate and plasma membrane 
fractions could be investigated further by use of PrP misfolding assays that do not 
incorporate a PrpSc seed. I hyPothesised that an alternative in vitro assay, such as an 
oligomerisation assay, would provide an understanding on how PrP refolding was 
affected when in the presence of plasma membrane-enriched fractions. This chapter 
details the optimisation and validation of an in vitro oligomerisation assay that 
involved the refolding of rPrP to p-sheet rich oligomers in the absence of any PrpSc 
seed. 
The in vitro refolding of rPrP into an infectious entity has been proposed as a means 
to effectively demonstrate the protein only hypothesis. Over the past few years, the 
seedless refolding of rPrP into a form which causes disease in animals has been 
published by several scientific groups (Legname et al., 2004, Legname et al., 2005, 
Castilla et al., 2006, Simoneau et al., 2007). However, these publications have met 
criticism due to either low infectivity titres of the newly generated synthetic prion or 
have not faithfully passed on strain properties onto nascent Prpc. To acquire the 
structural conformation associated with each strain of TSE requires the imprinting of 
the conformation from the infectious agent in the first instance and then segregating 
the original seed from the newly created Prpsc, prior to in vivo infection studies. In 
addition, it has been demonstrated that PrpSc potentially interacts with several 
interaction partners in vivo, which may play important roles in the make-up of the 
infectious agent and aiding in the differentiation of strains (Toyama et al., 2007). 
More specifically, recent studies have indicated the roles of polyanions, lipids and 
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glycogen as structural scaffold molecules that may play roles in the formation of 
distinct PrpSc conformations and fibril morphology. 
In vitro PrP-refolding assays in the absence of a PrpSc seed may also provide detailed 
information on the folding landscape of PrP, as well as clues about intermediate 
species between Prpc and the PrpSc isoform found in amyloid fibrils. Critical 
observations in the brains of some vCJD and GSS infected humans have shown that 
neurodegeneration has occurred iD. the absence of detectable amyloid fibrils (Budka 
et al., 1995, Budka et al., 1997). In addition, pathological examinations of certain 
lines of transgenic mice infected with GSS have indicated that even in the presence 
of amyloid fibrils, there was no neurodegeneration (Piccardo et al., 2007). These 
observations raised key questions about the nature of the infectious agent and the role 
of mature amyloid fibrils in disease. In other protein misfolding disorders, such as 
Alzheimer'S disease, the neurotoxic agent has been suggested to be smaller, soluble 
oligomers composed of a few subunits of AP rather than a mature polymeric fibril of 
aggregated protein (Lue et al., 1999, McLean et al., 1999). In fact, the higher order 
aggregation of protein is suggested instead, to be a protective measure during which 
neurotoxic oligomers are sequestered into inert fibrils. Therefore investigations of 
how PrP misfolds and the mechanisms that control such a process may reveal a better 
understanding as to what structures PrP can form and their relationship to 
neurotoxicity . 
The in vitro refolding of recombinant PrP has been demonstrated in many 
publications and a variety of different methods have been used to cause the refolding 
of either full length or truncated recombinant PrP, to p-sheet rich isoforms (Zhang et 
al., 1997, Lu et al., 2001, Sokolowski et al., 2003, Torrent et al., 2003, Tahiri-Alaoui 
et al., 2004, Bocharova et al., 2005, Rezaei et al., 2005, Martins et al., 2006, 
Redecke et al., 2006). The two known isoforms ofPrP, in vitro, that are p-sheet rich 
are referred to as oligomers and fibrils. Oligomers are smaller in size than fibrils and 
consist of only a few subunits of PrP. In contrast, the fibrilisation pathway forms 
mature fibrils of PrP consisting of many subunits. Fibrils are generally more resistant 
to proteolytic digestion and have a higher binding affinity to thioflavin-T, a chemical 
used to detect protein fibrils. 
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Oligomerisation of unfolded, truncated, recombinant human prion protein (trHuPrP) 
with a methionine at residue 129 (Metl29) proceeded at a faster rate than trHuPrP 
with a valine at residue 129 (Va1l29) (Tahiri-Alaoui et al., 2004). It was observed 
that trHuPrP(Va1l29) had a higher propensity to form a-helical rich monomers rather 
than ~-sheet rich oligomers. This correlates with in vivo data indicating that humans 
homozygous for Metl29 are more susceptible to vCJD than those who are 
homozygous for Va1l29 or MetlVal heterozygotes (Collinge et al., 1991, Palmer et 
al., 1991). Further work with these two polymorphic variants demonstrated that the 
trHuPrP(Va1l29), not trHuPrP(Metl29) had a higher propensity to form fibrils than 
trHuPrP(Metl29) when spontaneous or seeded fibrilisation was initiated (Baskakov 
et al., 2005). These publications therefore suggest that refolding of rPrP into 
oligomeric isoforms may be more physiologically relevant than rPrP induced into the 
fibrilisation pathway. This work has been supported by investigations into the 
neurotoxicity of oligomers in vitro and in vivo (Simoneau et al., 2007). In this work, 
oligomers and fibrils were made from full length rMoPrP by incubation of a-
monomeric PrP in an acidic buffer at 45°C (Rezaei et al., 2005, Eghiaian et al., 
2007). In vitro cultures of mouse cortical neurons were separately exposed to ~ 
oligomers and fibrils and, interestingly, only the ~-oligomers caused toxicity. The ~­
oligomers and fibrils were then intracerebrally injected into C57BL/6 Prp+l+ and 
PrPO/O mice whereupon neurodegeneration was observed in both mouse lines injected 
with ~-oligomers. Fibril preparations did not cause the same extent of 
neurodegeneration. Taken together, these publications would suggest that the in vitro 
oligomerisation pathway is more indicative of the misfolding of PrP into neurotoxic 
species in vivo during disease. Based on this data, this was the assay I chose for the 
oligomerisation of rPrP. 
The oligomerisation oftrHuPrP, as previously demonstrated, provided the basis of a 
method to optimise and set-up an in vitro refolding assay that could be used in 
conjunction with the CFCA to understand the role of co-factors in PrP misfolding. 
Although Tahiri-Alaoui's study used N-terminally truncated protein, for the current 
study the use of truncated variants of PrP was not ideal as the absence of the PrP N-
terminus (1-89) may inhibit the interaction between PrP and potential co-factors. In 
addition, this project was principally dealing with strains of mouse derived scrapie as 
a basis to understand the role of co-factors in strain variation. Therefore, full length 
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rMoPrP was the desired substrate for all assays, including the CFCA and the 
oligomerisation assay. 
Initially this chapter describes the development of an oligomerisation assay that 
involves the conversion of full length a-monomeric rMoPrP to p-sheet rich 
oligomers. The assay should be reproducible, and provide kinetic or thermodynamic 
data on the oligomerisation pathway such that variations to this pathway caused by 
the addition of putative co-factors could be quantified. Several methods were 
researched to find an assay that was experimentally robust and physiologically 
relevant. 
At the outset, the· main aim of this project was to determine the subcellular 
localisation of strain specific co-factors, their identities and how they interact with 
Prpc and PrpSc. Chapter 3 describes the subcellular fractionation of TSE susceptible 
cell lines into samples enriched for different compartments of the cell. In chapter 4, 
plasma membrane-enriched fractions from LD9 cells were shown to enhance the 
conversion efficiency of recombinant PrP seeded with PrpSc from two strains of 
scrapie, ME7 and 79A, in the CFCA. However, this enhancement of conversion was 
not strain specific which was an unexpected result since the cell line used was 
susceptible to the ME7 strain of mouse scrapie, but not to 79A. To determine the 
interaction between plasma membrane and rMoPrP and whether the addition of 
plasma membrane made rMoPrP more susceptible to generic misfolding, a protein 
misfolding assay was developed and optimised to investigate the effect of plasma 
membrane-enriched fractions on PrP misfolding (see chapter 6). In this chapter, I 
also describe the use of the oligomerisation assay to analyse the effect plasma 
membrane enhanced fractions from the LD9 cell line, on the refolding of rMoPrP to 
oligomeric isoforms. 
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6.2 Calibration of size exclusion chromatography column 
The oligomerisation assay involves the analysis of the misfolding of rPrP to a p-
oligomer isoform. However, it is difficult to detect PrP oligomers against a 
background of PrP monomers without prior separation of these two isoforms. To do 
this size exclusion chromatography (SEC) column was utilised which, when under 
high pressure, separated different solubilised molecular species by their molecular 
weight. A SEC column contains a column of densely packed gel filtration beads that 
are porous and of a very precise size. Under high pressure from the HPLC, the 
sample will be forced into the column, whereupon smaller proteins move in and out 
of the pores in the SEC beads and thereby take longer to pass through the column 
than proteins of a higher molecular weight. Proteins that elute from the column can 
be monitored by absorbance of UV at 280 nm (amino acid tryptophan), 220 nm 
(peptide bond). 
The optimisation and validation of the refolding of rPrP to a p-oligomer isoform in 
this chapter used oligomer quantitation based on two different SEC columns. The 
first column used was the TSKgel G3000SW (Tosoh Bioscience) which was 600 mm 
in length and contains particles with a diameter of 10 J'm and 250 A pores. This 
column had a separation limit of 10 kDa to 500 kDa for globular proteins. 
Calibration of this column was done by monitoring the elution of molecular weight 
standards including thyroglobulin (660 kDa), 'Y-globulin (150 kDa), ovalbumin (45 
kDa), ribonuclease A (13.7 kDa), p-aminobenzoic acid (137 Da). A graph of elution 
volume verses molecular weight for these standard proteins is shown in figure 6.1 
panelA. 
The second column was used to further separate higher molecular weight species 
from each other. This column was a TSKgel G4000SWxl (Tosoh Bioscience) and 
was 300 mm in length containing gel filtration particles with a diameter of 8 J'm and 
450 A pores. This column had a separation limit of 20 kDa to 7000 kDa for globular 
proteins. Calibration of this column was done by monitoring the elution of the 
molecular weight standards including thyroglobulin (660 kDa), apoferritin (443 
kDa), 'Y-globulin (150 kDa) and p-aminobenzoic acid (137 Da). A graph of elution 
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Figure 6.1: Size exclusion HPLC analysis of protein standard mixture as 
monitored by UV 280 om. 
Protein standards for the calibration of the TSKgel G3000SW and TSKgel 
G4000SWxl SEC columns were re-suspended in column running buffer (0.1 M 
sodium phosphate, 0.1 M sodium sulphate (PH 7)) and 10 III injected onto the SEC 
column) column attached to an AKTA Purifier HPLC instrument for each analysis. 
The eluate was monitored by absorbance at UV 280 nm. 
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volume verses molecular weight for these standard proteins is shown in figure 6.1 
panel B. 
6.3 Oligomerisation of denatured recombinant mouse PrP 
The aim of this project was to identify the subcellular localisation of co-factors that 
stimulated the conversion of Prpc to PrpSc using mouse scrapie as a model. I wanted 
to elucidate whether subcellular fractions from TSE susceptible cell lines that were 
identified to influence conversion efficiencies in the CFCA also affected non-seeded 
PrP misfolding. The oligomerisation of recombinant PrP offered a methodology to 
analyse the interaction of potential co-factors with PrP during misfo1ding to a Ji-sheet 
rich isoform. 
During optimisation of oligomerisation assays, full length rMoPrPWT (23-231) with 
the sequence from the s7 allele of Prnp was used. Recombinant MoPrPWT was over-
expressed and purified as described in chapter 2 (sections 2.1.2.11 to 2.1.2.14) with 
several alterations as per the published protocol (Tahiri-A1aoui et al., 2004). 
Following concentration of purified rMoPrPWT to 1 mglml, samples were lyophilised 
for 12 hours and the lyophilised protein was re-suspended in oligomerisation buffer 
(6 M guanidine hydrochloride, 50 mM tris-HCI, pH 7.2) to a concentration of 10 
mglml. Oligomerisation of denatured rMoPrP was carried out by placing 100 J11 
samples into dialysis cellulose tubing with a 3.5 kDa molecular weight cut-off and 
placed into 2 litres of dialysis buffer (5 M urea, 20 mM sodium acetate, 200 mM 
sodium chloride (PH 3.7». 10 J11 samples were extracted at sequential time points for 
analysis by means of size exclusion chromatography. The column used was a 
TSKgel G3000SW that was connected to an AKTA HPLC to monitor UV 
absorbance at 280 nm and equilibrated with the running buffer (1 M urea, 200 mM 
sodium chloride, 20 mM sodium acetate (PH 3.7» at a flow rate of 1 mVmin. Figure 
6.2 shows the oligomerisation time course of rMoPrPWT as determined by SEC 
analysis. 
The time course of refolding of rMoPrPWT when dialysed against 5 M urea, 0.2 M 
sodium chloride buffer (PH 3.7), rMoPrPWT refolds into nonspecific aggregates 
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Figure 6.2: Size exclusion HPLC analysis of rMoPrPWT (10 mg/ml), applied to a 
7.5 x 300 mm G3000SW column, monitored at UV 280 nm. 
The SEC profiles are a time course of the refolding of full length rMoPrP from a 
denatured state in 6 M guanidine hydrochloride, 50 mM tris-HCl (PH 7.2), into 
oligomers by dialysis against 5 M urea, 20 mM sodium acetate, 200 mM sodium 
chloride (pH 3.7). From a reaction volume of 250 Ill, 10 III aliquots were taken at 1, 
4, 8 and 24 hours and aliquots were analysed by means of SEC. Chromatogram 
peaks are labelled 1 to 4 and represent the four different isoforms of PrP as described 
in section 6.3 . 
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(peak 1), p-oligomers (peak 2) and monomeric PrP (peak 3) as separated by size 
exclusion chromatography (SEC) (figure 6.2). I know that peak 1 is caused by 
unspecified aggregates because this peak is present on the edge of the column void 
volume and therefore any protein that elutes at this point is very large. In addition to 
the frrst three peaks, there is a fourth peak in the chromatogram between 24 ml and 
26 ml (peak 4). The identity of the protein representing this peak in the UV 280 nm 
was unknown and therefore further analysis was done. From this point on peak. 
numbers 1 to 4 will be used to annotate each isoform of rMoPrPwr detected. To 
determine the different molecular isoforms of rMoPrP and their secondary structures, 
a 10 III sample of a-monomeric rMoPrPWT was injected onto the TSK G3000SW 
SEC column equilibrated with the oligomerisation buffer (5 M urea, 20 mM sodium 
acetate, 200 mM sodium chloride (PH 3.7) (figure 6.3 section A). This buffer was 
chosen as the SEC running buffer since peak 4 was only present when the protein 
was dialysed against this buffer. Samples of peaks 1, 3 and 4 were taken for 
separation by SOS PAGE gel and visualisation by silver nitrate (figure 6.3 panel B). 
The silver stained SOS PAGE gel demonstrates that all peaks in the chromatogram in 
figure 6.2 are proteinaceous and appear to be rPrP as determined by molecular 
weight markers. 
Samples of peaks 1, 3 and 4 were also taken for assessment of secondary structure by 
circular dichroism (figure 6.4). The CD analysis of peak 4 revealed the spectra of a 
protein that is partially folded into an a-helical conformation, however this spectra is 
missing a minima at 208 nm which, in conjunction with a minima at 222 nm, would 
be indicative of a fully folded a-helical protein (figure 6.4 panel A). The CD spectra 
of peak 3 shows that the presence of 5 M urea in the SEC column running buffer has 
partially unfolded rMoPrPWT, causing the shift in the CD spectra. CD analysis of 
peak 3 showed a protein with a structure that was difficult to interpret (figure 6.4 
panel B). However, it was assumed from figure 6.2 that peak 3 represents denatured 
rMoPrP. Peak 1 is an unspecified aggregation ofPrP, however, the CD spectra would 
suggest that there is some partial structure (figure 6.4 panel C). The minima at 216 
nm shows that there is some p-sheet present in this isoform. 
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Figure 6.3: Analysis of rMoPrPWT (0.6 mg/mn separated by a 7.5 x 300 mm 
G3000SW column monitored at UV 280 nm. 
(A) A 10 ).11 sample of u-monomenc rMoPrPWT was injected onto the TSK 
G3000SW SEC column equilibrated with the oligomerisation buffer (5 M urea, 20 
mM sodium acetate, 200 mM sodium chloride (pH 3.7). (B) Two samples 
encompassing the eluate from peaks 1, 3 and 4 were taken for analysis by separation 
on an SDS PAGE gel and stained with silver nitrate, which showed that peaks in the 
chromatogram are proteinaceous and were determined to be rMoPrP based on 
molecular weight (kDa). 
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Figure 6.4: Characterisation of prion isoforms by circular dichroism. 
The in vitro refolding of denatured rMoPrPWT in the oligomerisation assay with far-
UV circular dichroism spectra for (A) partially folded monomeric rMoPrPWT (peak 
4), (B) unfolded rMoPrPWT (peak 3) and (C) unspecified aggregations of rMoPrPWT 
(peak 1). The spectra were recorded using a 0.5 mm path length cell and data points 
from a blank run of just the SEC column buffer (1 M urea, 200 mM sodium chloride 
and 20 mM sodium acetate (PH 3.4» removed from experimental CD spectra. 
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The rMoPrPWT starting sample is in a denatured state in 6 M guanidine hydrochloride 
prior to dialysis against the oligomerisation buffer. When denatured rMoPrPWT was 
assessed by SEC, rMoPrP partially misfolds while on the SEC column, into 
unspecified aggregates (peak 1) due to the change in chaotrope concentration (from 6 
M guanidine hydrochloride to 1 M urea). This explains the abundance ofPrP in peak 
I at the start of this time course. However, during the time course, denatured rMoPrP 
is dialysed against a 5 M urea based buffer, which causes the desired refolding of 
denatured rMoPrP into a stable ~sheet oligomer prior to separation by SEC. 
The full length rMoPrP species used in this study has shown to be successfully 
oligomerised into a ~ligomeric isoform that was rich in p-sheet with a molecular 
weight similar to 10-12 subunits of rMoPrP. The studies by Tahiri-Alaoui and co-
workers had demonstrated that the use of trHuPrP with either a methionine or valine 
at position 129 dramatically affected the oligomerisation rate and final amount of p-
oligomer. To attempt to validate the current version of the assay, which used full 
length rMoPrP rather than trHuPrP, the oligomerisation of rMoPrP with a proline to 
leucine polymorphism at position 164 was investigated. The proline to leucine 
substitution at codon 168 in ovine PrP results in an increase in resistance to 
inoculation with experimental BSE of sheep expressing this protein variant 
(Goldman et al., 2006). Previously, the PI68L polymorphism had been made in a 
murine background, the equivalent codon in mice is 164 (rMoPrpl'l64L, Kirby et al., 
2006). In this publication, it was also demonstrated that rMoPrPPl64L was resistant to 
conversion in the CFCA by the mouse scrapie strain 87V. This study therefore 
showed that the PI64L polymorphism, in murine PrP, maintained phenotypic 
integrity. 
Figure 6.5 shows the investigation into the oligomerisation of rMoPrpPl64L and that 
the polymorphism at this position altered the progression of oligomerisation of 
rMoPrP. In comparison with rMoPrPWT there was a slower build up of the oligomer 
and unspecified aggregate, apparently by greater initial folding of the denatured 
protein to the u-monomer (figure 6.5). As the time course proceeded there was a 
notable loss of protein, which can be explained by the accumulation of protein 
aggregates not detected by SEC as a result of the relatively low concentration of urea 
in the HPLC running buffer. 
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Figure 6.5: Size exclusion HPLC analysis of rMoPrPP164L (10 mg/ml), applied to 
a 7.5 x 300 mm G3000SW column, monitored at UV 280 nm. 
The SEC profiles are a time course of the refolding of full length rMoPrP with a 
leucine at residue 164 from a denatured state in 6 M guanidine hydrochloride, 50 
mM tris-HCI (PH 7.2) into oligomers by dialysis against 20 mM sodium acetate (PH 
3.7). From a reaction volume of 250 JlI, 10 JlI aliquots was removed at 1, 4, 8 and 24 
hours and injected onto the SEC column. Denatured monomeric rMoPrPWT elute 
between 19 and 21 ml (peak 3), partially folded monomeric rMoPrPWT elute between 
24 and 26 ml (peak 4), oligomeric rMoPrPWT elute between 12 and 14 ml (peak 2) 
and unspecified aggregates of rMoPrPWT elute between 11 and 12 ml (peak 1). 
Chromatogram peaks are labelled 1 to 4 and represent the four different isoforms of 
PrP as described in section 6.3. 
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The oligomerisation assay was adapted from the publication in 2004 by Tahiri-
Alaoui and co-workers, however it had some deficiencies when the method was used 
with full length rMoPrPWT rather than trHuPrP. Firstly, the starting rMoPrP was 
denatured, into an unfolded state, by 6 M guanidine hydrochloride and this may not 
represent the state of Prpc in vivo during the initial stages of conversion. The 
presence of high concentrations of denaturant may also have an adverse affect on the 
structure of co-factor(s) and any potential interaction it may have with rMoPrP. 
Secondly, the magnitude of unspecified aggregates in this assay made it difficult to 
accurately measure oligomerisation rates and the percentage of total rMoPrP refolded 
to the ~-oligomer. During the setup of this oligomerisation assay it was observed that 
the amount of unspecified aggregate appeared to be random, with varying amounts of 
the soluble portion of unspecified aggregates represented in the SEC chromatogram. 
If the effect of co-factors on PrP misfolding is subtle, then interpretation of 
oligomerisation rates may be difficult with random aggregation also occurring in 
vitro. Alternatively, if the addition of co-factors to the assay destabilises rMoPrP 
then it may be more susceptible to aggregation when in the presence of aggregation 
processes in vitro. 
6.4 Heat induced oligomerisation of reeombinant ovine PrP variants 
In section 6.3 I outlined work aimed at developing a method of PrP oligomerisation 
in a buffer containing modest levels of denaturant and at a reduced pH. I found this 
method unsuitable and sought an alternative approach. Taking these factors into 
account, I decided that a different oligomerisation assay was needed, in particular an 
assay that used full length mammalian rPrP and would be physiologically relevant. 
Various other misfolding methods have been published and a particularly attractive 
method uses heat to induce oligomerisation of PrP (Rezaei et al., 2005). In this 
publication, full length a-monomeric OvPrP oligomerised by thermal refolding at 
45 °C under acidic conditions. Although this assay appeared to be similar to the work 
by Tahiri-Alaoui and co-workers, these reaction conditions resulted in the 
oligomerisation of rOvPrP into two distinct oligomeric species. The oligomers have 
measured sizes of a 12-mer and a 36-mer. They were soluble, displayed partial 
resistance to proteolytic digestion and also a capacity to bind thiotlavine T. The 
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oligomeric PrP was neurotoxic to mouse cortical neurons in vitro and exhibited 
higher intrinsic levels of neurotoxicity in vivo when compared to fibrils (Simoneau et 
al., 2007). 
Since work to develop the denaturant-based assay was problematic, partially 
confounded by the use of different length and PrP species to that used in published 
work, initial attempts to adopt a heat-induced oligomerisation method made use of 
the same protein used in the publication by Rezaei et ai, full length recombinant 
sheep PrP. In 2002, Rezaei' s group had presented data on differences in the 
unfolding intermediates of different ovine PrP variants leading to the correlation 
between genotypic susceptibility of sheep carrying different PrP variants and the 
kinetic energy required to unfold each of the corresponding proteins in vitro. Sheep 
carrying the prion protein variants ARR and AHQ tend to be resistant to classical 
scrapie, whilst those carrying the VRQ and ARQ prion protein variants tend to be 
susceptible. Rezaei demonstrated that VRQ and ARQ proteins have a higher thermal 
stability than ARR and AHQ, which were associated with resistance to infection. The 
stability of ovine PrP is likely to be associated with susceptibility to scrapie and 
incubation time before clinical onset (Rezaei et al., 2000, Rezaei et al., 2002). 
However, this publication did not investigate differences in the oligomerisation of 
different rOvPrP variants. 
I expressed recombinant OvPrP with the amino acid sequence A136-RI54-RI71 
(rOvPrpARR) in IB392 E.coli from the modified pTrcHisB vector and purified as 
outlined previously (chapter 2, sections 2.1.2.10 and 2.1.2.11) with some alterations. 
Inclusion bodies were re-suspended in 10 mUg !MAC buffer A (9 M urea, 0.1 M 
sodium phosphate, 0.01 M tris-HCl (PH 8». The suspension was repeatedly vortexed 
and stirred continuously to aid protein solubilisation. Solubilised inclusion bodies 
were centrifuged as described previously in chapter 2, to remove the insoluble 
fraction. The supematant was mixed with 5 % (v/v) Ni-NTA resin (Qiagen) that had 
previously been equilibrated with !MAC buffer A and incubated at 4 °C for 120 
minutes revolving on a tube rotator (Stuart Scientific). The homogeneous mixture 
was poured into a 10 ml disposable polypropylene column (Qiagen) and the loading 
run through collected. The Ni-NTA column was washed with 5 column volumes of 
!MAC buffer A and bound protein species were eluted with IMAC buffer B (500 
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mM imidazole, 0.02 M MOPS (PH 7» and eluate collected in 2 ml fractions. I made 
these changes to mimic experimental conditions described by Rezeai and colleagues 
(2000). 
Samples were resolved using SDS-PAGE and proteins visualised by staining with 
Instant Blue Coomassie. Recombinant OvPrpARR containing fractions were desalted 
using a PD-lO desalting column (GE Healthcare) equilibrated with 20 mM sodium 
citrate (PH 3.4). The eluate was collected in 500 ~l fractions and then analysed by 
UV spectroscopy at 280 nm to determine protein concentration. Full length 
rOvPrpARR at a concentration of 1.75 mglml were incubated at 45°C and 10 J.11 
samples taken every 15 minutes for the duration of the time course. Samples were 
separated by a 300 x 7.8 nm TSKG4000SWxl gel filtration HPLC column 
equilibrated with 20 mM sodium citrate (PH 3.4) at a flow rate of 1 mVmin. The 
eluate was monitored by UV absorbance at 280 nm for which the data was plotted 
against elution volume (ml) for each of the samples taken throughout the time 
course. 
A representative oligomerisation time course of rOvPrpARR as separated by SEC 
chromatography and analysed by UV 280 nm is shown in figure 6.6 and shows that 
the starting a-monomeric rOvPrpARR multimerises into two distinct oligomeric 
isoforms. Comparison of elution volumes against the calibration profile for the 
TSKG4000SWxl column indicated that the oligomers were consistent with the 
previously published sizes of a 12-mer and a 36-mer of rOvPrpARil. The small peak 
in UV absorbance at an elution volume of 5.5 ml is an unspecified aggregation of 
rOvPrpARR and is ignored from analysis from this point onwards. The identity of this 
PrP isoform is known as the elution volume is at the edge off the column void 
volume and therefore has a very large molecular weight. From four repeats, 
integration of the area under each of the peaks representing the three isoforms of 
rOvPrpARR allowed for further analysis into the refolding rate of oligomerisation for 
the rOvPrpARR (figure 6.7). From figure 6.7 it can be seen that, although initially 
there is an equal amount of refolding from Q-monomer to the 12-mer and 36-mer P-
oligomer isoforms, it is assumed that the reaction proceeds from a-monomer 
refolding to 12-mer and then the 36-mer p-oligomer isoform. This data is in line with 
that published previously and suggests that 12-meric p-oligomers seed the formation 
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Figure 6.6: Size exclusion HPLC analysis of rOvPrpARR (1.75 mg/ml), applied to 
a 7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
The SEC analyses from a time course of the re folding of full length rOvPrpARR 
variant from the native a-monomeric state in 20 mM sodium citrate (PH 3.7) into two 
distinct soluble oligomers by incubation at 45°C. From a reaction volume of 100 Ill, 
10 III aliquots were removed at 15, 30, 45, 60 and 75 minutes and injected onto the 
SEC column. Monomers elute between 10.5 and 11.5 ml (peak 3), the 12-mer 
oligomer elutes between 8 and 9 m1 (peak 2) and the 36-mer oligomer elutes between 
6 and 8 ml (peak I) . The oligomers have an apparent mass of approximately 360 kDa 
and 1080 kDa for the 12-mer and the 36-mer respectively, as based on calibration by 
globular protein size standards. 
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Figure 6.7: Semi-quantitative measure of the proportion of rOvPrpARR isoforms 
by integration of the area under each peak. 
Evaluation of the area under each chromatogram profile was carried out using the 
integration facility on the AKTA HPLC Unicorn 4.1.1 operating system. Blue line 
represents 36-mer oligomer (peak 1), the red line represents the 12-mer oligomer 
(peak 2) and the green line represents the u-monomer (peak 3). Results showed that 
monomeric rOvPrpARR refolded into a 12-mer oligomer which seeded the formation 
of the 36-mer oligomer. 
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of the 36-mer p-oligomer (Rezaei et al., 2005). 
Although the above results suggested that the heat-induced oligomerisation assay 
could provide a means of quantifying the rates of oligomerisation, I next wanted to 
assess whether variations in experimental conditions could produce different results. 
To do this I analysed the rates of heat-induced oligomerisation of an alternate ovine 
PrP variant with the amino acid sequence, V136-R154-Q17l (rOvPrPVR~. The same 
experimental protocol, including protein expression, purification and final 
concentration was used to allow results to be compared directly. The results from 
oligomerisation of rOvPrP VRQ are presented in figure 6.8 a representative 
chromatogram and figure 6.9, which represents the average of four repeats. 
Figure 6.8 shows the time course of the oligomerisation of a-monomeric rOvPrpVRQ 
to p-oligomer isoforms by thermal refolding, which has a similar rate of 
oligomerisation to tOvPrpARR as illustrated in figure 6.6. Further analysis of the area 
under each UV 280 run peak. using integration suggested that there were subtle 
differences in the kinetics of oligomerisation of tOvPrpARR and rOvPrpVRQ (figure 
6.7 and 6.9, respectively). Firstly, there was a slower rate of oligomerisation from a-
monomeric rOvPrpVRQ to the low molecular weight (3-oligomer. Secondly, less 36-
mer oligomer had formed than l2-mer oligomer after 15 minutes in the rOvPrPVRQ 
oligomerisation when compared against rOvPrpARR, at the same time point. After 15 
minutes the reaction appeared to have gone largely to completion and there appeared 
to be no further seeding of the tOvPrP VRQ 36-mer oligomer by the 12-mer oligomers. 
The differences observed in the oligomerisation of rOvPrP variants demonstrated 
that subtle sequence changes in the sequence of PrP alter conformational plasticity 
during thermal misfolding. The propensity of tOvPrpARR to oligomerise when 
compared against rOvPrPVRQ seemed counter-intuitive when disease susceptibility in 
vivo would dictate that an increase in misfolding potential would be associated with 
increased susceptibility to disease. However, I hypothesised that the l2-mer oligomer 
may have a higher capacity for neurotoxicity which in the case of tOvPrP VRQ, was 
the most prevalent p-oligomer formed. Alternatively, it could be that these assays 
measure propensity to misfold generally, rather than disease-specifically (see figure 
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Figure 6.8: Size exclusion HPLC analysis of rOvPrPVRQ (1.75 mg/ml), applied to 
a 7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
The SEC profiles are a time course of the refolding of full length VRQ rOvPrP 
variant from the native a-monomeric state in 20 mM sodium citrate (PH 3.7) into two 
distinct soluble oligomers by incubation at 45°C. From a reaction volume of 100 I.d, 
10 ).11 aliquots were removed at 15, 30,45 and 60 minutes and injected onto the SEC 
column. Monomers elute between 10.5 and 11.5 ml (peak 3), the 12-mer oligomer 
elutes between 8 and 9 m1 (peak 2) and the 36-mer oligomer elutes between 6 and 8 
ml (peak 1). The oligomers have an apparent mass of approximately 360 kDa and 
1080 kDa for the 12-mer and the 36-mer respectively, as based on calibration by 
globular protein size standards. 
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Figure 6.9: Semi-quantitative measure of the proportion of rOvPrPVRQ isoforms 
by integration of the area under each peak. 
Evaluation of the area under each chromatogram profile was carried out using the 
integration facility on the AKTA HPLC Unicorn 4.1.1 operating system. Blue line 
represents 36-mer oligomer (peak 1), the red line represents the 12-mer oligomer 
(peak 2) and the green line represents the u-monomer (peak 3). Results showed that 
monomeric rOvPrPVRQ refolds equally into 12-mer and 36-mer oligomers. 
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7.1). To elucidate, future work could incorporate other rOvPrP variants to be 
analysed or their propensity to refold in vitro. 
These experiments on the oligomerisation of rOvPrP variants demonstrated that the 
thermal refolding of rOvPrP in the presence of an acidic buffer formed the basis of 
an assay that was sensitive, quantitative and reproducible. Therefore, I next applied 
the oligomerisation assay to rMoPrP variants with a view of determining the kinetics 
of oligomerisation. 
6.5 Heat induced oHgomerisation of recombinant mouse PrP 
Vendrely and co-workers demonstrated that, like ovine PrP, full length rMoPrPWT 
also formed two distinct oligomeric isoforms by thermal refolding (2005). However, 
the experimental kinetics of refolding of a-monomeric rMoPrPWT to p-oligomers was 
not the same as observed for rOvPrP in Rezaei's or my investigations (section 6.4, 
Rezaei et al., 2005). Thermal refolding of a-monomeric rMoPrPWT to the 12-mer and 
36-mer appeared not to follow a three stage reaction from monomer to 12-mer to 36-
mer. Instead a-monomeric rMoPrPWT refolded equally into 12-mer and 36-mer 
oligomers. In addition the rMoPrPWT 36-mer appeared to have a more a-helical 
secondary structure and was considerably less stable than the 36-mer p-oligomer of 
rOvPrpARR. I therefore used the oligomerisation assay to analyse the oligomerisation 
ofrMoPrP. 
The expression, purification and oligomerisation of rMoPrP with the amino acid 
sequence from the s7 allele (rMoPrPWT), was performed as described for rOvPrP in 
section 6.3. Recombinant MoPrPWT, at a concentration of 2 mg/ml in a 20 mM 
sodium citrate (PH 3.4) buffer was heated to 45°C and aliquots were removed for 
analysis by size exclusion chromatography. Typical results of such an experiment are 
shown in figure 6.10 which shows that thermal refolding from the native a-
monomeric isoform ofrMoPrPWT produces two distinct oligomeric species, a 12-mer 
and a 36-mer. The experiment was repeated three times and the areas under the 
respective peaks were integrated and averaged. A plot of the relative proportions of 
each of the species against time is shown in figure 6.11 from which it can be seen 
that after only 15 minutes there is ...... 45 % a-monomer left with the remain4J,g 
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Figure 6.10: Size exclusion HPLe analysis of rMoPrPWT (2 mg/mll, applied to a 
7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
SEC analyses from a time course of the refolding of full length rMoPrP WT in the 
native a-monomeric state in 20 mM sodium citrate (pH 3.7) into two distinct soluble 
oligomers by incubation at 45 QC. From a reaction volume of 1 00 ~l, 1 0 ~l aliquots 
were removed at 15, 30, 45, 60 and 75 minutes and injected onto the SEC column. 
Monomers (peak 3) elute between 10.5 and 11.5 ml, the 12-mer oligomer (peak 2) 
elutes between 8 and 9 ml and the 36-mer oligomer (peak 1) elutes between 6 and 8 
ml. The oligomers have an apparent mass of approximately 360 kDa and 1080 kDa 
for the 12-mer and the 36-mer respectively, as based on calibration by globular 
protein size standards. 
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Figure 6.11: Semi-quantitative measure of the proportion of rMoPrPWT 
isoforms by integration of the area under each peak. 
The refolding of full length rMoPrPWT variant from the native a-monomeric state in 
20 mM sodium citrate (PH 3.7) into two distinct soluble oligomers by incubation at 
45 cC. Evaluation of the area under each chromatogram profile was carried out using 
the integration facility on the AKTA HPLC Unicorn 4.1.1 operating system. Blue 
line represents 36-mer oligomer (peak 1), the red line represents the 12-mer oligomer 
(peak 2) and the green line represents the a-monomer (peak 3). Results show that the 
there is a steady refolding ofmonomeric rMoPrPWT to 12-mer and 36-mer oligomers. 
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refolded into 12-mer (- 25 %) and 36-mer. (- 30 %). This figure also shows that 
after 15 minutes there was a slow progression from rMoPrPWT a-monomer to both 
12-mer and 36-mer oligomers which steadily proceeded throughout the time course. 
The oligomerisation of rMoPrPWT suggested that the heat-induced oligomerisation 
assay could also provide a means of quantifying the rates of rMoPrP oligomerisation. 
Therefore, I wanted to assess whether variants of rMoPrP could produce different 
results. To do this I analysed the rate of heat-induced oligomerisation of the alternate 
murine PrP variant with the PI64L polymorphism (rMoPrPPI64L). This rMoPrP 
variant was chosen to compare on the basis that differences were detected in the 
denaturant-induced oligomerisation of rMoPrPWT and rMoPrPPI64L in section 6.3. 
The same experimental protocol, including protein expression, purification and final 
concentration was used to allow results to be compared directly. The results from 
oligomerisation of rMoPrPPI64L are presented in figure 6.12 (representative 
chromatograms) and figure 6.13, which represents the average of three repeats. 
In comparison, the thermal refolding of rMoPrPPI64L was remarkably different to 
oligomerisation ofrMoPrPWT (compare data in figures 6.10 and 6.12) A typical SEC 
chromatogram from the oligomerisation time course is presented in figure 6.12. It 
can be clearly seen that there was an immediate and almost complete loss of a-
monomeric rMoPrPPI64L by the time the first sample was taken at 15 minutes and 
instead both 12-mer and 36-mer oligomeric species were formed. At each time point 
thereafter there was a noticeable reduction in the peak representing the 36-mer 
oligomer and a steady increase in the 12-mer oligomer. Further analysis of the area 
under each UV 280 nm peak by integration suggested that there were differences in 
the kinetics ofoligomerisation ofrMoPrPWT and rMoPrpPlS4L (figure 6.13). After 15 
minutes there was only - 10 % a-monomeric rMoPrP and the majority had refolded 
into the 36-mer oligomer (- 60 %) with the remaining - 25 % in the 12-meric 
isoform. As the time course progressed there was a slow reduction in the 36-mer, 
presumably as it broke down into a 12-mer oligomers. This assay therefore provides 
a means to study the addition of subcellular fractions to the oligomerisation of 
rMoPrP 
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Figure 6.12 Size exclusion HPLC analysis of rMoPrPPl64L (2 me/fill, applied to 
a 7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
The SEC profiles are a time course of the refolding of the full length rMoPrP variant 
with the P164L polymorphism from the native a.-monomeric state in 20 mM sodium 
citrate (PH 3.7) into two distinct soluble oligomers by incubation at 45 0 • From a 
reaction volume of 100 Ill, 10 III aliquots were removed at 15, 30, 45, 60 and 75 
minutes and injected onto the SEC column. Monomer (peak 3) elute between 10.5 
and 11.5 ml, the 12-mer oligomer (peak 2) elutes between 8 and 9 rnl and the 36-mer 
oligomer (peak 1) elutes between 6 and 8 rnl. The oligomers have an apparent mass 
of approximately - 360 kDa and - 1080 kDa for the 12-mer and the 36-mer 
respectively, as based on calibration by globular protein size standards. 
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Figure 6.13: Semi-quantitative measure of the proportion of rMoPrPP164L 
isoforms by integration of the area under each peak. 
The refolding of full length P164L rMoPrP variant from the native u-monomeric 
state in 20 mM sodium citrate (PH 3.7) into two distinct soluble oligomers by 
incubation at 45 0c. Evaluation of the area under each chromatogram profile was 
carried out using the integration facility on the .AKTA HPLC Unicorn 4.1.1 operating 
system. Blue line represents 36-mer oligomer, the red line represents the l2-mer 
oligomer and the green line represents the u-monomer. Results show that monomeric 
rMoPrPPl 64L refolds rapidly into 12-mer and 36-mer oligomers, however the 36-mer 
oligomer dissociates, presumnbaly back to 12-mer andlor monomer. 
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6.6 Addition of subcellular fractions to the oUgomerisadon assay 
Plasma membrane-enriched fractions from the LD9 cell line enhanced the conversion 
efficiency of ME7 and 79A in the CFCA (see chapter 4). It is likely that plasma 
membrane-enriched fractions contain generic co-factors as evidenced by the 
increased conversion efficiency ofME7 and 79A in the CFCA when in the presence 
of these fractions. However, it is also possible that generalised co-factors for all 
strains are present on the plasma membrane of LD9 cells and it is instead something 
else that is required, such as a specific cellular location, which provides strain 
specificity. Therefore, I wanted to assess whether the plasma membrane from LD9 
cells also enhanced non-seeded conversion ofrMoPrPWT. 
To replicate, in the oligomerisation assay, the exact ratio of rMoPrP and subcellular 
fraction present in each CFCA would not be possible due to the restrictions in protein 
concentration that are required for the successful oligomerisation of rMoPrP. 
Therefore, 50 % of the sample volume for oligomerisation was made up of the 
subcellular fraction. This required a doubling in the concentration of the rMoPrP 
stock to 4 mg/ml to give a fmal rMoPrP concentration of 2 mglml. The 
oligomerisation ofrMoPrP was carried out as described previously (section 6.5) with 
samples taken at 15 minute intervals throughout the time course. Comparisons were 
made between the effect of a plasma membrane enriched fraction and that of a 
mitochondrial enriched fraction on the oligomerisation of full length rMoPrP. 
The expression, purification and oligomerisation of full length rMoPrP with the 
amino acid sequence from the s7 allele (wild type) were performed as described in 
section 6.5. Full length wild type rMoPrP (rMoPrPWT) at a concentration of 2 mg/ml 
in a 20 mM sodium citrate (PH 3.4) buffer was heated to 45 °C which caused thermal 
refolding from the native a-monomeric isoform to two distinct oligomeric species, a 
12-mer and a 36-mer (figure 6.14). This figure is a typical chromatogram of the 
oligomerisation of rMoPrPWT as described previously in chapter 6 (figure 6.10), 
however there is a small degree of unspecified aggregates eluting at 5.5 ml. 
Next, an equivalent oligomerisation assay was performed, by use of rMoPrP, but in 
the presence ofa plasma membrane enriched fraction (fraction 3) from the LD9 cell 
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Figure 6.14: Size exclusion HPLC analysis of rMoPrPWT (2 mg/ml), applied to a 
7.5 x 300 mm G4000SWxl column. monitored at UV 280 nm. 
SEC analyses from a time course of the refolding of full length rMoPrP WT in the 
native a-monomeric state in 20 mM sodium citrate (PH 3.7) into two distinct soluble 
oligomers by incubation at 45°C. From a reaction volume of 100 Ill, 10 III aliquots 
were removed at 15, 30, 45, 60 and 75 minutes and injected onto the SEC column. 
Monomers elute between 10.5 and 11.5 ml (peak 3), the 12-mer oligomer elutes 
between 8 and 9 ml (peak 2) and the 36-mer oligomer elutes between 6 and 8 ml 
(peak 1). The oligomers have an apparent mass of approximately 360 kDa and 1080 
kDa for the 12-mer and the 36-mer respectively, as based on calibration by globular 
protein size standards. 
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line. A typical result from these experiments is shown in figure 6.15. The presence of 
plasma membrane in the oligomerisation assay appeared to inhibit the 
oligomerisation of rMoPrP. Instead, a-monomeric rMoPrPWf appeared to form two 
completely different isoforms, as assessed by SEC. There is a peak (peak 2) that 
elutes at approximately 9 ml which is consistent with a smaller oligomeric isoform of 
approximately 8 subunits of rMoPrPWf. The second novel isoform of rMoPrPWf to 
be observed was peak 4. which was represented by a shoulder (between 11 ml and 
11.5 ml) off peak 3 and it is not immediately clear what conformation of rMoPrPWf 
this peak represents. 
Circular dichroism was performed to determine the secondary structure of this 
shoulder in the chromatogram (peak 4 in figure 6.15) by collecting 500 Jil fractions 
using the fraction collector attached to the AKTA purifier FPLC. Representative CD 
spectra for peak 4 is shown in figure 6.16 and show a largely unstructured 
conformation for this isoform of rMoPrPWf. The CD spectra is rather weak and this 
is possibly due to either contamination of various salts in the sample originating from 
OptiPrepTM and/or the homogenisation buffer, or dilution of the protein sample post-
SEC. Nevertheless, analysis of peak 4 by CD has revealed a lack of structure. 
However, there is a resemblance to a typical p-sheet spectra and therefore I cannot 
discount that the rMoPrP Wf here is only partially unstructured. 
The subcellular fractions are composed of precipitated cellular material resuspended 
in the oligomerisation buffer and therefore should only contain minute amounts of 
OptiPrepTM and/or homogenisation buffer. To control for those factors, the 
oligomerisation assay was supplemented with a different fraction that was enriched 
for a different organelle and had previously shown to have no effect in the CFCA. 
Fraction 18 was enriched for mitochondria and did not contain the plasma membrane 
marker annexin-I1 as determined by Western blotting (see figure 3.6), and was 
therefore an appropriate sample for comparison. Resuspended cellular material from 
fraction 18 was added to the oligomerisation assay and the effect on the thermal 
refolding of full length rMoPrPWf was monitored. Full length rMoPrP Wf at a 
concentration of 2 mglml in 20 mM sodium citrate (PH 3.4) was heated to 45 °C 
from which 10 Jil samples were taken at 15 minute intervals and analysed by HPLC-
SEC. The eluate was monitored by UV 280 nm and for each of the different time 
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Figure 6.15: Size exclusion HPLC analysis of rMoPrPWT (2 mg/mn 
supplemented with an LD9 plasma membrane-enriched subcellular fraction and 
applied to a 7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
SEC analyses from a time course of the refolding of full length rMoPrPWT in the 
native a-monomeric state in 20 mM sodium citrate (PH 3.7) into two distinct soluble 
oligomers by incubation at 45 QC. To this reaction a 1:1 (v/v) ratio of fraction 3 from 
a subcellular fractionation of LD9 cells was added. From a reaction volume of 100 
J.lI, 10 J.lI aliquots were removed at 15, 30, 45, 60 and 75 minutes and injected onto 
the SEC column. Monomers elute between 10.5 and 11.5 m1 (peak 3), an oligomer of 
_ 8 subunits elutes between 9 and 9.5 ml (peak 2) and an unknown isoform of PrP 
elutes between 11.5 and 12 ml (peak 4). The peak at 5.5 m1 represents the 
unspecified aggregation ofPrP and there is the absence of the 36-mer oligomer (peak 
1) in this chromatogram. The oligomer has an apparent mass of approximately 240 
kDa as based on calibration by globular protein size standards. 
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Figure 6.16: Characterisation of prion isoforms by circular dichroism. 
240 
The in vitro oligomerisation of rMoPrP into two novel isoforms in the presence of 
low density subcellular fractions from a TSE susceptible cell line. Far-UV circular 
dichroism spectra for peak 4 from figure 6.15. The spectra were recorded in a 0.5 
mm path length cell and analysed against SEC column buffer (20 mM sodium citrate 
(PH 3.4» . Spectra shows that there is a minima at 216 DID which is indicative ofa 
protein with a secondary structure consisting of ~-sheet. 
181 
points the data was plotted. A typical result from these experiments is shown in 
figure 6.17. The mitochondrial enriched fraction did not have any discernable effect 
on the thermal refolding of rMoPrPWf. As demonstrated in figure 6.17, a-monomeric 
rMoPrPWf refolded into two oligomeric isoforms with elution times that are similar 
to those seen in the chromatogram ofrMoPrPWf in isolation (see figure 6.14). There 
is a slight shoulder to the peak representing a-monomeric however this is of low 
intensity and may be the result of a nonspecific interaction between mitochondrial 
plasma membrane and rMoPrPWf. 
6.7 Discussion 
The misfolding of recombinant PrP in vitro has previously been published with 
multiple different methods and refolding pathways proposed (Jackson et al., 1999, 
Baskakov et al., 2002, Sokolowski et al., 2003, Tahiri-Alaoui et al., 2003, Rezaei et 
al., 2005, Martins et al., 2006). A method to produce PrP oligomers, proposed by 
Baskakov in 2002 and again in 2003 by Tahiri-Alaoui, was suggested to be 
indicative of PrP misfolding in vivo and that the oligomers produced were 
energetically stable and did not mature into amyloid fibrils in vitro. The experimental 
protocol used rPrP denatured in 6 M guanidine hydrochloride, which after dialysis 
into an acidic buffer of less denaturant, refolded into a p-sheet rich oligomer. An 
acidic pH was necessary for the refolding to the j3-oligomer as a neutral pH caused 
the fibrilisation of rPrP. The acidic pH is believed to be physiologically relevant, as it 
was previously proposed that prion conversion may occur in the endocytic pathway 
of the cell (Borchelt et al., 1992). Unfortunately, this assay was designed with a 
truncated and therefore His-tagged, recombinant variant of HuPrP. The N-terminal 
His-tag is composed of 6 histidines, which was required for purification by Ni-IMAC 
chromatography. The presence of a His-tag reduces the physiologically relevancy of 
these experiments and, if used in the current study, may prevent association between 
rPrP and co-factors. In addition the removal of the N-terminal region may also have a 
negative impact on prion co-factor interaction due to a potential loss of co-factor 
binding site(s). When this assay was attempted using denatured full length rMoPrP 
without a His-tag, oligomerisation was largely successful and the differences in 
refolding between polymorphic variants were observed (figures 6.2 and 6.5). 
However, certain details of this assay prevented accurate analysis of the rate of 
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Figure 6.17: Size exclusion HPLC analysis of rMoPrPWT (2 mg/mll 
supplemented with an LD9 mitochondrial enriched subcellular fraction and 
applied to a 7.5 x 300 mm G4000SWxl column, monitored at UV 280 nm. 
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SEC analyses from a time course of the re folding of full length rMoPrP WT in the 
native a-monomeric state in 20 mM sodium citrate (PH 3.7) into two distinct soluble 
oligomers by incubation at 45 cc. To this reaction a 1: 1 (v/v) ratio of fraction 18 
from a subcellular fractionation of LD9 cells was added. From a reaction volume of 
100 )ll, 10 )ll aliquots were removed at 15, 30, 45 , 60 and 75 minutes and injected 
onto the SEC column. Monomers elute between 10.5 and 11.5 ml (peak: 3), the 12-
mer oligomer elutes between 8 and 9 ml (peak 2) and the 36-mer oligomer elutes 
between 6 and 8 ml (peak: 1). The oligomers have an apparent mass of approximately 
360 kDa and 1080 kDa for the 12-mer and the 36-mer respectively, as based on 
calibration by globular protein size standards. 
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oligomerisation due to the presence of an overbearing amount of unspecified 
aggregates, as determined by SEC. These aggregates of rMoPrP were caused by the 
sudden shift from a buffer with a high molar concentration of chemical denaturant to 
a buffer that had a much lower concentration of denaturant. The formation of 
aggregates was not controllable and thus could not be accounted for when 
determining rate calculations. In addition, during the time course of oligomerisation 
there appeared to be a large loss of total protein from the system, as determined by 
integration of SEC chromatograms. It was decided, therefore that this assay would 
not provide an accurate and quantitative assay for the analysis of rPrP refolding in 
the presence of potential prion conversion co-factors. 
The second refolding assay investigated involved the thermal refolding of full length 
rOvPrP to two distinct oligomers in the presence of an acidic buffer (Rezaei et al., 
2(05). Rezaei and colleagues had previously observed that incubating a-monomeric 
rOvPrP in 20 mM sodium citrate buffer (PH 3.4) at 45 °C allowed quantitative 
measures of oligomerisation rates by time course SEC analyses. Reaction kinetics 
suggested that the a-monomer refolded sequentially into a 12-mer p-oligomer, which 
with time, formed a 36-mer p-oligomer. Both oligomers were shown to be soluble, 
stable, and rich in p-sheet and displayed a slight resistance to protease degradation. 
The p-oligomeric isoforms of PrP have previously been hypothesised to play a role 
in neurotoxicity by disrupting cellular homeostasis (Moreira et al., 2002, Lashuel et 
al., 2002). Neurotoxicity was subsequently demonstrated by observations made on 
the in vivo and in vitro effects of the p-oligomers formed using the Rezaei 
methodology (Simoneau et al., 2007). In this publication, subcortical injection of p-
oligomers into a panel of mice resulted in more neurodegeneration than when 
compared against matured fibrils of the same recombinant protein. It was also shown 
that neuronal cultures were susceptible to cell death when exposed to p-oligomer 
preparations but not to mature fibril preparations. These experiments suggest that the 
oligomerisation assay and the methodology for refolding rPrP into the p-oligomer 
conformation was biologically significant. 
The oligomerisation of rOvPrP by thermal refolding of the Q-monomer has 
previously been shown to result in the production of two distinct p-oligomeric 
isoforms. However, differences in rates of oligomerisation between different 
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polymorphic variants of ovine PrP have not been investigated. There are three major 
polymorphic residues in ovine PrP at positions 136, 154 and 171. Sheep carrying 
different protein variants are either susceptible (PrpVR~ or resistant (PrpARA) to TSE 
disease. In chapter 1, table 1.2 is a list of the 16 polymorphic variants in sheep and 
their susceptibilities to scrapie infection. The oligomerisation of the ARR and VRQ 
polymorphic variants of tOvPrP revealed subtle differences in kinetic properties 
(figure 6.6 to figure 6.9). The Q-monomer of tOvPrpARll formed li-oligomers more 
rapidly than the tOvPrpVRQ variant. In addition, the tOvPrpVRQ formed more 12-mer 
oligomers than 36-mer oligomers which in the case of the tOvPrpARll variant formed 
approximately equal measures of 12-mer and 36-mer. This data would suggest that 
tOvPrP VRQ protein is kinetically less efficient at misfolding into the oligomeric 
isoform and therefore the equilibrium was shifted in favour of the 12-mer under these 
experimental conditions. 
A previous publication by Rezaei and co-workers had suggested that there was a 
correlation between conformational stability and disease susceptibility (Rezaei et al., 
2002). Allelomorphs such as the disease susceptible VRQ were thermodynamically 
more stable and exhibited less conformational plasticity than allelomorphs that are 
associated with resistance to disease. My results supported their observations 
outlined in this chapter where rOvPrpVRQ was slightly slower to oligomerise than the 
tOvPrpARR variant (figures 6.6 to 6.9). 
The investigations of thermal refolding of rOvPrP variants had shown that this assay 
was stable and reproducible in the laboratory and therefore the oligomerisation of 
rMoPrP was attempted. It was essential to be able to alter the assay to make use of 
murine rPrP for several reasons. Firstly, the main aim of this project was to 
investigate co-factors that are associated with the conversion of murine PrP by 
mouse scrapie PrpSc and in the interest of consistency the oligomerisation assay 
needed to use murine rPrP. Secondly, the subcellular fractions that enhanced 
conversion of rMoPrP in the CFCA were of murine origin and to avoid species 
incompatibility, rMoPrP was again used in the oligomerisation assay. Work 
published by Vendrely and co-workers demonstrated that rMoPrP could be 
oligomerised into two distinct p-oligomers using the methodology outlined by Rezaei 
and colleagues (Rezaei et al., 2005, Vendrely et al., 2005). However, the reaction 
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kinetics were observed to be different to those of ovine PrP and the sequential 
formation of monomer to 12-mer to 36-mer was not observed. Instead, the 12-mer 
and 36-mer appeared to form concomitantly and although the 12-mer was rich in Ji-
sheet, as assessed by FTIR spectroscopy, the 36-mer was an unstable isoform 
composed predominantly of a-helices. These observations are peculiar and it was 
suggested that the 36-mer oligomer formed under a different reaction scheme to that 
of the 12-mer oligomer. The importance and relevance of these observations are 
unknown at present. 
The oligomerisation of rMoPrPWf was compared against the oligomerisation of a 
polymorphic variant, in which residue 164 was changed from a proline to a leucine 
(figure 6.10 and 6.12). This change in amino acid has previously been associated 
with resistance of PrP to conversion in vitro and resistance of sheep to TSE disease 
in vivo, as previously described in this chapter (Goldmann et al., 2006, Kirby et al., 
2006). The thermal refolding of rMoPrPWf revealed that a-monomeric rMoPrPWf 
oligomerises into a 12-mer and 36-mer oligomer, as determined by SEC (figure 
6.10). The oligomerisation followed a similar reaction scheme to that published by 
Vendrely and co-workers where a-monomeric rMoPrPWf refolded equally into a 12-
mer oligomer and a 36-mer oligomer. However, rMoPrPPl64L oligomerised 
significantly more rapidly than rMoPrP Wf with a sudden and dramatic loss of a-
monomer within 15 minutes. In addition, it was also demonstrated that rMoPrPPl64L 
initially formed more 36-mer oligomers than 12-mer oligomers. The 36-mer 
oligomers were shown to be lost with time presumably by breaking down and 
refolding into 12-mer p-oligomers. 
To understand this result and explain it in relation to observations in vivo and in 
vitro, it has been observed that the PI64L polymorphism and other polymorphic 
variations at this residue, reduces the structural stability of rMoPrP (Or Andrew Gill, 
unpublished data). This loss of stability caused the quick refolding of the a-monomer 
to the 36-mer oligomer in the oligomerisation assay as shown in figure 6.12. 
Furthermore, it can be hypothesised that its association with resistance to conversion 
in vivo is acutely linked to its reduced structural stability. If PrP in vivo has this 
particular polymorphism it could be possible that proteins that are structurally less 
stable may misfold into a non-disease specific isoform more readily. These 
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misfolded isoforms would be recognised by cellular quality control machinery and 
therefore cleared more rapidly, thereby reducing the amount of PrP available for 
conversion in vivo. This may seem counter-intuitive, however if it is not in the a-
monomeric form then firstly, it may not be present at the correct cellular location for 
conversion by PrpSc and secondly, may be conformationally incompatible for 
conversion. This mechanism of resistance may be similar to that of the polymorphic 
variants of OvPrP and their effect on susceptibility to scrapie infection, as observed 
earlier in this chapter (section 6.4). 
The thermal refolding of rMoPrP in the presence of an acidic buffer to two distinct 
oligomeric isoforms, as assessed by SEC, was demonstrated to be a stable and 
reproducible assay for studying the refolding characteristics of rMoPrP. With a 
working oligomerisation assay I then went on and analysed the effect of low density 
subcellular fractions on the oligomerisation ofrMoPrPWT. 
Previously the subcellular fractionation of a TSE susceptible cell line had provided 
an insight into factors that enhance the conversion of rMoPrP into a PK-resistant p-
sheet rich isoform that is very similar to PrpSc (chapter 4). These fractions contained 
plasma membrane and were observed to enhance conversion in a nonspecific 
manner. The cell line that was fractionated to provide samples was the fibroblastic 
LD9 cell line and this is susceptible to various strains of mouse scrapie, including 
ME7, 22L and RML (Mahal et al., 2007). However, low density subcellular fractions 
enhanced the conversion efficiency of the mouse scrapie strains ME7 and 79A. If 
these fractions did not contain specific co-factors then it is reasonable to suggest that 
the plasma membrane was interacting with the rMoPrP substrate in a general way. It 
was hypothesised that plasma membrane caused a conformational change in the a-
monomeric conformation of rMoPrP that induced efficient conversion to a PK-
resistant isoform in the CFCA. If the presence of plasma membrane destabilised the 
conformation of the rMoPrP substrate then this would match previous publications 
that have demonstrated that a loss of thermodynamic stability increases the 
propensity ofrPrP for conversion (Harrison et al., 1999, Vanik and Surewicz, 2002). 
The subcellular fractionation of the LD9 cell line into fractions by 
ultracentrifugational separation, supplied samples enriched for different organelles as 
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determined by Western blotting for specific markers. Western blotting for the plasma 
membrane marker annexin-II showed that fraction 3 was the most highly enriched 
fraction for plasma membrane and was subsequently used to supplement the 
oligomerisation assay. Methanol precipitation of this fraction followed by 
centrifugation and re-suspension of the pellet in 20 mM sodium citrate (pH3.4) to 
give a final concentration of 2 mglml rMoPrP and, to control for this experiment, a 
sample of the same aliquot of rMoPrP was diluted I: 1 with just 20 mM sodium 
citrate (PH 3.4) and heated to 45°C as per the oligomerisation protocol described 
previously in this chapter (section 6.5). Recombinant mouse PrP in the absence of 
any subcellular fraction refolds from the Q-monomer conformation into a 12-mer and 
36-mer oligomer as separated by HPLC-SEC and analysed by UV absorbance at 280 
run (figure 6.14). When compared against the thermal refolding of rMoPrP in the 
presence of fraction 3 there was an inhibitory effect caused by this plasma membrane 
enriched fraction (figure 6.15). Instead of forming two oligomeric isoforms, there 
was instead two novel isoforms formed, which were of smaller size. Firstly there was 
an oligomer of approximately 8 subunits and the second novel isoform was observed 
to elute just after a-monomeric rMoPrP and circular dichroism suggested that it had a 
degree of j3-sheet secondary s1ructure in it. This change in conformation would 
explain the difference in elution time as size exclusion chromatography elutes 
proteins by size rather than actual molecular weight. The increase in p-sheet in the 
structure of this isoform has probably caused the size to become smaller by 
tightening the structure. Alternatively, low density subcellular fractions may contain 
cellular proteases that have 1runcated rMoPrP, which would also result in a peak that 
has a later elution volume. Further s1ructural analysis of the isoforms eluted from 
these oligomerisation assays would need to be performed prior to verification of the 
secondary structure; however this was not carried out due to lack of time. 
To verify that the effect observed in figure 6.15 was specifically related to the plasma 
membrane and not any artificial contaminants from OptiPrepTM or the 
homogenisation buffer used to homogenise and fractionate the LD9 cell line, the 
oligomerisation assay was supplemented with a non-plasma membrane enriched 
fraction. Fraction 18 represented a sample that was predominantly made up of 
mitochondria and which had no discernible plasma membrane present, as determined 
by Western blotting for those relevant subcellular markers. As can be seen in figure 
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6.17, the addition of fraction 18 to the oligomerisation assay did not have the same 
inhibitory effect as observed for fraction 3. The amount of 36-mer oligomer was not 
as great as that seen in the un-supplemented oligomerisation assay however this was 
deemed insignificant. These small effects on thermal refolding could be due to an 
nonspecific interaction with the mitochondrial membrane or other mitochondrial 
proteins present in this fraction. However, there is a definite progression from a-
monomer to 12-mer and 36-mer which is not what was observed when fraction 3 was 
added to the assay. 
The observation that the thermal refolding of rMoPrP was disrupted by the presence 
of plasma membrane has consequences for in vitro assays in general but also on the 
way that we view mechanisms of how rMoPrP reacts to refolding conditions in the 
cell. The CFCA was previously used to demonstrate the enhancing effects of plasma 
membrane on conversion seeded by two different stains of mouse scrapie however 
this would appear to not be in accord with the decrease in oligomeric species. This 
may have highlighted that the CFCA is a one step process that immediately converts 
rMoPrP into a PrpS': like isofonn rather than including an intermediate species such 
as an oligomer. This would explain the differences observed on the effect of plasma 
membrane in the CFCA and oligomerisation assay. Alternatively, the results may 
have demonstrated that PrP refolds into oligomeric species and amyloid fibrils in 
different parts of the cell, both of which contribute to neurodegeneration but by 
different pathways. These results have highlighted the difficulties in understanding 
the in vivo conversion process using in vitro methods. 
To try to understand the interaction between PrP and subcellular fractions further, 
ongoing work in the laboratory has made use of an alternative in vitro misfolding 
assay. Based on the protocol described previously by Bocharova and colleagues the 
pathway of PrP misfolding, leading to amyloid fibrils has been investigated (200S). 
In this assay, recombinant MoPrP WT, in a partially denaturing buffer, was induced to 
fibrilise by shaking at 37 °C for 24 hours and fibrilisation monitored by increase in 
thioflavin-T (ThT) fluorescence. This work was carried out by a research assistant in 
the laboratory (Miss Sonya Agarwal) but made use of subcellular fractions from LD9 
cells that I had previously produced. Typical results from the fibrilisation are shown 
in figure 6.18 from four different subcellular fractions of LD9 cells, and each panel 
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Figure 6.18: Analysis of rMoPrPWf (1 mg/mll supplemented with LD9 
subcellular fractions 1, 3, 5 and 17 by thioflavin-T fluorescence. 
Fibrilisation reaction contains 5.2 J.lM rMoPrP mixed with (A) LD9 subcellular 
fraction 1, (B) LD9 subcellular fraction 3, (C) LD9 subcellular fraction 5 and (D) 
LD9 subcellular fraction 17, in a reaction volume of 160 J.lI of fibrilisation buffer (2 
M guanidine hydrochloride, 0.05 M MES, 0.01 M thiourea, rMoPrPWT, 0.01 mM 
thioflavin-T) with three Teflon balls per well and incubated at 37 QC, shaking at 900 
rpm. Each experiment was repeated four times and data normalised to produce data 
between 0-100 % ThT fluorescence and plotted on the same graph. A noticeable dip 
in fluorescence immediately after the assay has been initiated is present in all traces 
and is particularly pronounced in panel B, since no fibrilisation occurs in these 
samples. 
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represents several repeat assays. In each case, ThT fluorescence has been normalised 
to give between 0-100 %. When rMoPrPWT was shaken in the presence of fraction 1 
(top) or fraction 17 (bottom) of the fractionation gradient, fibrilisation proceeded 
with short lag times, as evidenced by sigmoidal increase in ThT fluorescence at -
300 minutes. When in the presence of a LD9 plasma membrane enriched subcellular 
fraction (fraction 3), fibrilisation of rMoPrPWT was inhibited as defined by the 
absence of the sigmoidal curve for ThT fluorescence (figure 6.18 panel B). Instead, 
ThT fluorescence remained similar to background levels, although because the data 
has been normalised to fit the maximum fluorescence to 100 %, the graph appears to 
show an increase in fluorescence at early time points. With fraction 5 the fibrilisation 
of rMoPrPWT occurs with a dramatically increased lag time and in some replicate 
assays fibrilisation is not complete in the time scale of the experiment. This work is 
ongoing in the laboratory and represents initial findings; however these observations 
appear to support previously discussed experimental results where the interaction of 
LD9 plasma membrane with rMoPrP possibly causes stabilisation of the 
conformation which is not conducive for oligomerisation or fibrilisation, but is 
conducive for conversion in the CFCA. 
To conclude, the low density subcellular fractions from the subcellular fractionation 
of the LD9 cell line have given different effects depending on whether the in vitro 
assay used is unseeded, or seeded with mouse-adapted scrapie. 
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7. General discussion 
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7.1 Discussion 
Prions are self propagating infectious proteins that act autocatalytically, typically 
propagating a phenotypic change in the host. In 1982, Prusiner coined the term prion 
to describe a proteinaceous agent that was both pathogenic and transmissible in the 
absence of a pathogen specific nucleic acid (Prusiner, 1982). The prion protein is the 
principal component of this novel pathogen and causes disease by propagation of its 
unnatural conformation onto host Prpc. Different conformations of PrpSc appear to 
be specific to different TSE strains and this is believed to form the molecular basis 
for the different phenotypic properties of different strains (Bessen et al., 1995). 
However, PrpSc conformation may not be the only critical factor in strain 
differentiation since the multiplicity of different TSE strains would require a discrete 
conformation of PrpSc to encode each set of phenotypes. To account for the putative 
diversity of PrpSc conformers it has been suggested that prion co-factors play an 
important role in aiding Prpc conversion efficiency and dictating strain properties. 
Co-factors could play a variety of roles in prion conversion, including a chaperone 
function to reduce the energy required to refold Prpc, provision of a molecular 
scaffold to bring all the necessary molecules together or to specifically sequester 
Prpc and PrpSc in the correct subcellular domain and environmental conditions for 
conversion. This project involved the investigation into the subcellular localisation of 
potential prion co-factors that stimulate prion protein conversion. 
7.2 A method for the extraction and isolation of subcellular organelles of two 
TSE susceptible cell lines was developed 
To date, TSE susceptible cell lines have provided an important role in the analysis of 
the molecular mechanisms that govern cell susceptibility to infection and the 
mechanisms behind the spread of the infectious agent. The number of cell lines that 
are susceptible to infection ex vivo is limited and there are a number of strains that 
are yet to be demonstrably infectious to cell cultures (Vilette, 2007). These 
observations strengthen the possible role of strain specific factors in prion conversion 
because different cells may have differential expression of different proteins, which 
may have an effect on conversion efficiency. 
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Chapter 3 describes the development of a fractionation protocol for the isolation of 
subcellular organelles from two different cell lines. The 5MB-PS and LD9 cell lines 
are susceptible to different strains of mouse scrapie and were used in experiments 
aimed at determining the subcellular localisation of potential conversion enhancing 
co-factors. Cell lines were cultured to confluence and gently homogenised to release 
intact internal organelles prior to ultracentrifugation through a density gradient. 
Monoclonal antibodies that recognised organelle specific protein markers were used 
to analyse organelle distribution throughout the gradient (figure 3.6 and 3.8). 
The subcellular fractionation protocol allowed for the isolation and extraction of 
subcellular organeUes from the LD9 and 5MB-PS cell lines. A density gradient of 
10-20 % proved to effectively separate plasma membrane, lysosomes, Golgi body, 
endoplasmic reticulum and mitochondria to a degree that showed that there was 
enrichment for each of these organelles in distinct fractions. 
Understanding the cellular trafficking of Prpc is critical to aid understanding of the 
pathogenic conversion to PrpSc and ultimately cell death. There is evidence to 
suggest that PrpSc accumulates in lysosomes (Mayer et al., 1992, Grigoriev et al., 
1999), endosomes (Jeffrey et al., 2009), endoplasmic reticulum (Beranger et al., 
2002) and the plasma membrane (Caughey and Raymond, 1991a, Jeffrey et al., 
1992, Jeffrey et al., 1994, Paquet et al., 2007) of neuronal and glial cells, implicating 
these areas as sites for conversion. In addition to these observations, in vitro pulse 
chase experiments have shown that internal PrpSc is N-terminally truncated thereby 
suggesting that Prpc to PrpSc conversion takes place at the plasma membrane prior to 
internalisation and digestion (Caughey and Raymond, 1991). 
If prion conversion takes place at the plasma membrane then internalisation and 
'infection' of the cell has been proposed to happen via clathrin-coated pits (Peters et 
al., 2003, Sunyach et al., 2003, Sarnataro et al., 2009). The presence of PrpSc 
internally in the endocytic pathway can therefore be explained as an event that occurs 
post-initial contact. To support this statement, a recent study demonstrated that PrpSc, 
as well as, Prpc, is also internalised via clathrin coated-pits (Jeffrey et al., 2009). 
Therefore these observations suggest that the plasma membrane plays an important 
pathological role in prion conversion. However, different strains of scrapie have been 
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shown to infect different cell types causing strain specific pathological changes, 
possibly via differences in the site of conversion and/or PrpSc processing (Gonzalez 
et al., 2003, McGovern and Jeffrey, 2007). Alternatively, it has been suggested that 
conversion and uptake of PrpSc occurs independently of PrpSc variation and instead it 
is the presence of plasma membrane co-factors and the micro-environment that are 
key (Greil et al., 2008). The conflicting observations on the site of conversion serve 
to highlight the difficulty in understanding cellular infection by prions. It is likely 
that a number of entry points into the cell exist, which mayor may not be strain 
dependent, however the site of the first prion multiplication site is strongly suggested 
to be at the plasma membrane. This therefore was a primary objective to analyse for 
the presence of co-factors. However, the cellular internalisation of PrpSc is suggestive 
of other sites of prion conversion and therefore other implicated organelles cannot be 
discounted as sites ofprion conversion and strain specific co-factors. 
7.3 Four different strains of mouse scrapie were used successfully in the 
CFCA which highHghted dift'erentlal conversion emciencies 
Historically, the CFCA has been used with the mouse adapted scrapie strain, 87V, 
which converts approximately 20 % of the rMo3F4PrP substrate into Prpl'OI. 
However, this was not the only strain of mouse scrapie that has been tested in the 
CFCA. Other TSE strains successfully used in the CFCA include, ME7, 79A, 22F, 
30lV (mouse adapted BSE) and 263K (hamster adapted scrapie). In this project, the 
CFCA was therefore extended to include experiments seeded with the four mouse 
adapted scrapie strains, 87V, ME7, 79A and 22F, which showed that there were 
differences in the conversion efficiencies for each of the four different strains of 
mouse scrapie. For ME7, 79A or 22F seeded CFCA the approximate percentage of 
substrate converted to Prpm' was 18 %, 3.5 % and 2.5 % of the rMo3F4PrP substrate, 
respectively. Low conversion efficiency rates had implications for the reliability of 
results due to small differences in replicates resulting in large standard errors during 
analysis. 
The inability of mouse scrapie to convert 100 % of the substrate is not limited by 
time but could instead be due to either inadequate assay buffer conditions, or a 
deficiency of prion co-factors that are necessary for efficient conversion. Another 
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explanation for differences in conversion efficiencies between different strains of 
mouse scrapie is that fibril morphology could influence the number of free ends 
available to convert nascent Prpc to PrpSc. This theory has been applied to the PMCA 
assay to explain amplification of the protease-resistant product by multiple rounds of 
sonication. Cyclic sonication breaks up the fibrils, presenting new fibril ends for 
further nascent PrP molecules to be converted to the protease-resistant isoform. 
7.4 The CFCA was supplemented with subcellular fractions from TSE 
susceptible cell Unes to identify strain specific oraanelles that enhance 
conversion 
Using the protocol described in chapter 3, subcellular fractions were prepared and 
organelle distributions assessed by Western blotting and densitometric analysis. 
Subcellular fractions from both the 5MB-PS and L09 cell lines were tested in the 
CFCA as shown in chapter 4. Analysis of the effect of subcellular fractions on the 
conversion efficiency showed that fractions enriched for plasma membrane from 
L09 cells enhanced conversion in the CFCA seeded with both ME7 or 79A. This cell 
line is susceptible to ME7 infection but not to the 79A strain of mouse scrapie. This 
would suggest a physical rather than biochemical reason for enhancement of 
conversion by the presence of plasma membrane from this cell line. This could be 
through the increase in surface area and the plasma membrane proteins providing a 
point with which to anchor substrate and seed together. Conversely, when the CFCA 
was done with fractions enriched for 5MB-PS plasma membrane, no enhancement of 
conversion efficiency was evident This cell line is susceptible to 79A infection but 
not ME7 infection. Instead subcellular fractions enriched for Golgi body enhanced 
79A conversion in the CFCA. Unfortunately, the supplementation of an ME7 seeded 
CFCA with Golgi body enriched fractions from the 5MB-PS cell was not done, due 
to lack of time and resources. 
These data suggest the action of prion co-factors thus implying that L09 cells have 
the co-factors on the surface and that strain tropism is governed by other additional 
factors. Other factors could include PrP expression levels, PrP trafficking, prion co-
factor expression levels and environmental conditions that are necessary to generate 
a long term infection. This is true for the 5MB-PS cell line which presumably may 
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require endocytosis and retrograde transport of PrpSc to the Golgi body for 
conversion of Prpc. Another implication is that different cell types may have 
different locations of conversion, thereby explaining discrepancies in these results. 
7.S A variety of ditTerent proteins were detected in SAF preparations from 
ME7, 79A and llF mouse scrapie by mass spectrometry 
Chapter 5 describes the mass spectrometric analysis of SAF preparations from ME7, 
79A and 22F infected mouse brains. Mass spectrometric analysis was done in the 
hope of identifying proteins that are either located in the plasma membrane or the 
Golgi body, the two areas implicated in strain specific prion conversion. Preparation 
of SAF material was done by detergent extraction and differential centrifugation 
(Hope et al., 1986). This method is effective at partially purifying the infectious 
agent, however, other proteins not associated with disease will be co-purified. To 
account for these proteins and to exclude them from future experimental analysis, 
SAF preparations on uninfected wild type and PrpOIO brains were done. As expected, 
the proteins present within these control SAF preparations were either highly 
abundant or high molecular weight proteins. Mass spectrometric analysis of ME7, 
79A and 22F SAF preparations, after removal of proteins also identified in control 
preparations, showed a number of proteins that appear to be specifically associated 
with mouse scrapie fibrils. One of the more interesting proteins identified was the 
plasma membrane protein, Na+/K.+ transporting ATPase. This protein was detected in 
all three strains of SAF and has previously been reported to be associated with 
neurodegenerative disorders (Calandrlello et al., 1995, Palladino et al., 2003). 
Although this protein cannot be considered to be a strain specific co-factor, it has 
been hypothesised that Prpc may interact with Na+/K.+ transporting ATPase on the 
plasma membrane of neurones (petrakis et al., 2008). Recent findings support a 
physiological interaction of Na+/K.+ transporting ATPase with Prpc, where it was 
shown that these two proteins may be a member of a multiprotein complex 
incorporating the fW subunit of nicotinic acetycholine (Petrakis and Sklaviadis, 2006, 
Petrakis et al., 2008). Other proteins detected in this complex included 2',3' -cyclic 
nucleotide 3'-phosphodiesterase (CNP1) and synapsin-l, which were also detected 
by mass spectrometry in my SAF preparations (table 5.2). The detection of Na+/K.+ 
transporting ATPase, CNPl and synapsin-l may well be through nonspecific 
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interactions with PrpSc due to the possible proximity between the hypothetical 
multiprotein complex and the site of prion conversion. Conversely, the presence of 
these proteins may point to a key role of these proteins in facilitating prion 
conversion, potentially through localising Prpc on the plasma membrane in a 
topology amenable for interaction with PrpSc• Crucially, the other protein members 
of the functional complex may become amalgamated into the growing fibril because 
they originally provided a site of interaction. 
SAF preparations were pre-treated with proteinase K to digest any externally 
attached molecules to leave proteins that are integrated into the fibrils and therefore 
protected from proteolytic degredation. This reduced the number of tryptic peptide 
present after digestion and only single proteins were identified for each strain of 
mouse scrapie. Firstly, the prolow-density lipoprotein was detected in the ME7 SAF 
preparation, which is a multifunctional plasma membrane receptor involved in the 
endocytosis of many different types of extracellular proteins (Herz et al., 1992). 
Whether this protein has any involvement in Prpc cell biology is still to be 
elucidated, however its role in the endocytosis of metabolic products through 
clathrin-coated pits localises this protein to the same cellular location in which PrpSc 
entry has been suggested (Goldstein et al., 1985). The Dmxl2 protein was the single 
positive identification made in the PK treated 79A SAF preparation. Dmxl2 is a 
synaptic membrane protein that is hypothesised to be involved in MAP kinase 
activation and caspase-mediated cell death (Munton et al., 2007). One of the 
proposed functions of Prpc is to mediate cell signalling and cell survival through 
signal transduction mechanisms. Therefore the identification of Dmx12 in SAF 
preparations may perhaps implicate Prpc with proteins in the MAP kinase pathway. 
However, this does not discount Dmx12 as a strain specific co-factor as it is highly 
likely that a prion co-factor will either be localised in the same region as Prpc or 
alternatively, the function of the prion co-factor will be associated with the function 
of Prpc. 
The infectious agent is hypothesised to be primarily composed of a misfolded host 
protein, PrP. However, analysis of PrpSc fibrils found in the brains of TSE infected 
animals has demonstrated that there are other molecules that co-purify with PrpSc• 
The presence of these co-prions may be explained, firstly, by a nonspecific 
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interaction caused by the nature of aggregated protein to cause protein precipitation, 
secondly, co-prions are not strain specific but are necessary for fibril morphology, 
thirdly, these molecules are instead an integral part of conversion and also aid in 
strain variation or finally, co-prions aid in conversion but are only present in the 
fibril indirectly and do not influence fibril morphology. 
A long term aim in the TSE field is to prove the prion hypothesis by synthesising 
infectious prions in vitro from defined constituents. Legname and colleagues 
produced synthetic fibrils from recombinant PrP that caused a prion like disease in 
transgenic mice that over-express the same PrP construct (Legname et al., 2004, 
Legname et al., 2(05). Even though these results appear, at face value, to prove the 
protein-only hypothesis they were generally met with scepticism. Firstly, the 
transgenic mice that over-express PrP were known to produce a spontaneous TSE-
like disease in old age (Westaway et aI., 1994, Chiesa et al., 1998). Therefore the 
synthetic prions may not be completely responsible for disease and instead may seed 
misfolded PrP that is already present in these mice. Secondly, infectivity titres of 
these recombinant derived prions were an order of magnitude less than bona fide 
prions when disease was transmitted to wild type mice in a second passage. 
Since these experiments were published, a different group have shown that the de 
novo generation of infectivity was possible using the PMCA methodology (Castilla 
et al., 2(05). The PMCA technique involves the combination of brain homogenates 
from infected and uninfected animals. Serial amplification cycles of sonication and 
dilution with normal brain homogenate amplifies protease-resistant protein and also 
appears to amplify infectivity. However, the molecular composition of the infectious 
agent could not be determined due to the complexity of the brain homogenate 
material used in these initial PMCA reactions. Further to this, the PMCA technique 
was optimised to use partially purified constituents, limiting the presence of potential 
co-factors included in the assay (Deleault et al., 2005). By use of the simpified assay, 
it was observed that the addition of polyanionic accessory molecules amplified Prprcs 
in vitro and was both infectious and transmissible (Deleault et al., 2007). The 
polyanionic molecules tested included nucleic acids and sulphated glycans such as 
heparan sulphate proteoglycan. It was subsequently demonstrated that Prprcs 
formation could be initiated spontaneously in the PMCA assay by mixing just 
199 
purified Prpc and an accessory poly(A) RNA nucleic acid (Deleault et al., 2007). 
The role of polyanions in PrpSc formation is unclear, however it has been shown that 
sulphated glycans co-localise with PrpSc in vivo and are suggested to be receptors for 
PrpSc on the surface of the cell (Snow et al., 1989, Wong et al., 2001, Hijazi et al., 
200S, Horonchik et al., 200S). Therefore, the role of a polyanion could either be as a 
co-factor or a cellular receptor that is necessary for entry into the cell. Alternatively, 
polyanions could behave like a scaffold molecule that facilitates the polymerisation 
of the fibril. My results may indicate that the inclusion of a plasma membrane-
enriched fraction may also similarly behave like a scaffold. 
If it is plausible that the infectious agent is composed of PrP and other host-derived 
components, then it is possible that these non-PrP molecules may be involved in the 
conversion process. Certainly it has been suggested that the 37 kDal67 kDa laminin 
receptor is needed for prion propagation in neuronal cells (Leucht et al., 2003). Its 
role in conversion is still to be determined, but it has been suggested that it is a 
receptor for PrpSc and this interaction is necessary for cellular entry and the 
subsequent trafficking ofPrP (Gauczynski et al., 2006, Nikles et al., 2008). 
7.6 Different variants of rPrP have different thermal refolding rates in an 
oHgomerisation assay 
To further understand the enhancement of seeded conversion in the CFCA from low 
density subcellular fractions, these subcellular fractions were used to supplement an 
oligomerisation assay. This assay involved the heat refolding of a-monomeric 
rMoPrP at an acidic pH into two oligomeric isoforms, a 12-mer and a 36-mer. The 
oligomerisation of recombinant PrP in vitro is suggested to replicate in vivo 
mechanisms where Prpc refolds into a neurotoxic oligomer prior to maturation into 
the amyloid fibril (Chiesa et al., 2003, Nazor et al., 200S). 
The refolding of recombinant PrP was trialled extensively to find an assay that was 
as physiologically relevant to cellular conditions as possible. The method previously 
described by Rezaei and co-workers incorporated an increase in temperature and an 
acidic pH to refold recombinant PrP to two oligomeric isoforms (Rezaei et al., 2OOS). 
Preliminary development of this assay was done with different variants of rOvPrP, 
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rOvPrpARR and rOvPrpVRQ. These two variants are associated with resistance and 
susceptibility to scrapie in vivo, respectively. Results, described in chapter 6, 
indicated that there is an inverse correlation between the propensity to oligomerise in 
the oligomerisation assay and disease susceptibility in vivo. This correlation is 
supported by the literature and shows that ovine PrP variants associated with 
susceptibility to conversion are thermodynamically more stable and therefore less 
likely to misfold into isoforms such as oligomers (Rezaei et al., 2002). 
The oligomerisation of rMoPrPwr was compared against a polymorphic variant, in 
which residue 164 was changed from a proline to a leucine (Figure 6.10 and figure 
6.12). This polymorphism is associated with resistance to scrapie in sheep 
(Goldmann et al., 2006). The Pl64L polymorphism caused rMoPrP to oligomerise at 
a faster rate with a higher propensity to form more 36-mer oligomers than 12-mer 
oligomers when compared against rMoPrpwr. It was hypothesised that the Pl64L 
polymorphism reduced the structural stability of rMoPrPPl64L and this explained the 
observations made on the oligomerisation of these two rMoPrP variants. 
The oligomerisation assay was chosen as an alternative assay to the CFCA, over 
other assays such as the fibrilisation of rPrP, to analyse the effect of polymorphic 
variations in PrP for several reasons. Firstly, the oligomerisation of denatured rPrP 
has been shown to reflect in vivo observations such as the propensity of rPrP with a 
methionine at codon 129 to misfold into p-sheet rich oligomers when compared 
against rPrP with a valine at codon 129 (Tahiri-Alaoui et al., 2004). The higher 
susceptibility of this PrP variant to misfold, correlates with the increased 
susceptibility of individuals to sCID and veID. The fibrilisation of the same 
denatured proteins showed that rPrP with a valine at codon 129 had a higher 
propensity to form fibrils (Baskakov et al., 2005). 
Secondly, the oligomerisation of rPrP by thermal refolding has previously shown to 
produce oligomers that are neurotoxic to both ex vivo cultured neurones and to a 
panel of mice after subcortical injection (Simoneau et al., 2007). Finally, the 
incorporation of size exclusion chromatography to separate different isoforms of 
rPrP allows for the quantitative analysis and comparison of different rPrP variants 
during an oligomerisation time course. 
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7.7 Low density subceUular fractions reduced the refolding rate of rMoPrP ill 
vitro 
The oligomerisation assay was used to analyse the effect of plasma membrane-
enriched fractions on the refolding rate of rMoPrP in vitro. The refolding of rMoPrP 
into oligomeric isoforms was inhibited when in the presence of plasma membrane-
enriched fractions from the subcellular fractionation of the LD9 cell line. These 
fractions were previously shown specifically to enhance the seeded conversion of 
rM03F4PrP into PrpRl' (figure 4.4 panel A). However, figure 6.15 shows that instead 
of refolding into two distinct oligomers, a smaller ~-oligomer of PrP and a ~ 
monomer form under these oligomerisation conditions. A control oligomerisation 
assay that was supplemented with a fraction enriched for mitochondria rather than 
plasma membrane was carried out and results showed this fraction had no discernible 
effect on the oligomerisation ofrMoPrP (figure 6.17). 
The thermal refolding of rMoPrP into oligomeric isoforms was inhibited by the 
presence of a LD9 low density subcellular fractions and this result has consequences 
on understanding how PrP reacts in the CFCA. LD9 plasma membrane-enriched 
fractions conversely enhanced conversion in the CFCA seeded by ME7 and 79A 
mouse scrapie, thus indicating that a different in vitro refolding mechanism than 
when compared to the oligomerisation assay. This suggests that the CFCA requires 
the substrate to be a-monomeric, whereas the oligomerisation of rPrP may require a 
substrate that is partially unfolded. The addition of low density subcellular fractions 
to the oligomerisation assay reduces the amount of a-monomer possibly by unfolding 
and subsequent misfolding into the ~-monomer isoform. This reduction in a-
monomeric substrate by the presence of plasma membrane would reduce the 
availability of rMoPrPWT for oligomerisation but possibly put the protein into a 
conformation more amenable to conversion in the CFCA, thereby explaining the 
apparent contradictory results. 
Further to this the addition of plasma membrane fractions on the in vitro fibrilisation 
of rMoPrP showed that, when in the presence of a LD9 plasma membrane-enriched 
subcellular fraction, fibrilisation of rMoPrPWT was inhibited (figure 6.18 panel B). 
Control experiments with LD9 subcellular fractions 1 and 17 showed no effect on the 
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fibrilisation ofrMoPrPWT whilst fraction 5 increased lag times for fibrilisation (figure 
6.18 panels A, C and D). The interaction of LD9 plasma membrane with rMoPrP 
possibly causes a stabilisation of a-monomeric rMoPrP WT, which is not conducive 
for oligomerisation or fibrilisation, but is for the seeded conversion in the CFCA. In 
figure 7.1, a hypothesised reaction pathway is shown, which illustrates the effect of 
plasma membrane-enriched fractions have on the stability of rPrP and the influence 
these fractions have on seeded conversion and unseeded refolding. 
7.8 Summary 
I developed a method for the extraction and isolation of subcellular organelles of two 
TSE susceptible cell lines, LD9 fibroblasts and 5MB-PS microglial cells. Subcellular 
organelles were used initially to supplement the CFCA which showed that LD9 low 
density subcellular fractions enhanced the conversion efficiency of ME7 and 79A 
mouse scrapie in the CFCA. The LD9 cell line is susceptible to only ME7 and not 
79A thus highlighting that the plasma membrane-enriched fractions may either offer 
a scaffold that co-localises Prpc and PrpSc, or that the plasma membrane is a 
universal subcellular localisation for prion conversion. However, the conversion 
efficiency of ME7 and 79A was not enhanced by low density subcellular fractions 
from the 5MB-PS cell line. This cell line is differentially susceptible when compared 
to the LD9 cell line and is susceptible to 79A but not ME7. This result shows that 
there is a cell line specific enhancement associated with the plasma membrane 
fractions of LD9 cells. To complement this result, Golgi body enriched fractions 
from the 5MB-PS cell line enhanced 79A conversion efficiency in the CFCA thus 
suggesting a potential site for conversion in this cell line. To determine and identify 
potential prion co-factors, proteins that co-purified with PrpSc in SAF preparations 
were identified by mass spectrometry. A list of plasma membrane derived proteins 
was identified, of which a few have been previously identified to be associated in 
TSE disease. In addition, mass spectrometry was used to identify different protein 
constituents in three different strains of mouse scrapie which may represent strain 
specific co-factors and aid in strain variation. 
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Monomeric rPrP in either a partially denatured or a-helical conformation is an 
important factor for the successful misfolding of rPrP in vitro. Partially denaturising 
conditions such as an acidic pH or the presence of a chaotrope are conducive for the 
oligomerisation or fibrilisation ofrPrP, respectively. However, when these assays are 
supplemented with a plasma membrane-enriched subcellular fraction, there is a 
stabilisation of rPrP conformation back to a folded state thus preventing refolding 
into oligomers or fibrils. On the other side, the CFCA involves the disease-specific 
conversion of rPrP to PrpR' and when this assay is supplemented with a plasma 
membrane-enriched subcellular fraction, the conversion of a-monomeric rPrP is 
enhanced. However, it is likely that plasina membrane proteins preset in these 
subcellular fractions play an important role in strain specificity. 
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To further our understanding of the effect of low density subcellular fractions on the 
recombinant PrP substrate, an oligomerisation assay that involved the thermal 
refolding or rPrP into oligomeric isoforms was used. This assay had previously been 
used to identify different oligomerisation rates of rOvPrP variants which confer 
either susceptibility or resistance to sheep carrying the respective proteins, to scrapie. 
In addition, this assay also enabled the differentiation of rMoPrP variants that 
differed by the amino acid expressed at codon 164, which is also related to disease 
and resistance to conversion. The oligomerisation and fibrilisation assays were used 
to monitor the effects of plasma membrane-enriched fractions on the refolding of 
rMoPrP. These subcellular fractions appeared to specifically inhibit the refolding of 
monomeric rMoPrP to oligomeric and fibril isoforms. This result indicates that there 
are different mechanisms of rMoPrP refolding in the three assays used and that 
potentially the oligomerisation and fibrilisation assays are a generic misfolding of 
PrP rather than the specific seeding in the CFCA. 
7.8.1 Possible future Work 
From this study it can be seen that there are many unanswered questions concerning 
the specificity of conversion enhancing factors. 
1. Further validation of the proteins identified by mass spectrometry to 
facilitate our understanding of the role these molecules play in prion 
conversion. This could be done by several methods include, co-
immunoprecipitation to validate interactions, knockout of proteins 
identified in mice (dependent on viability) and finally, the identification 
and use of specific inhibitors that prevent the function of each of the 
proteins identified. 
2. Proteinaceous constituents of SAF could be purified ex vivo or made into 
recombinant proteins, over-expressed and purified for the addition to the 
CFCA and the oligomerisation assay. Proteins such as Na+/K.+ ATPase, 
synapsin-l, prolow density lipoprotein, DmxI-2 and CNPl have been 
shown to be integral parts of the amyloid fibril, as detected by tandem 
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MSIMS, and their activity on PrP during conversion or thermal refolding 
may show potential prion co-factor activity. 
3. Application of systems biology models to further understand how each of 
the proteins identified by mass spectrometry interact with each other and 
to elucidate commonalities and differences in different strains of moUse 
scrapie. 
4. The 79A-seeded CFCA showed that the Golgi body enriched fractions 
from the 5MB-PS cell line increased 79A conversion efficiency. It would 
be useful to determine whether these fractions also increased ME7 
conversion efficiency to determine whether the effect was strain or cell-
line specific. 
5. To further fractionate plasma membrane and Golgi body-enriched 
fractions to attempt to isolate the molecules that enhance conversion in 
the CFCA. This could be done, firstly, by the application of different 
OptiPrepTM gradients to sub-fractionate specific organelles and, secondly, 
by size exclusion chromatography to separate different molecules by their 
molecular weight. 
6. To further define the different PrP isoforms in the oligomerisation assay 
when including or excluding low. density subcellular fractions. Properties 
such as secondary structure could be analysed by circular dichroism or 
FT -IR and resistance to protease digestion could be measured by Western 
blotting after incubation with PK. 
7. To diversify CFCA experiments to include subcellular fractions from 
other TSE susceptible cell lines and seed these assays with other mouse 
scrapie strains. To elucidate whether plasma membrane fractions from the 
LD9 cell line enhances conversion with other stains of mouse scrapie. In 
addition, it would also be useful to see if other TSE susceptible cell lines 
have different localisations of conversion enhancing factors and what 
effect these factors have on the oligomerisation of rPrP. 
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8. Appendix 
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Appendix 1: Western blot analysis of 5MB-PS and LD9 subcellular 
fractionation for endogenous Prpc. 
Subcellular fractions (1-22) were prepared as outlined in section 3.6 for (A.) 5MB-
PS cell line and (B.) LD9 cell line. Fractions were separated by SDS PAGE and 
assessed by Western blotting using the anti-PrP antibody 8H4 to show the 
distribution of PrP throughout each cell line. Lanes indicted as X and Y are of cell 
homogenate and 20 ng rMoPrPWT, respectively. 5MB-PS and LD9 subcellular 
fractionation shows that Prpc is detected at very low concentrations throughout the 
subcellular fractionation a determined by the 27 kDa band of rMoPrPWT in lane Y. 
Molecular weight (kDa) is hown on the left hand side of each Western blot. 
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